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 Pharmaceutical cocrystals are emerging as a useful strategy for enhancing solubility, 
dissolution, and bioavailability for poorly water-soluble drugs.  One of the most important 
properties of cocrystals is their fine-tunable solubility.  This property enables cocrystals to 
increase or decrease solubility.  Cocrystal solubility is the result of intricate chemical interactions 
between cocrystal solution components and conditions such as additives and pH.  Without the 
critical knowledge of cocrystal solution behavior and the underlying solution interactions, 
studying cocrystals is a trial and error exercise that can be time consuming.  This dissertation 
determines the mechanisms by which the cocrystal solubility is influenced by pH and 
solubilizing agents and investigates the relationship between cocrystal supersaturation index and 
conversion kinetics. 
 The objectives of this work are to (1) determine the effect of pH and solubilizing agents 
on cocrystal solubility, supersaturation index, and dissolution, (2) derive mathematical equations 
that describe cocrystal solubility and supersaturation index behavior based on solution equilibria 
of cocrystal dissociation, component ionization, and component solubilization, (3) investigate the 
relationship between cocrystal supersaturation index and risk of solution-mediated conversion, 
and (4) assess the ability of cocrystals to generate and maintain supersaturation. 
 Three cocrystals (1:1 stochiometric ratio) composed of a basic drug, ketoconazole (KTZ), 
and acidic coformers, adipic acid (ADP), fumaric acid (FUM), and succinic acid (SUC), were 
used as model compounds.  While KTZ has shown orders of magnitude decreases in solubility 
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and dissolution as pH increases from 1 to 7, the cocrystal solubility increases with respect to 
drug at pH above pHmax (pHmax range 3.6 to 3.8).  Cocrystal solubility advantage (SA), also 
referred to as the supersaturation index, increased from 1 at pHmax to between 900 and 6000 at 
pH 6.5.  This range of SA translated into cocrystals that sustain supersaturation levels to different 
extents or not at all.  SA values ranged from 5 to 13 (FeSSIF), 13 to 36 (blank FeSSIF), 221 to 
1418 (FaSSIF), and 440 to 3118 (blank FaSSIF).  Maximum supersaturation with respect to drug 
and AUC ratio of cocrystal to drug during dissolution showed that cocrystals exhibited superior 
dissolution behavior over drug in all media except for the cocrystal with the highest SA (3118, 
KTZ-FUM in blank FaSSIF).  Cocrystals showed the highest supersaturation (22 to 30) and 
AUC ratio (10 to 16) values in FaSSIF.  Supersaturation and AUC ratio increased with SA in 
FaSSIF, and they leveled off at SA between 460 and 1400.  The lowest supersaturation (1.5) and 
AUC ratio (1.6) values were observed in FeSSIF, where cocrystals were fully dissolved and no 
drug precipitation occurred.  pH-shift dissolution studies also showed that the cocrystal Cmax and 
AUC values exhibited less sensitivity to gastric pH than the drug.  KTZ was also observed to 
undergo liquid-liquid phase separation when high levels of supersaturation (about 150) were 
generated by rapid pH-shift from 2 to 6.5.  These metastable forms exhibited higher solubility 
compared to the crystalline form, and their formation appeared to delay crystallization.  






Oral administration is the preferred way for dosing a drug product due to its 
noninvasiveness and convenience.1  Generally, an orally administered drug must be absorbed 
from the GI tract into the systemic circulation in order to reach its intended target site, and this 
process is determined by the ability of the drug molecules to dissolve in the GI fluid and 
permeate the intestinal gut membrane.1-2  The Biopharmaceutics Classification System (BCS) 
uses these two parameters, aqueous solubility and permeability, to define and describe oral 
absorption of drugs.2  For BCS Class II compounds, defined as having low solubility but high 
permeability, dissolution is the rate-limiting step for oral absorption, and improving their 
solubility can potentially improve their absorption.2-3  Pharmaceutical scientists explored many 
methods in attempt to improve the solubility of a poorly soluble drug including generating 
different solid forms of the drug such as polymorphs, amorphous materials, salts, and 
cocrystals.4-5 
Recently, cocrystals have gathered a lot of interest in the pharmaceutical industry due to 
their potential to improve drug in vitro and in vivo performances by increasing solubility, 
dissolution, and therefore bioavailability.4-14  Cocrystals are a class of multicomponent solid 
forms that contains two or more molecular components that are solids at room temperature 
(unlike solvates) in a single homogenous crystalline phase with well-defined stoichiometry.5, 9, 15-
20  The availability of a large variety of coformers offers flexibility in cocrystal composition and 
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stoichiometry for a single drug, and cocrystal solution behavior can be fine-tuned based on the 
molecular interactions in solution.5, 15, 21-23 
Cocrystals are supersaturating drug delivery systems (SDDS) and can generate 
supersaturation in solution relative to drug solubility in solution.11, 15, 21  A major challenge for 
cocrystals with very high solubility advantages (with respect toref drug) is the risk of rapid 
solution-mediated transformation to the less soluble, more thermodynamically stable drug form.  
This can lead to little or no improvement in dissolution and bioavailability despite the high 
cocrystal solubility advantage.9, 21  Generally, the higher the solubility and solubility advantage 
(SA) of a cocrystal, the greater the risk of failure during its kinetic measurements.15, 21  Cocrystal 
SA and stability relative to drug can be manipulated with pH and solubilizing agents with proper 
understanding of cocrystal solution behavior.15, 21, 23-26 
This chapter introduces some basic concepts and current understanding of cocrystal 
solubility, ionization, and solubilization through relevant cocrystal solution chemistry.  Research 
objectives will be in the conclusion of this chapter. 
 
Cocrystal Formation and Design 
  Pharmaceutical cocrystals are formed by supramolecular synthons of two or more 
components formed through molecular associations of the component functional groups, and the 
carboxylic acid moieties are amongst the most common functional groups used in the crystal 
engineering of cocrystals.27-28  Figure 1.1 demonstrates some of the common hydrogen bonding 




Figure 1.1. Common supramolecular synthons formed via hydrogen bonding between carboxylic 
acid and amide groups.27 
  
Figure 1.2 illustrates some of the common multicomponent solid forms used for 
modification of drug properties.  Cocrystals, being crystalline in structure, have stability 
advantage over amorphous materials, and cocrystal formation is much more predictable and less 
restrictive when compared to producing particular polymorphs of a material.5  Although salts can 
rival cocrystals in the ability to modify the solubility of a drug, salts require acidic and basic 
components that have ΔpKa greater than 2 or 3 in order to form, while cocrystals can form 
between neutral compounds as well as ionizable ones.5, 15, 18  Cocrystals also differ from solvates 
in that all of the cocrystal components are solids at room temperature.5, 15 
 
Figure 1.2. Comparison of multicomponent solid form modifications that can be used to alter the 




While coformers can be selected based on their functional group(s) potential to hydrogen 
bond with the drug substance, cocrystal formation is not guaranteed.15, 28  Thus, cocrystal 
discovery is done empirically with selected coformers under conditions that optimize 
cocrystallization.  Cocrystals screening and synthesis can be carried out by using a variety of 
methods such as slow evaporation, co-grinding, sublimation, melt crystallization, and solvent 
drop grinding.5, 15, 19, 27, 30-33  Some of the limitations of cocrystal screening methods include the 
crystallization of single components instead of cocrystal, difficulty in scaling-up, and large 
amount of materials and time required.  The reaction crystallization method (RCM) is 
particularly useful for synthesis and screening of cocrystals, and it is based on generating 
supersaturation with respect to cocrystal where the solution is at or below saturation with respect 
to its components.15, 34 
Similar to salts, cocrystal solubility behavior is governed by solution compositions and 
exhibits solubility product behavior.9, 35-36  RCM takes advantage of this solubility product 
behavior to generate supersaturation with respect to cocrystal in solvent systems where the 
cocrystals are more soluble and thermodynamically unstable compared to the drug.  Consider a 
1:1 (stochiometric ratio) cocrystal AB, its dissolution/precipitation in solution can be described 





              (1.1) 
where ABcocrystal represents the solid cocrystal, Asolution and Bsolution represent the drug and 
coformer dissolved in aqueous solution, respectively.  The solubility product, Ksp, is the 
equilibrium constant of this reaction. 
[ ][ ]spK A B=                   (1.2) 
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The terms in brackets represent concentration of the cocrystal component. 
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                 (1.3) 
Figure 1.3 demonstrates how RCM generates supersaturation with respect to cocrystal and forms 
cocrystal in solution, by simply dissolving its components and changing their concentrations in 
solution.15, 34 
 
Figure 1.3 Schematic phase solubility diagram indicating regions where cocrystal can form or 
dissolve and a possible cocrystal formation pathway.  Lines represent solubilities of drug A, 
coformer B, and cocrystal AB.  Cocrystal solubility decreases with coformer concentration [B]T.  
The subscript T represents analytical or total concentrations. The arrows represent a path along 
which only cocrystal can crystallize. Region I: solution is supersaturated with respect to drug, 
and cocrystal can convert to drug.  Region II: solution is supersaturated with respect to both drug 
and cocrystal, and both can crystallize.  Region III: solution is below saturation and drug, 
cocrystal, and coformer dissolve.  Region IV: solution is supersaturated with respect to cocrystal, 
and drug can convert to cocrystal.  Crystallization pathway involves: (1) solution saturated with 
respect to coformer (the most soluble component in this example), (2) dissolution of drug, and 
(3) cocrystal formation.15 
 
 At region IV (high excess coformer B concentration and supersaturated with respect to 
cocrystal AB) the cocrystal solubility is lower than that of the drug, and therefore the cocrystal is 
the thermodynamically stable form.  Manipulating the solution condition so that it resembles 
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region IV on the diagram would maximize the likelihood of synthesizing and obtaining the 
cocrystal through precipitation of the least soluble crystalline form from solution.  RCM has the 
advantages of that the cocrystal formation is not limited by different solubilities of its 
components, the range of solvents that can be used for cocrystallization is expanded, and 
cocrystals can be generated on both small and large scales.15, 34 
 
Lattice and Solvation Energy of Cocrystals 
Solubility is the thermodynamic equilibrium of a solute between two phases, in this case 
a solid and liquid phase, and the solubility enhancement of a material is based on the free energy 
of solution, which includes both lattice energy and solvation energy.21, 37 
solution lattice solvationG G G∆ = ∆ + ∆                 (1.4) 
In order for solubilization or dissolution to occur, the first step involves breaking the 
intermolecular bonds in both the solid (solute) and the solvent within themselves, and then 
followed by forming solute-solvent intermolecular bonds.21, 37  The interaction of the solute-
solvent must be stronger than the solute-solute and solvent-solvent bonds in order for a solid to 
dissolve in solution.21  Under ideal conditions where all the intermolecular forces are equivalent 
(solute-solute = solvent-solvent = solute-solvent), the strength of the solute crystal lattice 
determines solubility.5, 21  Formation of amorphous solids, polymorphs, solvates, salts, and 
cocrystals all reduce the lattice energy of the solid material in order to improve solubility. 
Realistically, ideal solutions are quite unusual, and therefore lattice energy alone cannot define 
the solubility of a material.5, 21, 38-39 
In aqueous environments, solvation energy, rather than lattice energy, is generally the key 
determining factor for the solubility of a poorly soluble drug compound and its cocrystals, 
7 
 
especially if the drug is hydrophobic.3, 9, 21, 25, 40  Solvation energy is based on solvent-solute 
interactions, and therefore it can vary greatly based on the hydrophobicity of the drug molecule 
and the nature of the solvent (organic vs. aqueous).  In the case of a cocrystal, the coformer can 
decrease the solvation barrier to an extent that is proportional to the pure coformer solubility.9, 15  
The linear correlation between the aqueous solubility of coformer and cocrystal is why highly 
soluble coformers are usually selected to screen for cocrystals for solubility enhancement. 
 
Cocrystal Solubility and Transition Points  
Cocrystals have the versatility to fine-tune solubility, and their solubility is highly 
dependent on the solution phase interactions of cocrystal components.5, 9, 15, 23, 41  Considering 
that cocrystals are composed of multiple components of large diversity, the molecular 
interactions in the solution phase can play an important role in determining cocrystal solubility.9, 
15, 21  As cocrystal dissolves in solution, the components dissociate and interact with the solution 
environment via ionization, partition, and complexation (figure 1.4).9, 21, 41-42  These solution 





Figure 1.4. Cocrystal solution phase interactions for a cocrystal RHA of a non-ionizable drug 
(R) and weakly acidic conformer (HA) and associated equilibria commonly encountered by 
pharmaceutical dosage forms, such as dissociation, complexation, ionization, and micellar 
solubilization.  Ksp represents the cocrystal solubility product, Ka is the ionization constant, Kc is 
the complexation constant and KsHA, KsA
− , KsR are the micellar solubilization constants for HA, A-, 
and R, respectively.5, 15, 21 
 
Due to different solubility-pH and solubilization behaviors exhibited by cocrystals from 
its parent drug, it is not uncommon for a cocrystal to be less, equal, or more soluble than the drug 
depending on solution conditions.15, 21, 23-24, 26, 39, 42-43  There are a few key cocrystal solubility 
transition points that define the thermodynamic stability regions of a cocrystal, and at above or 
below which the cocrystal SA with respect to drug is reversed.15, 24  Cocrystal transition points 
can be induced by pH, drug solubilizing agents, and coformer concentration in solution (figure 
1.5), and they are defined by pHmax, CSC/S*, and Keu, respectively.15, 23-24, 26  These transitions 




Figure 1.5. Cocrystal solubility can be fine-tuned by (a) pH, (b) drug solubilizing agents, and (c) 
coformer concentration.  Solution conditions change the cocrystal solubility relative to drug 
solubility and so the cocrystal thermodynamic stability.  The cocrystal is thermodynamically 
stable when Scocrystal ≤ Sdrug.  The cocrystal solubility advantage over drug (Scocrystal/Sdrug) when 
Scocrystal > Sdrug is however critical to achieve higher drug concentrations during cocrystal 
dissolution.15 
 
Cocrystal Ionization and pHmax 
Pharmaceutical cocrystals often composed of drugs and coformers with different 
ionization properties.  These components can be nonionic, acidic, basic, amphoteric, or 
zwitterionic.5, 15, 21, 23, 25, 41, 44-45  The wide range of drug and coformer ionization properties 
results in cocrystals with a great variety of solubility-pH behavior, even for cocrystals of the 
same drug.  It is imperative to acknowledge and understand that cocrystal solubility behaviors 
exhibit vastly different pH-dependence than that of the drug, and proper understanding of this 
behavior is essential for cocrystal characterization. 
The solution phase interactions in figure 1.4 can be described by the following 
equilibrium reactions and corresponding constants for 1:1 cocrystal RHA, where R represents a 
non-ionizable drug and HA represents a weakly acidic coformer.21, 41  The cocrystal dissolves in 
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[ ][ ]spK R HA=                (1.6) 
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=                 (1.8) 
Under stoichiometric conditions, the solubility of the cocrystal (Scocrystal) as a function of pH 
would be equal to the total concentration (T) of drug or coformer 
[ ] [ ]cocrystal T TS R A= =                (1.9) 










             (1.10) 
Sometimes, cocrystals can exhibit a solubility transition point with respect to solution pH, 
called the pHmax.5, 15, 21, 23, 26, 41  It is also known as the Gibbs pH, and it is not unique to 
cocrystals, but also commonly used to characterize pharmaceutical salts.46-48  The pHmax is an 
important parameter that identifies stability region of cocrystals.  At pHmax, both cocrystal and 
drug solid phases are thermodynamically stable and can coexist in equilibrium with solution.21, 26, 
41 
Figure 1.6 demonstrates the solubility-pH profiles of cocrystals with various ionization 
properties and how they differ from that of the parent drug.  In figure 1.6a and 1.6b, the non-
ionizable drug (R) does not exhibit solubility-pH dependence, as can be seen that the drug 
solubility is constant regardless of solution pH.  However, the cocrystals exhibit solubility-pH 
dependence based on the coformer ionization properties, with the acidic coformer (H2A) leading 
to cocrystal solubility increase with pH in figure 1.6a, and the amphoteric coformer (HAB) 
resulting in a U-shaped solubility in the pH range plotted (figure 1.6b).  A cocrystal composed of 
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a basic drug (B) and acidic coformer (H2A) also exhibit U-shaped solubility-pH profile, although 
in this case, both drug and coformer ionizations contribute to this phenomenon (figure 1.6c).  In 
the last case, represented by figure 1.6d, an acidic coformer (H2X) causes a steeper increase in 
cocrystal solubility at pH > 4, leading to an intersection of cocrystal and drug (-ABH+) solubility.  
This intersection, where the cocrystal and drug solubility are equal, is the transition point 
pHmax.39, 41, 43  In the case of gabapentin-3-hydroxybenzoic acid cocrystal (figure 1.6d), at 
solution pH < pHmax, the drug is more soluble than the cocrystal, but at pH > pHmax, this 





Figure 1.6. Cocrystals modulate the solubility dependence on pH as a result of the ionization 
properties of cocrystal components: (a) 2:1 R2H2A cocrystal, (b) 2:1 R2HAB cocrystal, (c) 2:1 
B2H2A cocrystal, and (d) 1:1 -ABH+H2X cocrystal.  Plots were generated from experimentally 
determined Ka and Ksp values of (a) carbamazepine-succinic acid,12 (b) carbamazepine-4-
aminobenzoic acid hydrate,41 (c) itraconazole-L-tartaric acid,49 (d) gabapentin-3-hydroxybenzoic 
acid.43  This plot shows that cocrystals can impart pH-dependent solubility to non-ionizable 
drugs, and modulate pH sensitivity of ionizable drugs.41  Cocrystals can also exhibit a pHmax as 
shown for the gabapentin-3-hydroxybenzoic acid.5, 41 
 
Figure 1.7 demonstrates the solubility-pH profiles of nevirapine (NVP) and its cocrystals 
with acidic coformers of saccharin (SAC), maleic acid (MLE), and salicylic acid (SLC).23  The 
NVP cocrystals are generally more soluble than the drug, and the cocrystal solubility advantage 
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over drug is highly dependent on pH.  At pH 1, the weakly basic drug NVP is highly soluble, and 
as solution pH increases, NVP solubility decreases until it reaches a constant value at pH above 
4.23  The NVP cocrystals, with the additional influence of the acidic coformers, exhibit U-shaped 
solubility dependence on pH.  NVP-SAC and NVP-SLC have pHmax values at pH 1.1 and 1.7, 
respectively.23  As pH nears the pHmax, the cocrystal SA (Scocrystal/Sdrug) approaches 1, meaning 
little or no advantage.  Frequently, solution pH is ignored in the evaluation of cocrystal solubility 
and dissolution measurements, but NVP cocrystals demonstrated that even small variations in pH 
can cause large changes in cocrystal solubility and solubility advantage over drug. 
 
 
Figure 1.7. Solubility of the basic drug NVP and its cocrystals with acidic coformers: (1:1) 
cocrystal NVP-MLE, and (2:1) NVP-SAC and NVP-SLC as a function of pH.  The symbols 
represent solubilities determined from the solutions saturated with NVP and/or cocrystal at 25ºC.  
The pH values correspond to equilibrium pH.  As pH increased, the cocrystal and drug solubility 
curves approach each other and intersect at pHmax.  The pH value at the intersection of the drug 
and cocrystal (NVP-SAC and NVP-SLC) solubility curves corresponds to pHmax or transition 
point above which a less soluble cocrystal becomes more soluble than drug.  The curves were 
calculated from cocrystal and drug solubility-pH dependence according to equations   




(1 + 10pKa,D−pH)2(1 + 10pH−pKa1,CF)
3
  and cocrystal Ksp values 1.96 x 10-5 
M2, 1.05 x 10-10 M3, and 3.63 x 10-11 M3 for NVP-MLE (1:1), NVP-SAC (2:1), and NVP-SLC 
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(2:1), respectively.  The symbols represent: NVP solubility (NVP hydrate-open circles, NVP 
anhydrous-filled circles) and cocrystal solubilities from eutectic points (squares).15, 23 
 
Cocrystal Solubilization, S*, and CSC 
Figure 1.4 also describes cocrystal solution phase interaction with drug solubilizing 
agents.  In the presence of surfactant micelles, the non-ionizable drug R can partition into the 
hydrophobic micellar core, according to the micellar solubilization constant of the drug, KsR.26, 42 
aq m
RsK
R M R+ 

                (1.11) 
[ ]






=               (1.12) 
Subscript “aq” refers to drug or coformer dissolved in the aqueous phase, subscript “m” refers to 
drug and coformer in the micellar pseudophase, and “[M]” represents surfactant micelle 
concentration, which is equal to the total surfactant concentration minus the critical micellar 
concentration (CMC). 
The non-ionized and ionized coformer (HA and A-) can also partition into surfactant 




HA M HA+ 

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−=               (1.16) 
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The assumption is that micellar solubilization, or the partition of drug and coformer species into 
the surfactant micelles, is independent.42  The mass balance for cocrystal components in solution 
can be expressed as:41-42, 50 
[ ] [ ] [ ]T aq mR R R= +               (1.17) 
[ ] [ ] [ ] [ ]T aq m mA HA HA A
−= + +             (1.18) 
By combining equations 1.6, 1.9, 1.17, and 1.18, and substituting in appropriate 
equilibrium constants, the cocrystal solubility in the presence of micellar surfactant can be 
derived as 
, (1 [ ])(1 [ ] [ ])[ ] [ ]
R HA Aa a
cocrystal T sp s s s
K KS K K M K M K M
H H
−
+ += + + + +       (1.19) 
where Scocrystal,T represents the total cocrystal solubility in aqueous and micellar environments. 
The drug solubility in surfactant solutions can be described by 
, [ ] (1 [ ])
R
drug T aq sS R K M= +             (1.20) 
where Sdrug,,T represents the total drug solubility. 
Based on the relationship presented in equation 1.19, if the surfactant micelles solubilize 
the drug to a higher extent compared to the coformer, cocrystal solubility will exhibit a non-
linear dependence on surfactant concentration (figure 1.8).  This can lead to a solubility 
transition point based on surfactant concentration.42  This transition point induced by surfactants 
is defined by CSC (critical solubilization concentration) and S*.24, 26, 42 
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(a)    (b)  
Figure 1.8. (a) Schematic illustration of the equilibria between the cocrystal phase and its 
components in the aqueous and micellar pseudophases.  This scheme represents micellar 
solubilization of one cocrystal component (drug), leading to excess coformer in the aqueous 
pseudophase and in this way stabilizing the cocrystal phase.  (b) Schematic representation of the 
cocrystal (RHA) and drug (R) solubility with respect to the total surfactant concentrations 
according to equations 1.19 and 1.20.  Differential solubilization of cocrystal components 
represented by the relative values of HAsK  and 
R
sK  leads to nonlinear cocrystal solubility 
dependence and to intersection of the cocrystal and drug solubility curves.  CSC refers to the 
critical stabilization concentration, at which both cocrystal and drug are thermodynamically 
stable.42 
 
In the presence of a drug solubilizing agent, a cocrystal can display higher, equal, or 
lower solubility than the parent drug with respect to the solubilizing agent concentration.26, 42, 51  
The preferential solubilization of the drug over the coformer by the solubilizing agent is 
responsible for this behavior.26, 42, 51  Generally, pharmaceutical cocrystals are composed of a 
hydrophobic drug and a hydrophilic coformer, and therefore the drug will be more solubilized by 
the solubilizing agents in solution.21, 24, 26, 42, 51-52  As solubilizing agent concentration increases in 
solution, the drug solubility increases at a higher rate than the cocrystal, and this can lead to an 
intersection of the solubility curves of cocrystals and drug.  This point of intersection is a 
cocrystal transition point characterized by the solubilizing agent concentration (CSC) and the 
















= = =            (1.21) 
The values of superscripts “m” and “n” are derived from the stoichiometry of the cocrystal, 
where m = 2 and n = 1 for 1:1 cocrystals, and m = 3 and n = 2 for 2:1 cocrystals.15 
CSC value is dependent on the effectiveness of the solubilizing agent, but the S* value is 
independent of solubilizing agents as long as the coformer is not solubilized.15, 24  A stronger 
drug solubilizing agent (larger drug Ks value) would result in a lower CSC value for the cocrystal 
compared to a weaker one (smaller Ks value).24  Unlike the CSC, the value of S* is constant.24  
S* is governed by the aqueous solubility of the cocrystal and drug in aqueous solutions, as can be 
seen in equation 1.21.24  The concept of this cocrystal transition point, CSC and S*, is illustrated 
in figure 1.9. 
 
Figure 1.9. Transition point (S* and CSC) for a cocrystal (red line) and its constituent drug (blue 
line) in two different solubilizing agent, a and b.  S* is constant, and CSC varies with the extent 
of drug solubilizing by the solubilizing agent.  Drug is solubilized to a greater extent by a than 
by b, and thus CSCa < CSCb.  The curves were generated from equations 1.20 and 1.23 with 
parameter values Sdrug,aq = 0.5 mM, Scocrystal,aq = 2.4 mM (Ksp = 5.76 mM2), and Ks
drug= 1.5 mM-1 





Cocrystal SR and SA 
When the solubilizing agent impact on coformer solubility is negligible, equation 1.19 
can be simplified to 
, (1 [ ])
drug
cocrystal T sp sS K K M= +              (1.22) 
where drug solubilization constant is represented by drugsK .  Equation 1.22 can be rewritten in 
terms of Scocrystal,aq, which is the cocrystal solubility in aqueous phase.24 
, , 1 [ ]
drug
cocrystal T cocrystal aq sS S K M= +               (1.23) 
By combining equations 1.20 and 1.23, the relationship between cocrystal and drug 
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              (1.24) 
where Saq is the aqueous solubility, sum of non-ionized and ionized forms, of drug and cocrystal. 
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              (1.26) 
where A and B are the cocrystal constituents, drug and coformer, and x and y are the 





   
=      
   
               (1.27) 
19 
 








=                 (1.28) 
Equation 1.28 shows that S* value is determined by the drug and cocrystal aqueous solubilities at 
a given pH and temperature for a 1:1 cocrystal.15, 24 
Solubilization ratio (SR) is defined as the total solubility in surfactant media (ST = Saq + 
Ss) divided by the aqueous solubility (Saq), where Ss represents the cocrystal/drug solubilized by 
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                 (1.29) 
Replacing the term SR into equations 1.24, 1.25, and 1.26, the equations simplifies to 
cocrystal drugSR SR=                 (1.30) 





+=               (1.32) 
The relationships based on equations 1.30 to 1.32 only hold when the solubilizing agent 
solubilizes the drug but not the coformer, and this can be justified due to pharmaceutical 
cocrystals are generally composed of hydrophobic drugs and hydrophilic coformers.  In the 
absence of any experiments of cocrystal solubility, the simple equation 1.32 can give a general 
idea of cocrystal behavior in media containing solubilizing agents. 
The relationships between SRcocrystal and SRdrug is shown in figure 1.10 for a 1:1 and 2:1 






Figure 1.10. Dependence of SRcocrystal on SRdrug according to equations 1.30 and 1.31 for 
cocrystal stoichiometries 1:1 ( — ) and 2:1 (- - -), using typical range of SRdrug values.24 
  
Due to preferential solubilization of the drug, SRcocrystal is smaller than SRdrug, and SR for a 1:1 
cocrystal is lower than SR for a 2:1 cocrystal.24  Since cocrystal solubility increases at a slower 
rate than that of the drug with solubilizing agent concentrations, a cocrystal that possesses higher 
solubility in aqueous solution can become less soluble than the drug when a certain amount of 
solubilizing agent is added to the solution.24, 26, 42  This demonstrates the importance of 
understanding how solubilizing agents affects drug and cocrystal differently when examine 
cocrystal solution properties in the presence of additives or excipients. 
Cocrystal solubility advantage over drug (SA), also known as the supersaturation index 
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SAaq is the aqueous cocrystal solubility advantage in the absence of drug solubilization (SRdrug = 
1).  Cocrystal SA values can be fine-tuned with drug solubilization, through the incorporation of 
any solubilizing agents such as polymers, surfactants, or lipids that preferentially solubilizes the 
drug over coformer.15  Equation 1.34 can be rewritten in logarithmic form and plotted in figure 
1.11. 
1log( ) log( ) log( )
2aq drug
SA SA SR= −               (1.35) 
 
Figure 1.11. Cocrystal solubility advantage over drug or supersaturation index (SA) decreases in 
a predictable way with increasing (SRdrug).  The full lines represent (1:1) cocrystals with SAaq = 
2, 10, and 100.  The dashed line indicates SA = 1.  The intersection of the cocrystal SA and SA = 
1 line represents the SRdrug at which Scocrystal = Sdrug, and identifies transition points, which in 
these examples are at SRdrug = 4, 100, and 10,000 for the corresponding cocrystals, Below the 
SRdrug limit, the cocrystal is more soluble than the drug but becomes less soluble than the drug 
above this SRdrug value.15 
 
Figure 1.11 shows the drug solubilization regions where the cocrystal is more, equal, or 
less soluble than the drug.  The intersections of the cocrystal SA line with the dotted line (SA = 
1) defines the regions where cocrystals can generate supersaturation (SRdrug < intersection).15  A 
cocrystal with lower SAaq will require a lower SRdrug at the transition point, meaning that the 
cocrystal SA can be eliminated with low level of drug solubilization by pharmaceutical additives.  
The assumptions here include that 1) the coformer is not solubilized by the drug solubilizing 
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agent 2) no other solution phase interactions occur between the drug, coformer, and additives.15  
Solubilization of the coformers will cause deviations in this relationship, which can be quantified 
by a factor ԑ.15, 24  Consider a weakly monoprotic acidic coformer, 
( ),
,














             (1.36) 
and for a 1:1 cocrystal solubilization becomes 
( )cocrystal drugSR SRε=                (1.37) 
If the coformer is not solubilized, the Kscoformer = 0, and ԑ would be equal to 1, turning equation 
1.37 to 1.30.15, 24  The simple equations enable one to get an initial approximation and evaluation 
of cocrystals, and can provide guidance for further selection, analysis, and formulation of these 
cocrystals under the right conditions. 
Cocrystal Eutectic Point and Keu 
The cocrystal eutectic point has been well established in the literature as an important 
transition point that characterizes the cocrystal thermodynamic stability relative to its 
components.9, 12, 35, 53  At the eutectic point, both drug and cocrystal solid phases coexist in 
solution at equilibrium.9  Generally the equilibrium of drug and cocrystal solid phases is used 
since drug is usually the least soluble component.  Since the solution is saturated with two phases 
(drug and cocrystal), the eutectic concentrations are independent of the mass ratio of the solid 
phases at the eutectic.21  The eutectic concentrations of drug and coformer can lead to 
information regarding cocrystal solubility under stoichiometric conditions.  Cocrystal eutectic 
constant, Keu, is the ratio of coformer to drug activities (a) at the eutectic point and can be 
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Keu can also be expressed in terms of the cocrystal to drug solubility ratio (Scocrystal/Sdrug) under 
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Figure 1.12 uses 1:1 and 2:1 cocrystals of nevirapine with acidic coformers as examples to 
illustrate the relationships between Keu and cocrystal SA (Scocrystal/Sdrug). 
 
Figure 1.12. Predicted and experimental values of Keu and cocrystal solubility advantage 
(Scocrystal/Sdrug) for 1:1 NVP-MLE and 2:1 NVP-SAC and NVP-SLC cocrystals.  Keu is a key 
indicator of Scocrystal/Sdrug.  Keu dependence on pH reveals the cocrystal pHmax as well as the 
cocrystal increase in solubility over drug as pH increases.  At pHmax, Keu = 1 for 1:1 cocrystals 
and Keu = 0.5 for 2:1 cocrystals.  Log axes are used due to the large range of values.  Symbols 
represent experimental values.  Numbers next to data points indicate pH at eutectic point or 
equilibrium pH.  Lines were generated according to equations 1.39 and 1.40.  Solid lines 




Keu is an indicator of the thermodynamic stability region(s) in the cocrystal phase 
diagram, and its value is dependent on solution chemistry including cocrystal stoichiometry, 
component ionization, and solution conditions.9, 15, 21  For example, for a 1:1 cocrystal, Keu > 1 
indicates that the cocrystal is more soluble and thermodynamically unstable with respect to the 
drug.15  If Keu value for the 1:1 cocrystal decreases to less than 1, then the thermodynamic 
stability reverses and the cocrystal becomes more stable (less soluble) than the drug.15  When Keu 
= 1 for a 1:1 cocrystal, it indicates that the cocrystal solubility is equal to that of the drug.  
Similarly, for a 2:1 cocrystal, Keu > 0.5 indicates the cocrystal is thermodynamically unstable, 
while Keu < 0.5 indicates the cocrystal is more stable.15  The pH of the solution and the presence 
of solubilizing agents can influence cocrystal Keu, solubility, and thermodynamic stability.23, 25-26, 
53 
Figure 1.13 illustrates the phase solubility diagrams and the eutectic points for a stable 
cocrystal (cocrystal 1) and a metastable cocrystal (cocrystal 2) with respect to drug.15  The 
coformer solubility is assumed to be much higher than that of the drug, and the curves indicate 
cocrystal solubility product behavior as a function of its component concentrations according to 
Ksp = [drug][coformer].  Cocrystal 1 exhibits lower solubility compared to drug, and its solubility 
can be measured by suspending solid cocrystals in solution without concerns for cocrystal to 
drug conversion.  For metastable cocrystal 2, where determining their solubility in solution is 
challenging due to solution-mediated transformation, eutectic measurement provides an 
alternative way to accurately assess the cocrystal’s thermodynamic solubility.  To measure 
cocrystal solubility at the eutectic point, the drug and cocrystal solid phases are suspended in 
solution over sufficient time to allow the system to come to equilibrium.  Once it is confirmed 
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that both drug and cocrystal solid phases are present, the solution concentrations of both drug 
and coformer are measured and used to evaluate cocrystal (stoichiometric) solubility. 
 
Figure 1.13. Schematic phase diagram indicating the eutectic points (*) where cocrystal and 
drug solid are in equilibrium with solution.9  Ceu represents the eutectic concentrations of drug 
and conformer. Two different cocrystals are considered based on their stability with respect to 
drug under stoichiometric conditions: a stable cocrystal (cocrystal 1) and metastable (cocrystal 2) 
where the cocrystal generates supersaturation with respect to drug. Drug solubility is indicated 
and is much lower than the solubility of the conformer, which is not shown.  The circle 
represents the solubility of cocrystals under stoichiometric conditions.  The dashed line 
illustrates stoichiometric concentrations of cocrystal components which dissolution could follow.  




Cocrystal Dissolution and Supersaturation Index (SA) 
Cocrystallization can potentially provide huge solubility enhancements to drugs, but 
supersaturation with respect to the most stable, least soluble component (usually the drug) can 
also lead to solution-mediated conversion from cocrystal to drug.11, 15, 21  The rate of cocrystal 
conversion is affected by factors such as the solubility of drug and cocrystal, dissolution rate, 
supersaturation level with respect to drug, and crystallization rate of drug.9, 15, 21  Cocrystal 
conversion to drug under these conditions can be so rapid that no dissolution advantage can be 
observed.  This can lead to incorrect interpretations of cocrystal dissolution results for a highly 
soluble cocrystal, if the thermodynamic solubility/stability of the cocrystal is not considered.   
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Despite the potential failures of kinetic measurement (dissolution), it is often the first 
approach used when evaluating a cocrystal.  Since most pharmaceutical cocrystals are designed 
to be more soluble than the drug, they are susceptible to solution-mediated phase transformation.  
If conversion occurs during dissolution, cocrystals will not be able to reach its true solubility, as 
figure 1.14 illustrates.  The maximum drug concentration achieved (Cmax) is determined by 
cocrystal dissolution and drug crystallization rate, and not a reliable solubility indicator for 
highly soluble cocrystals.21  If the drug Cmax from a kinetic measurement is used to evaluate the 
solubility of a cocrystal, one could underestimate the cocrystal solubility.  Therefore, the most 
reliable way to evaluate cocrystal solubility is through eutectic measurement, which would 
establish the true solubility and the thermodynamic stability region(s) of the cocrystal.  
Understanding the thermodynamic behavior of a cocrystal allows one to gain insights for its 
kinetic behavior, and manages the conversion rate by manipulating the cocrystal SA. 
 
Figure 1.14. Dissolution methods may provide Cmax for moderately soluble cocrystals and may 
not detect highly soluble cocrystals.  As cocrystals dissolve and drug precipitates, drug 
concentrations can reach a maximum in the case of moderately soluble cocrystals, whereas 
highly soluble cocrystals may undergo such rapid conversion that eludes detection and drug 




 The rate at which a cocrystal converts to drug can be reduced by decreasing the SA of the 
cocrystal with respect to drug.  Solubilizing agents that preferentially solubilize the drug over the 
coformer can be used as additives to reduce cocrystal SA.15, 24, 26, 52  Cocrystal solubilization 
behavior in the presence of solubilizing agents were presented in detail in the previous sections 
and would not be explained again here.  This section instead focuses on the effect of the 
solubilizing agent and reduction of SA on the kinetic dissolution and conversion behavior of 
cocrystals. 
Physiologically Relevant Surfactants 
Physiologically relevant surfactants such as bile salts present in the GI tract can solubilize 
drug and cocrystals.  Cocrystal dissolution in fed-state simulated intestinal fluid (FeSSIF) and in 
aqueous buffer of the same pH (FeSSIF without surfactants) showed how the surfactants present 
in FeSSIF helped to prevent or slow cocrystal conversion to drug and improved dissolution 
performance.  Powder dissolution studies of indomethacin-saccharin (IND-SAC) and piroxicam-
saccharin (PXC-SAC) cocrystals were conducted to determine the impact of SA on the 
dissolution profile, supersaturation during dissolution, and transformation kinetics.  IND-SAC 
was predicted to have SA value of 220 in pH 5 buffer, and this SA value is reduced in FeSSIF to 
be about 57.54  This large reduction of SA lowered the driving force for cocrystal transformation 
in FeSSIF compared to aqueous buffer, and can lead to slower cocrystal conversion to drug. 
IND-SAC achieved and maintained higher drug concentrations during dissolution in 
FeSSIF compared to buffer (figure 1.15).  In the absence of surfactants, IND-SAC achieved peak 
concentration at around 10 minutes, and then rapidly decreased until, by the end of the 
experiment, the IND concentration (0.034 mM) was close to the solubility of IND (0.023 mM).54  
The final solid phases in aqueous buffer showed a mixture of drug and cocrystal, indicating the 
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cocrystal, IND-SAC, had transformed during dissolution.  However, in FeSSIF, the final solid 
phase remains pure IND-SAC, indicating no solution-mediated transformation had occurred 
during the 4-hour dissolution period. 
 
Figure 1.15. IND-SAC dissolution in FeSSIF (red square) and buffer (blue diamonds) at 25°C. 
(a) [IND]T vs time profile for dissolution and (b) supersaturation generated by IND-SAC during 
dissolution ([IND]T/STIND).15, 54 
 
PXC-SAC is 520 times more soluble than PXC drug in buffer, and 370 times more 
soluble than the drug in FeSSIF.54  Similar to IND-SAC dissolutions, powder dissolution of 
PXC-SAC achieved and maintained higher drug concentration in FeSSIF compared to buffer 
(figure 1.16).  The final solid phases indicated that the cocrystal had transformed to PXC(H), 
which is the hydrated form of PXC, in buffer, while in FeSSIF no such transformation was 
observed.  For both IND-SAC and PXC-SAC cocrystals, dissolution in FeSSIF yielded higher 
drug concentrations than in aqueous buffer.  Cocrystal SA values were reduced in FeSSIF 
compared to in buffer, and SA was shown to be a good indicator for cocrystal to drug conversion 
for these systems.  Decrease in cocrystal SA from aqueous buffer to FeSSIF led to sustained 
supersaturation of drug and slower conversions.54  This also shows that very high SA values may 
not be ideal for a supersaturation drug delivery system, such as cocrystals, due to the potential of 
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rapid transformation which could eliminate all dissolution advantage to the parent drug.  A 
balance must be struck between solubility and solution stability in order to fully exploit the 
advantage offered by cocrystals. 
 
 
Figure 1.16. PXC-SAC dissolution in FeSSIF (red squares) and buffer (blue diamonds) at 25°C. 
(a) [PXC]T vs time profile for dissolution from cocrystal and (b) supersaturation generated by 
PXC-SAC during dissolution ([PXC]T/STPXC).15, 54 
 
Synthetic Additives 
Danazol-vanillin cocrystal (DNZ-VAN) has SA value of 280 with respect to DNZ drug in 
aqueous buffer, while DNZ cocrystal with 4-hydroxybenzoic acid (DNZ-HBA) has an even 
higher SA value of 660 in the same media.52, 54  However, this large SA can generate very high 
levels of drug supersaturations in solution, and increase the driving force for cocrystal 
conversation and drug precipitation during dissolution studies.11, 15, 21  In some cases, this can 
result in cocrystals demonstrating no dissolution advantage despite large solubility advantages 
with respect to drug.  Cocrystal SA can be reduced not only by physiologically relevant 
surfactants, but also synthetic drug solubilizing agents.  For example, SA values for DNZ-HBA 
and DNZ-VAN is reduced by FeSSIF surfactants to 28 and 14, respectively.54  When 150mM of 
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Tween 80 was added to FeSSIF media, DNZ-HBA SA value was further reduced to 7.7, and 
DNZ-VAN SA value was reduced to 5.3.54  Powder dissolution of DNZ-VAN in FeSSIF and 
FeSSIF+150 mM Tween 80 demonstrated how the reduction of DNZ-VAN SA values 
influenced the dissolution behavior for this cocrystal (Figure 1.17). 
 
Figure 1.17. DNZ-VAN dissolution in FeSSIF (□) and FeSSIF + 150mM Tween 80 (□) at 
25°C.  (a) [DNZ]T vs time profile and (b) supersaturation generated by DNZ-VAN during 
dissolution ([DNZ]T/SDNZ,T).  The pH of both media had an initial and final pH of 5.00.54 
 
A study of DNZ-VAN cocrystal published in 2013 by Scott Childs and colleagues 
demonstrated the effect of vitamin E-TPGS (D-α-Tocopheryl polyethylene glycol 1000 
succinate) and HPC (Klucel LF Pharm hydroxypropylcellulose) on this cocrystal in vitro and in 
vivo behavior (figure 1.18).11  The “unformulated” (0.5% w/v PVP K-25) suspension of DNZ-
VAN showed little improvement both in in vitro dissolution and in vivo bioavailability when 
compared to the drug polymorph.  However, when 1% w/v of TPGS and 2% w/v of HPC were 
added to solution (formulated), the in vitro dissolution showed improvement for both drug and 
cocrystal.  The “formulated” cocrystal achieved a maximum concentration of 0.35 mg/mL for 
DNZ during dissolution, which is about 5.5 times higher than DNZ drug under the same 
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condition.11 The DNZ bioavailability (plasma concentration AUC) from the cocrystal in 
formulated aqueous suspension was improved by about 10 fold when compared to the drug 
polymorph under the same conditions.11  The results suggested that the presence of the 
solubilizing agents (TPGS and HPC) was able to enhance both DNZ drug and DNZ-VAN 
cocrystal solubility and dissolution, and decreased the rate of cocrystal conversion allowing 
higher bioavailability of DNZ to be achieved. 
 
Figure 1.18. In vitro dissolution data and in vivo plasma concentration for the danazol cocrystal 
and polymorph, shown for the unformulated suspension (a) containing 0.5% PVP K-25 as a 
suspending agent, and the formulated suspension (b) containing 1% TPGS and 2% HPC.11 
 
Effect of Interfacial pH on Cocrystal Dissolution 
For BCS class II drugs (low solubility, high permeability) dissolution is the rate limiting 
step in absorption.2  Based on the Noyes-Whitney and Nernst-Brunner equation, the dissolution 
rate is dependent on the properties of the dissolving components, such as solubility and 
diffusion.55-56  Cocrystals can alter the solubility of the parent drug, which can lead to alterations 
in dissolution rate.  Cocrystal components can have different ionization properties, and one drug 
can form cocrystals with a large variety of coformers with different ionization properties. 
Different ionization properties can alter the pH at the dissolving solid surface (interfacial pH) 
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compared to the bulk solution, which can influence the cocrystal solubility at the interface.57  
Interfacial pH and dissolution rate for a substance is determined by the concentration of the 
species at the interface.  The component concentrations at the dissolving surface are dependent 
on both the solubility and diffusion coefficients of each component.57  Since drug components 
tend to have much higher molecular weight than the coformers, the drug component are expected 
to have slower diffusion than the coformer.  This difference in diffusion coefficients between 
drug and coformer species causes unequal, or non-stoichiometric, concentrations of cocrystal 
components at the dissolving surface, affecting cocrystal solubility.57 
It was found that the dissolution of cocrystal is heavily influenced by the interfacial pH 
instead of the bulk solution pH (figure 1.19).15, 57  Cocrystals with ionizable components can 
modulate the pH microenvironment at the dissolving interface by self-buffering.  Within the 
buffering region of the cocrystal components, the interfacial pH is not expected to change as bulk 
pH changes.  The flux dependence for drug and coformer would follow the interfacial pH 
conditions instead of bulk pH.  Carbamazepine (CBZ) is a non-ionizable drug, and therefore 
cannot alter the interfacial pH from the bulk, and its flux is independent of both bulk and 
interfacial pH.  However, CBZ cocrystals with acidic coformers, saccharin (SAC) and salicylic 
acid (SLC), imparted the ability to buffer the pH at the dissolving interface when the bulk pH is 
increase above the coformer pKa values.57  Without the knowledge of interfacial pH, one might 
expect that the dissolution rates of both cocrystals would be purely dependent on the bulk pH.  
Due to the pH buffering effect of the coformers, the interfacial pH plateaus as bulk pH increases, 




Figure 1.19. Interfacial pH (a) and flux (b) of CBZ (red) and its two cocrystals, CBZ-SAC (blue) 
and CBZ-SLC (orange) predicted using developed mass transport models as a function of bulk 
pH.  The dotted lines in the flux plot represents the flux prediction with the assumption that 
interfacial pH is the same as bulk pH.  The solubility product of CBZ-SLC is 1.00 mM2 and 
CBZ-SAC is 0.4 mM2.  The pKa values of SAC and SLC are 1.6 and 3.0, respectively.57 
 
 
pH-Dependent Dissolution and Bioavailability of Basic Drugs 
 Poorly water soluble basic drugs often rely on the acidity of the gastric compartment to 
dissolve and then be absorbed in the intestine.  Elevated pH in the stomach, either due to disease, 
food intake, or medication, can have serious negative impact on the oral absorption and 
bioavailability for this type of drugs.58-64  The pH-dependent solubility, dissolution, and 
absorption behavior of basic drugs can lead to highly variable and/or poor bioavailability, 
causing difficulty in oral dosing.  
 Ketoconazole (KTZ) is a basic drug with poor aqueous solubility.59, 62-63, 65-66  Figure 1.20 
shows that KTZ was poorly absorbed when administered to healthy volunteers with cimetidine, 
which inhibits stomach acid production, and bicarbonate solution.63  KTZ plasma levels in figure 




Figure 1.20.  Ketoconazole plasma concentrations: Dependency on the gastric pH in healthy 
fasting volunteers.62-63 
 
Another study conducted by Zhou et al. also shows high variability in dissolution and 
absorption behavior of KTZ based on pH.59  KTZ tablets were able to fully dissolve in pH 1.2 
media, but dissolution in pH 4.5 and pH 6.8 media only reached 43% and 4% after one hour.59  
Since it is a BCS class II compound (high intestinal permeability),2, 67 KTZ oral absorption is 
limited by dissolution.  Therefore, good correlation can be seen between its pH-dependent in 
vitro dissolution and in vivo absorption in beagle dogs (figure 1.2).59  Solubility enhancement for 
such drugs can help reduce the negative impact of high pH on its bioavailability.  Strategies to 
increase solubility include the use of additives (surfactants, lipids), amorphous formation, salt 
formation, and cocrystallization.44, 46, 60, 68-69 
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(a) (b)  
Figure 1.21. (a) Ketoconazole pH-dependent dissolution release profile. Test was performed on 
ketoconazole tablets in 1000 mL of 0.1 N HCl, 0.05 M acetate buffer, and 0.05 M phosphate 
buffer, maintained at 37°C at a paddle rotation speed of 50 rpm for 1 h.  Results are plotted as 
mean ± SD (n = 6).  (b) Ketoconazole plasma profile in dogs, pH-dependent absorption.  Results 
are control (no treatment), pentagastrin-, and famotidine-treated dogs shown as mean 
concentration (ng/ml, ± SEM, n = 4).59 
 
Adachi et al. have shown that organic acids can act as pH-modifiers to enhance the in 
vitro dissolution and in vivo bioavailability of KTZ when incorporated as part of the 
formulation.70  In 2013, Martin et al. discovered three cocrystals of KTZ with dicarboxylic acid 
coformers: fumaric acid (FUM), succinic acid (SUC), and adipic acid (ADP), along with a KTZ 
salt with oxalic acid.44  Dissolution in DI water of the cocrystals and salt resulted in much higher 
drug concentrations compared to dissolution with pure drug.44  The solubility and dissolution 
enhancement by these cocrystals (and salt) can lead to improvement in KTZ bioavailability, but 
further study and understanding of their solution behavior are needed to accurately assess their 
true potentials. 
 
Statement of Dissertation Research 
 The purpose of this dissertation is to determine the ability and the mechanism by which 
cocrystals enhance solubility and dissolution behavior of basic drugs under elevated pH 
conditions.  Cocrystals composed of ionizable components have been known to exhibit pH-
dependent solubility behavior, which can differ from that of the parent drug.  There remains a 
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lack of understanding of how pH influences cocrystal solubility, solubility advantage (SA), and 
thermodynamic stability relative to drug.  Such knowledge is critical for the proper evaluation of 
a cocrystal both in vitro and in vivo.  The main objective of this work is to develop mathematical 
models that describe cocrystal solubility behavior and establish thermodynamic parameters to 
explain cocrystal kinetic behavior including dissolution and solution-mediated conversion. 
 Chapter 2 investigates the influence of solution pH on the solubility and dissolution 
behavior of three cocrystals composed of a basic drug and acidic coformers in 1:1 stoichiometry: 
ketoconazole-adipic acid (KTZ-ADP), ketoconazole-fumaric acid (KTZ-FUM), and 
ketoconazole-succinic acid (KTZ-SUC).  This chapter aims to show how cocrystallization can 
help reduce pH-sensitivity and improve solubility under high pH conditions for the basic drug.  
Previous work has shown that cocrystals with ionizable components can exhibit different 
solubility-pH behavior compared to the parent drug, and mathematical models have been derived 
to describe their solubility.23, 25, 41, 43  KTZ cocrystals have a basic and an acidic component, and 
they are expected to behave quite differently from KTZ in aqueous solution.  Mathematical 
equations that predict the solubility for KTZ drug and cocrystals were derived based on solution 
equilibria that consider component ionization and cocrystal dissociation.  The equations can 
quantitatively predict drug and cocrystal solubility under a wide range of pH conditions, and the 
predicted values were validated with experimental solubility values.  The cocrystals were found 
to exhibit very different solubility-pH profiles compared to the drug, leading to the existence of 
pHmax for each cocrystal.  Above pHmax, KTZ cocrystals gain solubility and dissolution 
advantage over drug.  The ability of these cocrystals to generate and sustain supersaturation of 
the drug during dissolution at pH > pHmax was also investigated in this chapter. 
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 Chapter 3 studies the combined effect of pH and drug solubilizing agents, specifically 
physiologically relevant surfactants, on KTZ cocrystal solubility and dissolution behavior.  
Previous work has shown that preferential solubilization of lipophilic drug over hydrophilic 
coformers can lead to reduced cocrystal SA values and impact drug supersaturation behavior 
during dissolution in surfactant containing media.15, 24, 42, 50, 52  Cocrystal and drug solubility 
equations from Chapter 2 were expanded to take into account micellar solubilization of drug and 
coformer components.  The predictions from the equations are in excellent agreement with 
experimentally measured solubility values.  Cocrystal solubility enhancement by surfactant 
containing media (FaSSIF and FeSSIF) from the corresponding blank aqueous buffers was less 
pronounced than that of the pure drug.  Decreases in the cocrystal SA values, also referred to as 
the supersaturation index of the cocrystal, can lead to slower solution-mediated transformation of 
cocrystal to drug and sustained supersaturation of drug during dissolution. 
 Chapter 4 evaluates the ability of KTZ cocrystals to generate and maintain drug 
supersaturation during pH-shift dissolution simulating conditions along the gastrointestinal tract, 
and assesses the potential of cocrystals to improve KTZ oral absorption under elevated gastric 
pH conditions.  KTZ typically has good oral absorption when gastric pH is low, but it is known 
to perform poorly in vitro and in vivo when pH becomes elevated.59, 63  KTZ drug and cocrystal 
dissolution behavior under different fasting gastric pH conditions were evaluated based on a 
novel pH-shift microdissolution method published by Mathias et al.71  When initial (gastric) pH 
is low (pH 2), the drug and cocrystals have similar dissolution profiles that indicate full 
dissolution occurred in the initial media.  Cocrystal dissolution studies conducted under high 
fasting gastric pH condition (initial pH 6) resulted in much higher KTZ solution concentrations 
and about 3-fold increase in drug AUC compared to pure drug dissolution.  Cocrystal dissolution 
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behavior demonstrated less sensitivity to solution conditions compared to the parent drug, and 
this can lead to reductions of the negative impact from elevated pH on drug bioavailability. 
 The conclusions of this dissertation and future directions for this research are discussed in 
Chapter 5.  Several of the chapters are being prepared for publication.  Chapter 2 has been 
adapted and submitted for publication in Crystal Growth and Design 2017. 
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COCRYSTALS MITIGATE NEGATIVE EFFECTS OF HIGH pH ON SOLUBILITY 
AND DISSOLUTION OF A BASIC DRUG 
 
Introduction 
Solubility and permeability are the major factors that govern the oral absorption of a drug 
according to the Biopharmaceutical Classification System (BCS).1  For BCS class II drugs, 
which have low solubility and high permeability, drug dissolution in vivo is the rate controlling 
step in drug absorption.1  Much focus has been placed on the enhancement of drug solubility in 
order to improve dissolution and bioavailability, and some of the approaches include amorphous 
forms, salts, and cocrystals.2-6   
These supersaturating drug delivery systems generate supersaturated solutions with 
respect to the crystalline parent drug, which can in turn enhance absorption and bioavailability if 
sustained over sufficient period of time.7  Cocrystals have gained much interest in recent decades 
due to their capability to incorporate both ionizable and non-ionizable drug/coformer 
components (unlike salts), their crystalline stability advantage over amorphous solids, and their 
ability to impart or alter solubility-pH dependence with coformers of different ionization 
properties.5, 8-10   
While cocrystals are capable of increasing drug solubility by orders of magnitude, they 
often exhibit different ionization and solubilization behavior from their parent drugs, which alter 
the solubility enhancement by cocrystals based on solution conditions.11-14  Therefore, in order to 
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comprehend cocrystal solubility, it is important to understand cocrystal solution phase 
interactions, such as component ionization and solubilization by additives.  Previous work by our 
laboratory has shown that cocrystallization with saccharin has imparted solubility-pH 
dependence to non-ionizable drug carbamazepine and altered this dependence for acidic drug 
indomethacin.9  Indomethacin-saccharin cocrystal went from being 13 times more soluble than 
the drug at pH 1 to 65 times more soluble at pH 3, while carbamazepine-saccharin cocrystal 
solubility advantage over carbamazepine dihydrate increased from 2 to 10 between pH 1 and 3.9  
These two cocrystals demonstrate that cocrystal solubility advantage over parent drug is not a 
constant value, but it is dependent on solution conditions such as pH. 
Cocrystals of gabapentin and nevirapine can be more or less soluble than their parent 
drugs depending on solution pH.10, 15  These cocrystals exhibit pHmax values, which is a solubility 
transition point between drug and cocrystal based on solution pH.8, 10, 15  Similar to salts, pHmax is 
a parameter that identifies stability regions of a cocrystal and its parent drug.2, 8, 16  At the pHmax, 
cocrystal and drug solubilities are equal, and both cocrystal and drug solid phases are 
thermodynamically stable and coexist in equilibrium with solution.8  Cocrystals of the basic drug 
nevirapine with acidic coformers are less soluble than the drug below the pHmax, but become 
more soluble above the pHmax.15  The nevirapine cocrystal study demonstrated that cocrystal 
solubility advantage over drug can be fine-tuned by changing solution pH.15 
Weakly basic drugs often rely on low gastric pH to dissolve prior to transfer to the small 
intestine for absorption into the systemic circulation.7, 17-18  Thus, elevated gastric pH, whether 
due to disease state, food, or medication, can negatively impact this type of drug’s absorption 
and efficacy.18-21  Ketoconazole (KTZ) is one such drug.  KTZ is a lipophilic, BCS class II drug 
and is able to dissolve to a much higher extent under low pH conditions (< 3) compared to high 
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or neutral pH conditions.1, 19, 22-23  Its poor solubility at neutral pH (~7) and high solubility-pH 
dependence result in variable oral absorption due to pH effect.20, 22-23  Drug label of oral KTZ 
tablets warns that reduction in gastric acidity either due to achlorhydria condition caused by 
certain diseases or medications that suppress production or neutralize gastric acid can adversely 
affect the absorption of the drug.24  Considering its use as an anti-fungal agent and that diseases 
such as gastric cancer and AIDS can cause elevated gastric pH conditions, it is essential to 
address the solubility-pH issue in order to ensure efficacy during treatment.25-27 
In order to enhance its poor aqueous solubility, three new cocrystals and a salt of KTZ 
with dicarboxylic acids were synthesized and published by Martin et al. in 2013.28  The three 
cocrystals are ketoconazole-fumaric acid (KTZ-FUM), ketoconazole-succinic acid (KTZ-SUC), 
and ketoconazole-adipic acid (KTZ-ADP), all of which are of 1:1 stoichiometric ratio.28  In this 
fine article, the authors not only conducted solid-state characterization for the cocrystals (and 
salt) but also studied their dissolution behavior in water.  The cocrystals were found to achieve 
much higher solution concentrations of KTZ (up to 100 times) during dissolution than that of the 
parent drug, and, somewhat surprisingly to us, none of the cocrystals transformed in solution 
during the dissolution experiment.28  Highly soluble cocrystals are known to undergo solution-
mediated conversion back to less soluble drug forms, which is why the most soluble cocrystal 
may not always generate high levels of supersaturation in solution.8, 29  While studying this 
article we noticed that solution pH was not considered in their analysis, and this is important 
since pH is known to have profound effects on the solubility of ionizable drugs and cocrystals.8-9, 
11-12, 30 
This study focuses on the effect of pH on KTZ cocrystal solubility and dissolution.  The 
study aims to (1) develop and validate mathematical models for predicting the solubility of KTZ 
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cocrystals, (2) compare solubility-pH behavior of cocrystals and pure drug, (3) determine the 
dissolution advantage of cocrystals as a function of pH, and (4) relate the dissolution-precipiation 
behavior of cocrystals to their solubility advantage, SA = Scocrystal/Sdrug. 
 
Materials and Methods 
Materials 
Ketoconazole (lot # BS1203355108, 98% purity) was purchased from Bosche Scientific 
(New Brunswick, NJ) and used as received.  Adipic acid (lot # 06807BE, 99% purity), succinic 
acid (lot # 037K0021, 99% purity), fumaric acid (lot # 09426EE, 99+% purity), acetic acid (lot # 
074K3658, 99%), sodium acetate anhydrous (lot # 100K0272), dipotassium hydrogen phosphate 
(lot # 103H0287, ACS reagent), and sodium chloride (lot # 094K0183, ACS reagent) were 
purchased from Sigma-Aldrich (St. Louis, MO) and used as received.  
HPLC grade methanol, HPLC grade 2-propanol, sodium phosphate monobasic (lot # 
017316), and hydrochloric acid (lot # 2AJK15038, ACS grade) were purchased from Fisher 
Scientific (Fair Lawn, NJ).  Acetone (ACS reagent 99.5%) and phosphoric acid (lot # B0506524, 
85+%) were purchased from Acros Organics (NJ) and used as received.  Trifluoroacetic acid 
(spectrophometric grade, 99%) was purchased from Aldrich Company (Milwaukee, WI).  
Sodium hydroxide pellets was purchased from J.T. Baker (Philipsburg, NJ).  Water used in this 
study was filtered through a double deionized (DI) purification system (Milli Q Plus Water 
System) from Millipore Co. (Bedford, MA). 
Cocrystal Synthesis 
Cocrystals were prepared by reaction crystallization method at room temperature.31-32  
KTZ-FUM and KTZ-SUC were synthesized in acetone.  KTZ-ADP was synthesized in 2-
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propanol.  Full conversion of drug to cocrystal was observed between 24 to 48 hours.  The solid 
phases were verified by X-ray powder diffraction (XRPD) and differential scanning calorimetry 
(DSC), and the stoichiometries were verified by HPLC. 
Media Preparation 
Solubility media:  
Phosphate buffers at pH 2.02 (± 0.02) and 8.04 (± 0.01) were prepared at concentrations 
of 12 mM and 100 mM, respectively, with the appropriate amount of phosphoric acid and 
dipotassium hydrogen phosphate.  Acetate buffer at pH 5.00 (± 0.01) and concentration of 100 
mM was prepared with sodium acetate anhydrous and acetic acid.  pH 1.01 (± 0.01) HCl solution 
(100 mM) was prepared by diluting concentrated hydrochloric acid solution (~12 M).  All 
buffers were prepared at room temperature with DI water filtered by Milli Q Plus Water System.  
1 M NaOH and 1 M HCl solutions were used to adjust the pH of the buffer to target pH. 
Dissolution media:  
Dissolution media were prepared based on the conditions of fasted gastric, fasted 
intestinal, and fed intestinal pH published by Jantratid et al. without surfactants and pepsin.33  pH 
1.60 (± 0.01) buffer (34 mM) was prepared with the appropriate amount of NaCl and HCl 
solution.  pH 5.00 (± 0.03) acetate buffer (144 mM) was prepared with the appropriate amount of 
NaOH (pellets), acetic acid, and NaCl.   pH 6.50 (± 0.04) phosphate buffer (29 mM) was 
prepared with appropriate amount of NaOH (pellets), sodium phosphate monobasic 
(NaH2PO4•H2O), and NaCl.  The pH values of all dissolution media were adjusted to target pH 
with 1 M NaOH and 1 M HCl solutions.  All media were prepared at room temperature with DI 





Drug solubility was measured by adding excess solid to 3 mL of solution media.  The 
solutions were magnetically stirred and were kept in water bath at 25 ± 0.1°C over 96 hours.  
0.5mL aliquots of the suspension were sampled every 24 hours.  Collected samples were filtered 
via centrifuge through a 0.45 µm pore cellulose acetate membrane, and the pH of the solutions 
was measured.  The concentrations of KTZ in the solutions were analyzed by HPLC after proper 
dilutions with the mobile phase. 
Cocrystal Solubility 
Method 1: 
Equilibrium solubility of the KTZ cocrystals can be directly measured when the solution 
pH is below 3.  Excess solid for each cocrystal was added to 3 mL of solution media, and the 
solution was magnetically stirred in water bath at 25 ± 0.1°C up to 96 hours.  0.5mL aliquots of 
the suspension were sampled every 24 hours and filtered via centrifuge through a 0.45 µm pore 
cellulose acetate membrane.  The solid phases were analyzed by XRPD and DSC to ensure only 
cocrystal solid phases were present.  The solution pH values were measured, and the cocrystal 
component concentrations were analyzed by HPLC after appropriate dilution with mobile phase. 
Method 2: 
At solution pH above 3, the equilibrium solubility of the cocrystals was determined at the 
eutectic point, where the drug and cocrystal solid phases are in equilibrium with the solution.5, 8, 
34  The eutectic points are approached by cocrystal dissolution, where 150 – 200 mg of cocrystal 
and 50 – 80 mg of KTZ were suspended in 3 mL of solution, and cocrystal precipitation, where 
50 – 80 mg of cocrystal and 100 – 150 mg of KTZ were suspended in 3 mL of near saturated 
solution of coformer.  The solutions were kept in water bath at 25 ± 0.1°C and magnetically 
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stirred for up to 96 hours.  Solution samples (0.5 mL) were collected every 24 hours and were 
filtered via centrifuge through a 0.45 µm pore cellulose acetate membrane, and the pH values 
were measured.  The solid phases were analyzed by XRPD and DSC to confirm both drug and 
cocrystal solid phases were present, indicating the solutions were at the eutectic point.  The 
filtered solutions were then analyzed by HPLC after proper dilutions with the mobile phase. 
Cocrystal and Drug Powder Dissolution  
 Powder dissolution of drug and cocrystal were conducted using an overhead stirrer with a 
glass propeller at 150 rpm over 3 hours.  30 mL of dissolution media were used to dissolve 30 
mg of KTZ drug or 30 mg KTZ-equivalent amount of cocrystal.  Both drug and cocrystal 
powders were sieved through mesh screens and particles between 106 – 125 µm size was used.  
The dissolution experiments were conducted in a water bath with temperature of 24.5 (± 0.5) °C. 
Solution pH was measured at the beginning and at the end of each dissolution run.  Aliquots of 
0.5 mL were taken with syringe at appropriate time points for up to 180 minutes (min). The 
solution samples were filtered with syringe filter with PVDF membrane of pore size of 0.45 µm. 
The solution concentrations of drug and coformers were analyzed with HPLC after proper 
dilution with mobile phase. 
High Performance Liquid Chromatography (HPLC) 
Solution concentrations of the drug and coformer were analyzed by a Waters HPLC 
equipped with a UV spectrometer detector.  A Waters Atlantis C18 column with the dimension 
of 250 x 4.6 mm and 5 µm particle size was used for separation at ambient temperature.  The 
flow rate was set at 1mL/min and the injection volume was 20 µL.  For KTZ-ADP and KTZ-
FUM cocrystals, the mobile phase used was composed of 60% methanol and 40% water with 
0.1% trifluoroacetic acid (TFA).  For KTZ-SUC cocrystal, different methods were used to 
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analyze each component due to poor separation of SUC peak from the solvent peak.  The KTZ 
component of KTZ-SUC cocrystal was analyzed using mobile phase composed of 60% methanol 
and 40% water with 0.1% TFA.  The SUC component was analyzed using a gradient method 
with flow rate of 1mL/min starting with mobile phase composed of 25% methanol and 75% 
water with 0.1% TFA.  The composition changed to 80% methanol and 20% water with 0.1% 
TFA after 2.5 min then reverted back to 25% methanol and 75% water with 0.1% trifluoroacetic 
acid after 6 min. The wavelengths used for the analytes were as follows: 230 nm for KTZ, 220 
nm for FUM, and 210 nm for SUC and ADP. 
X-Ray Powder Diffraction (XRPD) 
A Rigaku Miniflex X-ray diffractometer (Danverse, MA) using Cu-Kα radiation, a tube 
voltage of 30kV, and a tube current of 15mA was utilized for analysis and characterization of 
solid phases.  Measurements were taken from 5° to 40° at a continuous scan rate of 2.5°/min. 
Thermal Analysis 
TA instrument differential scanning calorimetry (DSC) (Newark, DE) was used to 
analyze the collected solid phases from the solubility studies, after they were dried at room 
temperature.  The heating rate of the experiments was 10°C/min under dry nitrogen atmosphere.  
Standard aluminum sample pans and lids were used for these measurements. 
 
Results and Discussion 
Cocrystal Experimental Solubility 
Solubility of drug and cocrystal were measured under different solution pH conditions.  
Solution concentrations of drug and coformer at equilibrium (table 2.1) were used to determine 
stoichiometric cocrystal solubility (Scc,T) at the corresponding pH with the following equation: 
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, [ ] [ ]cc T T TS KTZ CF=                 (2.1) 
where [KTZ]T and [CF]T represent total KTZ and total coformer concentrations, respectively. 
The subscript, T, indicates that the concentration includes all non-ionized and ionized species of 







































Table 2.1.  Cocrystal solubilities determined from KTZ and coformer concentrations in 























































































































































a. Drug concentration is the drug solubility in solutions saturated with respect to 
cocrystal and drug phases.  
b. Determined using equation 2.1. 
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KTZ concentrations decreased with increasing solution pH, while the acidic coformer 
solution concentrations increased with increasing pH.  The self-buffering effect of the basic drug 
and acidic coformers caused the pH at equilibrium to fall within a narrower range (2.03 – 5.05) 
compared to the initial pH of the media (1.01 – 8.04).  As the cocrystals dissolved in media of 
pH 1 and 2, high degrees of ionization of the basic drug elevated the pH of the solution, and the 
acidic coformers decreased the solution pH when the cocrystals were dissolved in pH 5 and pH 8 
buffers.  In this study, the equilibrium pH values have shown to change as much as 3.5 units 
from the initial media pH.  This illustrates the importance of pH measurement during solubility 
studies involving ionizable components. 
At pH < 3, KTZ cocrystals are less soluble than the drug and thermodynamically stable in 
solution.  Cocrystal solid phase can be suspended under those pH conditions without the risk of 
conversion to drug.  As pH increases to ≥ 4, the cocrystals become more soluble and less stable, 
which can lead to supersaturation and precipitation of the drug.  This can result in 
underestimation of cocrystal solubility if only drug concentrations were measured.  Measuring 
both drug and coformer concentrations at the cocrystal-drug eutectic point provides a simple 
alternative to assess cocrystal solubility.  To confirm eutectic point was reached, one needs to 
ensure both drug and cocrystal solid phases are present at equilibrium.  The solid phases in table 
2.1 represent those present at equilibrium.  The stoichiometric solubility of a cocrystal can then 
be calculated with component (non-ionized + ionized) eutectic concentrations using equation 2.1. 
One may notice in table 2.1 that the drug and coformer concentrations measured in HCl 
solution (initial pH 1.01) were similar but not identical.  In theory, dissolution of a 1:1 molar 
ratio cocrystal in the absence of conversion should result in the same drug and coformer solution 
concentrations.  The small discrepancies could be from measurement errors, but they could also 
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come from impurities in the cocrystals used.  This impurity refers to small amount of excess 
drug/coformer present to the cocrystal stoichiometry, and this can impact cocrystal solubility due 
to common ion effect.   
The purity of the cocrystals used in the solubility studies were analyzed with XRPD, 
DSC, and HPLC.  DSC and XRPD showed only cocrystal solid phases and did not indicate any 
impurities in terms of excess drug or coformers.  HPLC analysis of the cocrystals was also used 
to check stochiometric ratios of drug and coformer.  KTZ-FUM and KTZ-SUC drug to coformer 
ratio were found to be between 0.95 – 1.05 by HPLC.  KTZ-ADP was found to have drug to 
coformer ratio of about 1.27 ± 0.02 by HPLC.  Coformers ADP and SUC have poor UV 
absorbance which resulted in larger uncertainties in their concentrations analyzed by HPLC.  
SUC has shown approximately 2.5% error and ADP has about 3.8% error of their standard 
curves at the concentrations used for the analysis in the solubility study.  FUM and KTZ standard 
curves has about 0.3% error at their concentrations used for analysis.  By measuring both 
component concentrations and using equation 2.1 to determine cocrystal solubility, one can 
minimize errors caused by these analytical uncertainties and cocrystal impurities. 
Inaccuracy in cocrystal solubility evaluation can result from (1) solution-mediated 
transformation of cocrystal to less soluble form and (2) common ion effect imparted by 
impurities in the form of one component in excess to its stoichiometry.  These common problems 
can be avoided by assessing cocrystal solubility at the eutectic point and using both component 
concentrations to calculate the stoichiometric cocrystal solubility. 
Cocrystal Solubility as a Function of Ksp, pKa, and pH 
Pharmaceutical cocrystals include a wide range of molecular components, and cocrystal 
solubility behavior can vary greatly based on component physicochemical properties.  The 
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following equations were derived to describe KTZ drug and cocrystal solubility with 
consideration of solution pH, component ionization, and cocrystal dissociation.  The details of 
their derivation can be found in appendix 2A. 
 KTZ drug solubility as a function of solution pH can be described by 
2, 1, 2,- -2
, ,0[ ] (1 10 10 )a KTZ a KTZ a KTZ
pK pH pK pK pH
drug T T KTZS KTZ S
+= = + +        (2.2) 
where Sdrug,T represents KTZ solubility, [KTZ]T is the total (ionized + non-ionized) KTZ 
concentration in solution, SKTZ,0 is the non-ionized KTZ concentration in solution, and pKa,KTZ 
represents KTZ ionization constant. 
For a 1:1 cocrystal of KTZ and dicarboxylic acid coformer, the solubility can be 
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where Scc,T is the cocrystal solubility, Ka,CF represents the ionization constant for the coformer, 
Ksp is the solubility product of the cocrystal.  With equations 2.2 and 2.3, KTZ cocrystal and 
drug solubilities can be quantitively predicted as a function of pH, SKTZ,0, pKa, and Ksp (figure 
2.1).  Parameter values of SKTZ,0 and Ksp can be found in table 2.2. 
Ksp describes the dissociation of cocrystal in solution into its components, and it is 
defined as the product of the non-ionized drug and coformer concentrations for a 1:1 cocrystal.5, 
32   
[ ][ ]spK KTZ CF=               (2.4) 
In the absence of other solution phase interactions, cocrystal solubility is governed by 
Ksp, pKa of the components, and solution pH.11  pKa values for KTZ and coformers (ADP, FUM, 
and SUC) are reported and can be obtained from literature.35-38  Cocrystal Ksp values were 
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determined by linear regression based on equation 2.3 and are listed in table 2.2.  Details can be 
found in appendix 2B. 
 
Table 2.2.  Cocrystal Ksp and intrinsic solubilities of cocrystals and drug at 25°C.  
Drug/Cocrystal Kspa (M2) R2 pKspb 
  S0 a,c 
(mM) 
KTZ -- -- -- a4.7(±0.2) x 10-3 
 KTZ-ADP 3.4(±0.2) x 10-8 0.91 7.5 c1.84 (±0.05) x 10-1 
KTZ-SUC 2.7(±0.1) x 10-8 0.77 7.6 c1.64 (±0.03) x 10-1 
KTZ-FUM 1.5(±0.2) x 10-9 0.99 8.8 c3.9 (±0.3) x 10-2 
a. Ksp and SKTZ,0 determinations are shown in appendix 2B. 
b. pKsp = -log(Ksp). 
c. SKTZ,0 is the intrinsic (non-ionized) solubility of KTZ; Cocrystal (1:1) intrinsic solubility 
calculated from Scc,0 = �Ksp. 5 
Out of the three cocrystals studied, KTZ-ADP has the highest Ksp, while KTZ-FUM has 
the lowest Ksp.  In the absence of ionization, larger Ksp (or smaller pKsp) indicates a more soluble 
cocrystal.5   pKsp values of 1:1 cocrystals of BCS class II drugs have been reported to be in the 
range of 1 to 9.39  S0 refers to the solubility of cocrystal and drug under non-ionized conditions.  
All three cocrystals exhibited higher S0 values (between 8 and 39 times) compared to the drug.   
Ionizable coformers, such as the acidic coformers of KTZ cocrystals, can alter cocrystal 
solubility behavior from that of the drug in aqueous environments.  The influence of different 
ionization properties of drug and coformer on KTZ cocrystal solubility with respect to solution 




Figure 2.1. Predicted (lines) and experimental (symbols) KTZ cocrystal and drug solubilities as 
a function of pH.  Predicted solubility-pH curves of KTZ drug and cocrystals were generated 
using equations 2.2 and 2.3 with parameters of component pKa values (table 2.3), SKTZ,0, and 
cocrystal Ksp values (table 2.2).  Drug is represented in black and symbol “◊”, KTZ-ADP is 
represented in blue and symbol “○”, KTZ-FUM is represented in green and symbol “□”, KTZ-
SUC is represented in red and symbol “∆”.  Cocrystal stoichiometric solubility values were 
determined experimentally using equation 2.1.  pH values correspond to equilibrium pH.  The 
standard errors for experimental solubility values are less than 4% and are within the 
experimental data points. 
 
Solubility-pH profiles for KTZ drug and cocrystals were generated using equations 2.2 
and 2.3 with corresponding parameter values of Ksp, pKa, and SKTZ,0 (figure 2.1).  The cocrystal 
and drug solubility values obtained experimentally were plotted as data points and compared to 
the predicted solubility values.  Excellent agreement between experimental and predicted 
solubility values demonstrated that the equations are effective in predicting drug and cocrystal 
solubilities. 
Figure 2.1 illustrates the influence of solution pH on the solubility of KTZ and its three 

























increases, while the cocrystals show U-shaped solubility-pH dependence due to the presence of 
both basic and acidic components.  The acidic coformers caused the solubility of the cocrystals 
to be elevated at higher pH when compared to the parent drug.  Cocrystallization with acidic 
coformers altered the solubility-pH profile of KTZ and reduced the magnitude of solubility 
variations as a result of solution pH.  The self-buffering effect of the basic drug and acidic 
coformer narrowed the pH range in which the cocrystal equilibrium solubility could be 
experimentally determined.  However, equation 2.3 enables quantitative prediction of cocrystal 
solubility at any pH, giving valuable insights for cocrystal solubility beyond the experimentally 
measurable pH range. 
KTZ cocrystal solubility as a function of pH is largely governed by Ksp values and 
component ionization properties.  KTZ-ADP and KTZ-SUC cocrystals have relatively similar 
Ksp and coformer pKa values, which leads to similar solubility-pH behavior of the two cocrystals 
in the pH range studied.  As pH increases to above 4.5, the difference between KTZ-ADP and 
KTZ-SUC solubilities becomes more noticeable as the effect of coformer ionization becomes 
more prominent.  KTZ-FUM has the smallest Ksp out of the three cocrystals, and this contributed 
to it having the lowest solubility at pH < 4.  However, because fumaric acid is the most acidic 
coformer (lowest pKa values) and ionizes to a higher extent compared to the other coformers as 
pH increases, the fumaric acid cocrystal showed an earlier and steeper increase in solubility with 
pH.  This resulted in KTZ-FUM solubility exhibiting the most variability with pH out of the 
three cocrystals. 
In order to understand cocrystal solution behavior, one must first realize that cocrystal 
solubility is not a single number, and that it can exhibit drastically different behaviors than the 
parent drug based on the component properties.  Cocrystal solubility is highly sensitive to 
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solution environment, in this case, the pH.  KTZ cocrystals exhibited lower, equal, or higher 
solubility than the drug as solution pH increased from 1.5 to 7 in figure 2.1.  This indicated the 
existence of solubility transition point, called the pHmax, which is the point of reversal in 
solubility advantage and relative stability for a cocrystal and its drug.10, 15, 29  Cocrystal solubility 
advantage at pH above pHmax can lead to improvements in dissolution and oral absorption of 
KTZ in patients with elevated gastric pH.22-23  The implications of this transition point will be 
discussed in more detail in the following section. 
Cocrystal Solubility Advantage and pHmax 
The intersections of cocrystal and drug solubility curves in figure 2.1 correspond to the 
pHmax of each cocrystal.  pHmax is a solubility transition point with respect to pH, meaning that 
both cocrystal and drug solid phases coexist in equilibrium with solution at that particular pH 
value.8, 11-12, 30  This is analogous to pHmax in salts, where the salt and free base/acid solubility 
curves intersect, and at which point both free base/acid and salt solid forms coexist in 
equilibrium with solution saturated with respect to both species.2, 40-42 
pHmax identifies pH regions where a cocrystal is thermodynamically stable and where it 
can generate supersaturation with respect to drug solubility.8, 12, 15, 30  KTZ cocrystals are 
thermodynamically stable at pH < pHmax, and they are less soluble than the parent drug under 
those solution conditions.  As pH increases and surpasses pHmax, the relative stability of cocrystal 
and drug is reversed as the cocrystal becomes the more soluble form.  KTZ cocrystal pHmax and 
the corresponding solubility values (table 2.3) were determined using MATLAB, with equations 
2.2 and 2.3 and parameters including SKTZ,0, cocrystal Ksp, and component pKa values.  Cocrystal 





Table 2.3.  KTZ cocrystal pHmax, Scc,pHmax, and component pKa values. 





KTZ-ADP 3.6 8.2 a4.44, 5.44 
3.17, 6.63 KTZ-SUC 3.6 7.8 b4.00, 5.24 
KTZ-FUM 3.8 4.2 b2.85, 4.10 
a.  From reference38. 
b. From reference36. 
c. From reference35. 
 
KTZ cocrystal pHmax values range from 3.6 to 3.8.  The location of pHmax is dependent on 
cocrystal Ksp and component pKa values.  KTZ-ADP and KTZ-SUC cocrystals exhibited similar 
pHmax due to their similar Ksp and coformer pKa.  KTZ-FUM cocrystal has the lowest Ksp and 
coformer pKa values out of the three cocrystals, and the combination resulted in a slightly higher 
pHmax for KTZ-FUM than the other cocrystals. 
 The influence of cocrystal Ksp/pKsp and coformer pKa on cocrystal pHmax is illustrated in 
the following figures generated using initial parameter values from KTZ-FUM (figure 2.2), 
KTZ-ADP (figure 2.3), and KTZ-SUC (figure 2.4).  For simplicity, only the first pKa of the 
coformers were altered in each figure to show the effects.  The figures show that pHmax values 
are directly proportional to changes in pKsp and coformer pKa, while the Scc,pHmax values exhibit 




(a)  (b)  
Figure 2.2.  Influence of (a) cocrystal pKsp, where pKsp = − log(Ksp) and (b) coformer pKa 
(pKa1,CF) on KTZ-FUM solubility and pHmax.  Drug and cocrystal solubility curves were 
generated using equations 2.2 and 2.3 with the initial parameter values of SKTZ,0 = 4.7 x 10-6 M 
and KTZ-FUM pKsp/Ksp, pKa,KTZ, and pKa,CF values listed in tables 2.2 and 2.3. pKsp value 
changes by 1 for every magnitude (10 fold) change of Ksp.  Only pKa1,CF is altered while pKa2,CF 
and pKa,KTZ values are held constant in plot (b). 
 
KTZ-FUM and its corresponding pKsp and pKa values were used in figure 2.2 to illustrate 
the effect of these parameters on cocrystal pHmax.  With each unit change in pKsp, the pHmax 
changed by ~ 0.4 unit, and Scc,pHmax changed between 3 - 3.5 fold, where Scc,pHmax value is more 
sensitive to decrease of pKsp.  One unit change of pKa1,CF resulted in ~ 0.4 unit change of pHmax 











































 (a)  (b)  
Figure 2.3.  Influence of (a) cocrystal pKsp, where pKsp = − log(Ksp), and (b) coformer pKa 
(pKa1,CF) on KTZ-ADP solubility and pHmax.  Drug and cocrystal solubility curves were 
generated using equations 2.2 and 2.3 with the initial parameter values of SKTZ,0 = 4.7 x 10-6 M 
and KTZ-ADP pKsp/Ksp, pKa,KTZ, and pKa,CF listed in tables 2.2 and 2.3. Only the first pKa of the 
coformer (pKa1,CF) was altered in plot (b) while pKa2,CF remained unchanged. 
 
The degree of pHmax and Scc,pHmax shift per unit change of pKsp and pKa are not the same 
for all cocrystals.  KTZ-ADP in figure 2.3 shows that one unit change in pKsp leads to ~ 0.7 unit 
change in pHmax and 7 – 9 fold change in Scc,pHmax.  Decreasing pKsp has a larger impact on the 
value of Scc,pHmax.  For this cocrystal, the effect of increasing pKa1,CF on the pHmax and Scc,pHmax 
values is less pronounced in comparison to decreasing pKa1,CF.  One unit increase of pKa1,CF only 
changes pHmax and Scc,pHmax by ~ 0.03 unit and ~ 1.1 fold, whereas one unit decrease of pKa1,CF 









































(a) (b)  
Figure 2.4.  Influence of (a) cocrystal pKsp, where pKsp = − log(Ksp), and (b) coformer pKa 
(pKa1,CF) on KTZ-SUC solubility and pHmax.  Drug and cocrystal solubility curves were 
generated using equations 2.2 and 2.3 with the initial parameter values of SKTZ,0 = 4.7 x 10-6 M 
and KTZ-ADP pKsp/Ksp, pKa,KTZ, and pKa,CF listed in tables 2.2 and 2.3. Only the first pKa of the 
coformer (pKa1,CF) was altered in plot (b) while pKa2,CF remained unchanged. 
 
KTZ-SUC pKsp and pKa,CF values are similar to those of KTZ-ADP, leading to the two 
cocrystals exhibiting very similar behavior.  Figure 2.4 shows that for every unit change in KTZ-
SUC pKsp, the pHmax changes by ~ 0.6 and Scc,pHmax changes by 5 – 8 fold.  One unit increase of 
pKa1,CF causes ~ 0.1 and ~ 1.3 fold changes in pHmax and Scc,pHmax values, and decreasing pKa1,CF 
by the same magnitude leads to ~ 0.3 and ~ 2 fold changes in those values, respectively. 
The figures 2.2, 2.3 and 2.4 show that altering pKsp lead to parallel shifts of cocrystal 
solubility curves.  Increasing pKsp decreases the minimum cocrystal solubility value but have no 
influence on the pH at which it occurs.  Changing coformer pKa (pKa1,CF) alters the curvature of 
cocrystal solubility-pH profiles, where increasing pKa1,CF led to lower values of minimum 
cocrystal solubility and delayed its occurrence with respect of pH. 
Figure 2.5 illustrates the cocrystal solubility advantage over drug, defined as the ratio of 
cocrystal and drug solubility (SA = Scc/Sdrug), in the pH range between 1.5 and 7.  Cocrystals 









































above the pHmax, the cocrystals gained the ability to generate supersaturation with respect to the 
parent drug, and this can potentially lead to superior dissolution and even in vivo behavior.  The 
cocrystal SA is expected to change quite dramatically with pH, as one can observe from figure 
2.5.  KTZ-FUM is predicted to be about 300 times LESS soluble than KTZ at pH 1.5 (SA ≈ 
0.003) but would become more than 10,000 times MORE soluble than KTZ at pH 7 (SA > 
10,000).  Cocrystals KTZ-ADP and KTZ-SUC went from being 64 and 72 times less soluble to 
about 3,800 and 7,000 times more soluble than KTZ, respectively, in the same pH range. 
 
  
Figure 2.5.  Cocrystal solubility advantage over drug (SA = Scc/Sdrug) as a function of pH.  Solid 
lines represent predicted SA based on Sdrug and Scc values calculated using equation 2.2 and 2.3 
and appropriate parameters.  KTZ-ADP is represented in blue and with symbol “○”.  KTZ-FUM 
is represented in green and with symbol “□”.  KTZ-SUC is represented in red and with symbol 
“∆”.  The dotted line represents where the cocrystal solubility and drug solubility are equal, and 
the cocrystal exhibit no solubility advantage over drug (SA = 1). The standard errors for SA 
values are less than 7% and are within the experimental data points. 
 
The thermodynamic stability of KTZ drug and cocrystals can be altered by simply 
modifying solution pH.  Proper understanding of cocrystal solution behavior is needed when 























The true solubility of these cocrystals might be underestimated if they undergo solution-mediated 
transformation during kinetic dissolution studies at pH > pHmax, and experiments conducted at 
pH < pHmax would not yield any solubility or dissolution advantage by the cocrystal.  If cocrystal 
solubility-pH behavior is not understood, one may end up with contradicting results when 
attempting to correlate dissolution of these cocrystals under different solution conditions. 
Our findings on cocrystal and drug solubilities are not in agreement with those reported 
in an earlier study.28   Cocrystals were reported to be 75 to 100 times more soluble than KTZ, but 
the pH of the cocrystal and drug solutions were not considered during the comparison in that 
study.28  The dissolution/solubility studies were conducted in water, and the final pH for each 
cocrystal was measured to be 3.8, 3.9, and 4.1 for KTZ-FUM, KTZ-ADP, and KTZ-SUC, 
respectively.28  Unfortunately, the pH corresponding to KTZ solubility was not reported nor 
considered.  A saturated solution of KTZ has a pH of about 8.  KTZ is a basic compound and 
will increase the pH of aqueous solutions, in contrast to the cocrystals that will lower the pH as 
they have acidic coformers.  Therefore, the comparison between cocrystal and drug solubility in 
is not representative of the true solubility advantage of the KTZ cocrystals, because the pH 
conditions were different.28 
The previous study also reported that in spite of the high cocrystal solubility 
enhancement there was no conversion to the less soluble drug.28  The reason for the lack of 
conversion is likely due to the pH during cocrystal solubility studies were very close to the pHmax 
(table 2.3), where drug and cocrystal are both thermodynamically stable.   In fact, based on the 
final dissolution pH, KTZ-ADP and KTZ-SUC are only 1.7 and 2.5 times more soluble than the 
drug, respectively, while KTZ-FUM is equally soluble to the drug.  The cocrystal 
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solubility/dissolution advantages are therefore much lower than the enhancements originally 
suggested by the authors of this fine publication. 
Cocrystal Keu and Solubility Advantage 
In the previous sections, we have demonstrated how the eutectic point measurement 
enables the evaluation of cocrystal solubility in a solvent where the cocrystal is metastable.5, 34  
Aside from cocrystal solubility determination, the eutectic concentrations of drug and coformer 
can also be used to identify stability regions for the cocrystals.  The eutectic constant (Keu) is 
defined as the activity ratio (a) of coformer to drug at the eutectic point and can be approximated 
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≡ ≈                 (2.5) 
The terms [CF]eu,T and [drug]eu,T represent the total concentrations of coformer and drug at the 
eutectic, respectively. 
KTZ cocrystal component eutectic concentrations between pH 3.3 and 5.1 (at 






























Figure 2.6.  KTZ cocrystal component eutectic concentrations at different pH values indicate the 
relative thermodynamic stability of cocrystal to drug.  (a) KTZ-ADP.  (b) KTZ-FUM.  (c) KTZ-
SUC.  X-axis values represent the solution pH at equilibrium, which has been altered from the 
initial media pH due to the buffering effect of drug and coformer.  The initial media pH values 
are (from left to right) 2.02, 5.00, and 8.04.  Keu < 1 or [coformer]eu < [drug]eu indicates that the 
cocrystal is less soluble than the drug at that given pH.  As pH increases, this trend is reversed 
for all three cocrystals, indicating the existence of a solubility transition point, pHmax. Error bars 





















































The drug and coformer eutectic concentrations change with solution pH, and this led to changes 
in the Keu values.  At the lowest pH values (pH 3.35 – 3.37), [KTZ]eu,T > [CF]eu,T, resulting in 
Keu < 1 and indicating that the cocrystal is less soluble and more stable compared to the drug.  At 
higher pH values (pH 4.34 – 5.05), KTZ eutectic concentrations become less than that of the 
coformers.  This resulted in Keu values increasing to > 1, which indicated a reversal in the 
relative thermodynamic stability, and the cocrystals became more soluble than the drug.  At 
pHmax, KTZ and CF eutectic concentrations are equal (Keu = 1), and this indicates that the 
solubility of drug and cocrystal are equal.  Keu is a useful tool to assess cocrystal stability relative 
to drug, and it is easily accessible experimentally under equilibrium conditions.9, 15, 34 
 For a 1:1 cocrystal, regardless of ionization, cocrystal SA can be expressed in terms of 
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The correlation between Keu and SA is described by equation 2.7 and illustrated in figure 2.7, 




Figure 2.7.  Predicted and experimental values of Keu and cocrystal SA for KTZ-ADP, KTZ-
FUM, and KTZ-SUC cocrystals.  Prediction (dotted line) was generated using equation 2.7.  The 
numbers by the symbols are pH values.  Standard errors of Keu values for most data points are 
less than 4%, except for Keu standard error of KTZ-SUC at pH 4.63, which is 11%.  Standard 
errors are within the experimental data points. 
 
Cocrystal and Drug Dissolution 
Powder dissolution studies of KTZ drug and cocrystals were conducted in aqueous buffer 
media at pH 1.60, 5.00, and 6.50 to represent the pH conditions in fasted gastric, fasted 
intestinal, and fed intestinal states.33  Dissolution pH ranges from below to above the cocrystal 
pHmax.  At pH > pHmax, the cocrystals gain solubility advantage over drug.  The mass of pure 
drug and cocrystals used was 1 mg KTZ equivalent per mL (1.9 mM), which correspond to the 
oral dose of KTZ 200 mg if dissolved in 200 mL.1, 24, 43-45  The dose is below KTZ solubility at 
pH 1.6, but at pH 5 and 6.5 it is 9 and 173 times above drug solubility.  The dose is below 
cocrystal solubility at all pH values studied and will generate supersaturation with respect to 

































dissolve at all pH values studied.  Full dissolution of cocrystals can be confirmed by examining 
coformer concentrations during dissolution (appendix 2C). 
Figure 2.8 shows that in general, the cocrystals outperformed the drug in pH 5 and pH 6.5 
media and had similar performance to the drug in pH 1.6.  Drug and cocrystals were fully 
dissolved in 20 min or less with similar dissolution profiles in pH 1.6 media.  Percent drug 
dissolved in solution was calculated by multiplying the ratio of measured KTZ concentrations 
during dissolution to the fully dissolved concentration (~ 1.9 mM) with 100.  In pH 5 media, 
cocrystal dissolutions showed that between 73% and 88% of the total KTZ (from cocrystals) 
were dissolved at corresponding Cmax, which was huge improvements from the pure drug 
dissolution where only 11% of total KTZ was dissolved.  In pH 6.5 media, KTZ-ADP and KTZ-
SUC outperformed the drug, achieving about 13% drug dissolved at their Cmax, whereas less than 
1% dissolved during pure drug dissolution.  KTZ-FUM dissolution in pH 6.5 exhibited high 
variabilities and showed little to no improvement from drug dissolution. 













































(c)  (d)  
Figure 2.8.  Percent KTZ dissolved during drug and cocrystals dissolution at initial pH values 
relevant to the pH of the fluid in the gastrointestinal tract.  % drug dissolved was calculated from 
the ratio of measured KTZ in solution as a function of time to the theoretical concentration from 
the initial mass added, 100 × [KTZ] dissolved / [KTZ] total cocrystal or pure drug added.  
Legend indicate the initial pH of the dissolution media.  Error bars indicate standard errors. 
 
While cocrystal equilibrium solubility may be hundreds, even thousands, of times higher 
than that of the parent drug, the supersaturation level achieved by cocrystal dissolution may not 
be as high.8  This is due to solution-mediated transformation of cocrystals back to its less soluble, 
more stable, drug form.  The rate of conversion and level of drug concentration achieved through 
kinetic measurements depend on many factors, including cocrystal SA, also referred to as the 
supersaturation index, with respect to the parent drug.7-8, 15, 29, 46  A highly soluble cocrystal can 
exhibit rapid solution-mediated transformation leading to no observable dissolution advantage 
over drug, while a less soluble cocrystal may be able to achieve and sustain a higher 
concentration over drug due to slower transformation.7-8  Therefore, the concentration achieved 
during dissolution for a cocrystal may not always be proportional to its true solubility. 
Influence of Cocrystal Supersaturation Index on Dissolution 
KTZ supersaturation levels achieved during cocrystal dissolution are limited by 













































at the dissolving surface, where the solution is saturated with cocrystal,47-48 we considered the 
supersaturation index (SA) as the driving force for cocrystal to drug conversion.  As the SA 
value increases, the expected higher drug levels during cocrystal dissolution may be dampened 
by faster precipitation to the less soluble drug. 
Cocrystal dissolution in pH 5 and 6.5 media decreased the pH of the solutions.  Although 
these pH changes are relatively small (< 0.3 pH units in this study), they can lead to substantial 
changes in solubility and cocrystal SA values.  Therefore, the maximum supersaturation (σmax), 
defined as Cmax/Sdrug, and cocrystal SA in tables 2.4 and 2.5 were calculated using solubility 
values corresponding to the final dissolution pH instead of initial media pH. 
 
Table 2.4.  Cocrystal supersaturation index (SA), dissolution Cmax, Tmax, AUC, and maximum 
supersaturation (σmax) in pH 6.5 media with standard errors.  








(min) σmax a 
AUC 
(mM × min) 
KTZ 6.48  ± 0.01 -- 0.012 ± 0.001 -- -- 2.11 ± 0.08 
KTZ-ADP 6.23  ± 0.02 440 0.24 ± 0.03 30 14.7 ± 0.9 13.3 ± 0.5 
KTZ-FUM 6.30  ± 0.09 3118 0.04 ± 0.03 2 2 ± 2 2.1 ± 0.4 
KTZ-SUC 6.24  ± 0.05 822 0.24 ± 0.02 60 14.7 ± 0.6 26 ± 3 
a. Scc and Sdrug values represent KTZ solubility at corresponding final pH of dissolution for 
each drug and cocrystal, calculated with equations 2.2 and 2.3. 
 
Table 2.4 shows that KTZ-FUM dissolution in pH 6.5 media has a huge SA value (SA > 
3,000) which might have led to rapid conversion to drug during dissolution, resulting in no 
dissolution advantage compared to that of the drug.  KTZ-ADP and KTZ-SUC SA values are 
more modest in comparison (440 and 822, respectively), and they each achieved σmax values of 
about 15 during dissolution.  KTZ-SUC sustained supersaturation the longest (~ 2 hours), which 
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led to it having nearly two-fold higher AUC compared to the ADP cocrystal, even though they 
had similar Cmax values. 
 
Table 2.5.  Cocrystal supersaturation index (SA), dissolution Cmax, Tmax, AUC, and maximum 
supersaturation (σmax) in pH 5.0 media with standard errors. 








(min) σmax a 
AUC 
(mM × min) 
KTZ 5.01 ± 0.02 -- 0.208 ± 0.001 -- -- 35 ± 2 
KTZ-ADP 4.94  ± 0.02 13 1.4 ± 0.3 10 5.9 ± 0.7 98 ± 9 
KTZ-FUM 4.94  ± 0.06 36 1.41 ± 0.09 30 5.9 ± 0.2 160 ± 10 
KTZ-SUC 4.99  ± 0.02 21 1.7 ± 0.2 30 7.8 ± 0.6 210 ± 20 
a. Scc and Sdrug values represent KTZ solubility at corresponding final pH of dissolution for 
each drug and cocrystal, calculated with equations 2.2 and 2.3. 
 
Table 2.5 shows that the cocrystal SA values were much smaller in pH 5 media (13 – 16) 
than in pH 6.5 media (440 – 3118).  The Cmax and AUC values from cocrystal dissolution were 
higher in pH 5 media than in pH 6.5 media, suggesting that the reduction of cocrystal SA also 
reduced cocrystal to drug conversion rate.  The cocrystals achieved σmax in the range of 6 to 8 
with respect to drug during dissolution in pH 5 media.  KTZ-SUC once again exhibited the best 
dissolution performance out of the three, achieving the highest Cmax and AUC.  KTZ-FUM 
achieved similar drug Cmax and σmax as KTZ-ADP during dissolution, but the AUC values of the 
two cocrystals indicate that the FUM cocrystal sustained supersaturation longer. 
Dissolution of KTZ cocrystals demonstrated how having very large SA values may not 
be a desirable property for a cocrystal.  Solution-mediated transformation of highly soluble 
cocrystals back to less soluble drug form can be accelerated as supersaturation level increases, 
leading to little or no dissolution advantage from the cocrystal.  KTZ-FUM dissolution in pH 6.5 
media is an excellent example of this. 
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In comparison to pure drug dissolution, cocrystal dissolution in media of different pH 
demonstrated less variation and higher drug concentrations (figure 2.9).  In general, cocrystals 
outperformed the drug during dissolution, except KTZ-FUM in pH 6.5 buffer, where the 
conversion to drug was too rapid to allow for concentration enhancements.  Higher drug 
concentrations and reduced variability at Cmax in different media indicated that cocrystal in vitro 
dissolution behavior is less sensitive to pH compared to drug.  This further implicates that these 
cocrystals may help reduce in vivo dissolution and absorption variability, and they can 





























Figure 2.9.  (a) Cmax of KTZ during dissolution and (b) AUC of KTZ from 0 - 180 min for 
dissolution in pH 5.0 and 6.5 media, and from 0 – 120 min for dissolution in pH 1.6 media. 
Numbers on top of the columns represent (a) σmax and (b) AUC ratio of cocrystal to drug 
(AUCcc/drug). pH values in legend indicate initial media pH.  Error bars indicate standard error. 
 
The significance of cocrystal SA on the rate of conversion to drug can be appreciated in 
figure 2.10.  Where σmax indicates the highest supersaturation achieved by each cocrystal and the 
AUC ratio of cocrystal to drug indicates the cumulative drug exposure during cocrystal 






























Figure 2.10.  Cocrystal σmax (○) and AUCcc/drug (Δ) as a function of cocrystal SA.  Letters “A”, 
“S”, and “F” above the symbols represent cocrystals KTZ-ADP, KTZ-SUC, and KTZ-FUM, 
respectively.  Error bars indicate standard error. 
 
The range of SA values was found to be as low as 13 (ADP cocrystal, pH 5) and as high 
as 3,100 (FUM cocrystal, pH 6.5).  Cocrystals with extremely high SA values, such as 3100 for 
KTZ-FUM in pH 6.5, are not expected to be able to sustain supersaturation in solution for very 
long.  As can be observed in figure 2.10, this high SA value led to the lowest σmax and AUCcc/drug 
values out of all the cocrystals and pH conditions.  At pH 5, with cocrystal SA values between 13 
and 40, enhancement in both σmax and AUCcc/drug were observed.  However, in pH 6.5, the much 
higher SA values between 440 and 3100 resulted in more variability in cocrystal dissolution 
behavior.  KTZ-SUC achieved the highest σmax and AUCcc/drug with SA of 822.   Interestingly for 
KTZ-ADP, a lower SA (440) reached a high σmax but a much lower AUCcc/drug.  It appeared that 
KTZ-SUC experienced the highest exposure levels with the slowest rate of conversion to drug 
among the three cocrystals.  This might be a consequence of coformer effects on KTZ 





































This work demonstrates that cocrystal solubility and dissolution are highly dependent on 
pH.  Cocrystals of a weakly basic drug with acidic coformers dampen the negative effects of 
decreasing drug solubility with increasing pH.  Solubility-pH dependence of cocrystals can be 
generated from determination of cocrystal Ksp.  Different solubility-pH behavior exhibited by 
these cocrystals resulted in a pHmax, above which the cocrystal solubility and dissolution 
advantage over drug.  Cocrystal Keu can be used as a quick evaluation of cocrystal stability 
relative to drug.  The equations presented in this work have demonstrated their ability to 
quantitatively predict solubility and to evaluate cocrystal supersaturation index under different 
solution pH conditions.  SA is a useful in the interpretation of cocrystal dissolution-precipitation 
behavior, and is a meaningful parameter to assess the risk of cocrystal conversions. 
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KTZ Solubility as a Function of pH 
The drug studied in this Chapter is ketoconazole (KTZ).  Drug solubility can be described by the 
equilibrium of the solid drug KTZ with solution according to the following equilibrium 
expression: 
crystal aqKTZ KTZ               (2A.1) 
where the dissolved drug, or the KTZ present in the aqueous phase, is expressed as KTZaq.  KTZ 
is a dibasic drug, and can become ionized under certain aqueous conditions.  Therefore, the total 
KTZ concentration ([KTZ]T) in aqueous solution can be described by the sum of its non-ionized 
and ionized species in solution: 
2
2[ ] [ ] [ ] [ ]T aq aq aqKTZ B BH BH
+ += + +         (2A.2) 
Where B, BH+, and BH22+ are KTZ in its non-ionized, first protonated, and second protonated 
states.  The subscripts T and aq denote the solubility and species in the aqueous phase, 
respectively.  The non-ionized KTZ concentration in solution, [B]aq, is also the intrinsic 
solubility of KTZ, which is expressed in later equations as SKTZ,0. 
The conjugate acids of the dibasic drug, KTZ, dissociate in solution according to their 






BH H BH+ + ++

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+=            (2A.6) 
Substituting in relevant equilibria into the mass balance equation, KTZ solubility can be 




[ ] [ ]
[ ] (1 )aq aqdrug T T KTZ





= = + +      (2A.7) 
Equation 2A.7 can be expressed in terms of pH and pKa 
2, 1, 2,- -2
, ,0 (1 10 10 )a KTZ a KTZ a KTZ
pK pH pK pK pH
drug T KTZS S
+= + +       (2A.8) 
Acidic Coformer Ionization 
Total concentration of diprotic acid coformer ([CF]T) in aqueous solution can be described by the 
sum of its non-ionized and ionized species in solution (mass balance). 
2
2[ ] [ ] [ ] [ ]T aq aq aqCF H A HA A
− −= + +          (2A.9) 
where H2A represents the non-ionized form of coformer.  HA- and A2- are the ionized species of 
the coformer. 
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=                      (2A.13) 
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Substituting in relevant equilibria into the mass balance equation, total coformer concentration in 
solution can be described by the equation: 
1, 1, 2,
2 2[ ] [ ] (1 )[ ] [ ]






= + +                    (2A.14) 
Equation 2A.14 can be expressed in terms of pH and pKa: 
1, 1, 2,- 2 - -
2[ ] [ ] (1 10 10 )a CF a CF a CF
pH pK pH pK pK
T aqCF H A= + +                            (2A.15) 
Cocrystal Solubility as a Function of pH, pKa, and Ksp 
For 1:1 cocrystals of KTZ and dicarboxylic acid, the cocrystal solubility (Scc,T) under 
stoichiometric condition can be described as: 
, [ ] [ ]cc T T TS KTZ CF= =                      (2A.16) 
Cocrystal dissociates in solution according to its solubility product, Ksp 
- cocrystal aq aq
spK
KTZ CF KTZ CF+

                  (2A.17) 
2[ ][ ] [ ] [ ]sp aq aqK KTZ CF B H A= =                     (2A.18) 
where KTZ and CF refer to the non-ionized species of drug and coformer. 
Considering cocrystal component mass balance (equations 2A.2 and 2A.9) and substituting in 





[ ] [ ]
(1 )(1 )
[ ] [ ]
aq aq a CF a CF a CF
cc T sp
a KTZ a KTZ a KTZ aq aq
H H K K K
S K
K K K H H
+ +
+ += + + + +                (2A.19) 
Equation 2A.19 can be rewritten in terms of pH and pKa:     
2, 1, 2, 1, 1, 2,- -2 - 2 - -
, (1 10 10 )(1 10 10 )a KTZ a KTZ a KTZ a CF a CF a CF
pK pH pK pK pH pH pK pH pK pK
cc T spS K





Equation 2A.20 can be linearized by squaring both sides. 
 2, 1, 2, 1, 1, 2,
- -2 - 2 - -2
, (1 10 10 )(1 10 10 )a KTZ a KTZ a KTZ a CF a CF a CF
pK pH pK pK pH pH pK pH pK pK
cc T spS K
+= + + + +          (2B.1) 
According to the relationship presented in equation 2B.1, by plotting the cocrystal solubility 
squared on the y-axis against the corresponding ionization terms of drug and coformer on the x-
axis under difference pH conditions, the resulting slope of the line is the Ksp for the cocrystal 
(figure 2B.1). 
 (a)  






























 (b)  
(c)  
Figure 2B.1.  Cocrystal Ksp determination from linear regression based on equation 2B.1, where 
Ksp is the slope of the regression line. 
 
Under ideal conditions, cocrystal Ksp should be constant regardless of solution pH.  
Equation 2.3 can be rearranged to solve for Ksp at each pH.  





















































2, 1, 2, 1, 1, 2,
2
,
- -2 - 2 - -(1 10 10 )(1 10 10 )a KTZ a KTZ a KTZ a CF a CF a CF
cc T
sp pK pH pK pK pH pH pK pH pK pK
S
K += + + + +
     (2B.2) 
KTZ cocrystal Ksp values were determined for each pH condition studied.  Ksp values calculated 
for each cocrystal under different pH conditions are summarized in table 2B.1 and compared to 
Ksp obtained from linear regression analysis. 
Table 2B.1.  Cocrystal Ksp. 

















3.37(±0.01) 3.1 (±0.1) x 10-8 













3.36(±0.01) 2.5 (±0.2) x 10-8 
2.1 (±0.5) x 10-8 2.7 (±0.1) x 10-8 Phosphate 
buffer  
(8.04 ±0.01) 





3.35(±0.01) 1.5 (±0.1) x 10-9 








4.53(±0.01) 1.5 (±0.3) x 10-9 
 
Ksp of the KTZ cocrystals determined under different pH conditions showed some 
variability.  Theoretically, Ksp should be a constant value that is based on the activities of 
cocrystal constituents.5, 8  Under ideal conditions, the activities can be approximated by solution 
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concentrations of non-ionized drug and coformer, which was how the Ksp for KTZ cocrystals 
were estimated.5, 8  It has been shown in the literature that the apparent Ksp of salts can vary with 
counter-ion concentration, solution pH, and ionic strength, due to the limitations of the 
determination method to account for all variables including ionic strength and pH.49-50  
In the case of KTZ cocrystals, the apparent Ksp calculated for each cocrystal was usually 
the lowest at the pH where the measured cocrystal solubility was also the lowest, for example, 
KTZ-ADP in pH 5 acetate buffer (equilibrium pH = 4.63) and KTZ-SUC in pH 8 phosphate 
buffer (equilibrium pH = 5.06).  KTZ-FUM equilibrium pH expanded a narrower range (3.35 - 
4.53) compared to the other two cocrystals, and KTZ-FUM solubility changed very little (4.8 - 
5.7 mM) in this pH region, which might help explain why its apparent Ksp values were the most 
consistent.  The combined effect of cocrystal solubility (total concentration of drug and coformer 
in solution) and the extent of the ionization of its components influenced by solution pH may 
have contributed to the variability in apparent Ksp.  The range of the apparent Ksp values for each 
KTZ cocrystal is less than 1 order of magnitude, which is consistent with reported variabilities of 












Intrinsic Solubility of KTZ 
 The intrinsic (non-ionized) solubility of KTZ was not able to be measured directly due to 
the poor solubility of the basic drug at pH > 7 (figure 2B.2), which was below the quantification 
limit of the HPLC instrument used in this study.  Therefore, KTZ solubility was measured, either 
as pure drug or at eutectic point with cocrystal, under different pH conditions and used to 
calculate the non-ionized drug solubility (table 2B.2). 
 
Figure 2B.2.  KTZ solubility-pH profile generated with equation 2.1 and SKTZ,0 = 4.7 x 10-6 M. 
Experimental solubility of KTZ at different pH is represented with data points.  Standard errors 














































3.35 ±0.01 Eutectic 1.55 (±0.05) x 10-2 4.88 x 10-6 
4.7 (±0.2) 
x 10-6 
3.36 ±0.01 Eutectic 1.53 (±0.02) x 10-2 4.92 x 10-6 
3.37 ±0.02 Eutectic 1.52 (±0.09) x 10-2 5.10 x 10-6 
3.38 ±0.01 Single comp 1.382 (±0.004) x 10-2 4.81 x 10-6 
Acetate 
buffer 
(5.00 ±0.01)  
4.34 ±0.01 Eutectic 1.09 (±0.04) x 10-3 5.19 x 10-6 
4.58 ±0.01 Eutectic 5.01 (±0.08) x 10-4 5.77 x 10-6 
4.62 ±0.05 Eutectic 4.9 (±0.2) x 10-4 6.1 x 10-6 




4.52 ±0.01 Eutectic 6.7 (±0.4) x 10-4 5.0 x 10-6 
5.04 ±0.01 Eutectic 1.89 (±0.04) x 10-4 4.66 x 10-6 
5.05 ±0.01 Eutectic 2.1 (± 0.1) x 10-4 5.4 x 10-6 





Cocrystal Dissolution in pH 6.5 Media 
Both KTZ and coformer concentrations were measured to monitor the extent of cocrystal 














































Figure 2C.1.  KTZ cocrystal component concentrations during dissolution in pH 6.5 media. 
Purple dashed line indicates the concentration at which the cocrystal is fully dissolved.  Blue 
dashed line indicates KTZ drug solubility.  Error bars on the symbols indicate standard errors. 
 
As cocrystal dissolved, both coformer and drug were released into the solution.  The coformer 
concentration plateaued between 60 and 90 min, and the concentration at plateau indicated that 
the cocrystal added to solution was fully dissolved.  KTZ concentration initially increased to 
reach Cmax, then decreased as the rate of drug precipitation overtook the rate of cocrystal 
dissolution.  The highly soluble coformers remained dissolved in solution, since the 
concentration used was below their solubility.  The coformer concentration can be used to assess 
the extent of cocrystal dissolution.  The poorly water soluble drug, however, was precipitating 
out of the solution as the cocrystals were dissolved. 
Cocrystals have a larger impact on the bulk pH of the solution than the drug (figure 
2C.2).  KTZ drug has no or very little effect on pH, while the cocrystals decreased media pH 

























Figure 2C.2.  Bulk pH as a function of time during KTZ drug and cocrystal dissolution in pH 
6.5 media. 
 
Cocrystal Dissolution in pH 5.0 Media 
In pH 5.0 media (acetate buffer), the buffer species interfered with the UV absorbance of 
coformer SUC and ADP, and therefore their solution concentrations during dissolution were not 
able to be determined (figure 2C.3).  However, the amount of solid used was below cocrystal 
solubility at the dissolution media pH, therefore the cocrystals were able to fully dissolve.  KTZ-
FUM was the only cocrystal in this media which coformer concentration could be measured, and 
FUM concentrations in figure 2C.3(b) indicate that the cocrystal was fully dissolved by 60 min.  
Drug precipitation also appeared slower in pH 5 media, allowing the solution to generate and 
































































Figure 2C.3.  KTZ cocrystal component concentrations during dissolution in pH 5.0 media.  
Purple dashed line indicates the concentration at which the cocrystal is fully dissolved.  Blue 
dashed line indicates KTZ drug solubility.  Error bars on the symbols indicate standard errors. 
 
Figure 2C.4 shows that cocrystals and drug have very little impact on the bulk pH (< 0.1 
unit change) during dissolution in pH 5 media. 
 








































 CHAPTER 3 
EFFECT OF PHYSIOLOGICALLY RELEVANT SURFACTANTS ON COCRYSTAL 
SOLUBILITY AND DISSOLUTION 
 
Introduction 
 Cocrystallization can enhance aqueous solubility of a poorly water soluble drug, which 
can lead to improvements in dissolution and bioavailability.1-8  With a wide range of coformers 
to choose from, cocrystals of the same drug constituent can exhibit solution behavior as diverse 
as the coformer physicochemical properties.2-3, 7, 9-11  Cocrystal solubility can be orders of 
magnitude above that of the parent drug.  However, this huge solubility advantage can also lead 
to undesirable effects such as solution-mediated transformation of the cocrystal back to less 
soluble drug forms, which can prevent sustained supersaturation and lead to no observed 
dissolution advantage over the drug.  Endogenous and synthetic solubilizing agents can reduce, 
and sometimes even eliminate, the solubility advantage (SA) of the cocrystal depending on the 
strength and concentration of the solubilizing agent.  Reduction in cocrystal SA, also known as 
the supersaturation index, can help stabilize cocrystals in solution and achieve higher drug 
concentrations. 
 The mechanism by which drug solubilizing agents reduces the potential for cocrystal 
conversion in solution is through preferential solubilization of drug over coformer.11-14  Most 
pharmaceutical cocrystals are composed of hydrophobic drugs and hydrophilic coformers, and 
the drug component is expected to be solubilized to a higher extent than the coformer when in 
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the presence of solubilizing agents such as surfactants and lipids.12, 14-16  Rodriguez and 
coworkers have found that when only drug, but not coformer, is solubilized by a solubilizing 
agent, cocrystal (1:1 molar ratio) solubility exhibits a square-root dependence on solubilizing 
agent concentration, while the parent drug solubility has a linear dependence.11-14, 16-18  This 
means that cocrystal solubility has a weaker dependence on solubilizing agent concentration 
compared to drug, which translates to reduced SA as solubilizing agent concentration increases. 
 Drug solubilizing agents can exist in many different forms including pharmaceutical 
additives, lipids from food, and bile salts present in the gastrointestinal (GI) tract.  A drug or a 
cocrystal may encounter some, if not all, of these types of solubilizing agents during 
pharmaceutical development and oral dosing.  FeSSIF (fed-state simulated intestinal fluid) and 
FaSSIF (fasted-state simulated intestinal fluid) media are frequently used in in vitro solubility 
and dissolution studies to evaluate solution properties of drugs, cocrystals, and various other 
solid forms.19-24  FeSSIF and FaSSIF contain sodium taurocholate and lecithin, which can form 
mixed micelles in aqueous solutions and can solubilize cocrystal components based on their 
lipophilic properties.19-20, 25  Proper understanding of solution phase interactions of cocrystal 
components is essential for accurate prediction and interpretation of cocrystal solution behavior 
under various in vitro and in vivo conditions.  The purpose of the work presented here is to 
evaluate the effect of drug solubilizing agents on cocrystal solubility, supersaturation index (SA), 
and dissolution behavior. 
The cocrystals studied in this chapter are 1:1 cocrystals of ketoconazole-adipic acid 
(KTZ-ADP), ketoconazole-fumaric acid (KTZ-FUM), and ketoconazole-succinic acid (KTZ-
SUC).  KTZ is a weakly basic compound with pKa values of 3.17 and 6.63 (pKa values 
determined with 0.15 M KCl background electrolyte at 25.0 ± 0.1°C and a blanket of heavy inert 
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gas of argon or nitrogen).26  The coformers are all diprotic carboxylic acids, ADP pKa values are 
4.44 and 5.44, SUC pKa values are 4.00 and 5.24, and FUM pKa values are 2.85 and 4.10 at 
25°C with 0.1 M ionic strength.27-28  KTZ drug is also much more lipophilic (logD7.4 = 3.83, 
determined with water saturated n-octanol and 50 mM phosphate buffer of pH 7.4) 26, 29 than the 
coformers (logP range between -0.59 and 0.46),30 and KTZ has been shown to be solubilized by 
the surfactants present in FeSSIF and FaSSIF.19, 31-33  In Chapter 2, we presented the effect of pH 
on the solubility and dissolution behavior of KTZ drug and cocrystals.  Here we consider not 
only the effect of pH, but also the solubilization by physiologically relevant surfactant micelles.  
Equations have been derived in the past to predict cocrystal solubility behavior in the presence of 
solubilizing agents by Rodriguez and coworkers,12-16 but no solubility equation of such has been 
derived for cocrystals of dibasic drug and diprotic acid coformers until now.  It is expected that a 
cocrystal composed of hydrophobic drug and hydrophilic coformer will exhibit preferential 
solubilization of drug by these micellar systems.  This can lead to lower SA, slower cocrystal to 
drug conversion, and sustained supersaturation of drug component during dissolution. 
 
Theoretical 
Drug Solubilization by Surfactant Micelles 
 The solubility of 1:1 cocrystals of KTZ, assuming solution complexation of cocrystal 
components is negligible, can be described by cocrystal dissociation, component ionization, and 
micellar solubilization of all solution species (ionized + non-ionized cocrystal components).  
Cocrystal dissolves in aqueous solutions and dissociates into its components according to Ksp, 
2 2cocrystal aq aq
spK
B H A B H A− +

            (3.1) 
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where B is the basic drug KTZ, and H2A is the diprotic acid coformer CF.  Both are in their non-
ionized forms.  Subscript “aq” represents the drug and coformer species dissolved in the aqueous 
phase.  Cocrystal Ksp is defined as the solubility product of non-ionized concentrations of drug 
and coformer 
2[ ] [ ] [ ][ ]sp aq aqK B H A KTZ CF= =            (3.2) 
where, KTZ and CF are the non-ionized species of the drug and coformer in solution, and they 
are equal to [B]aq and [H2A]aq, respectively. 
Under stochiometric conditions, cocrystal solubility can be represented as 
, [ ] [ ]cc T T TS KTZ CF= =              (3.3) 
where Scc,T is the cocrystal solubility, and subscript “T” denotes total solution concentration 
(ionized + non-ionized species in both aqueous and micellar pseudophases) of each cocrystal 
component. 
Total KTZ in solution, [KTZ]T, is the sum of its non-ionized (B) and ionized species 
(BH+ and BH22+) in both aqueous (aq) and micellar (m) pseudophases.   
2 2
2 2[ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ]T T aq aq aq m m mKTZ B B BH BH B BH BH
+ + + += = + + + + +        (3.4) 
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+=              (3.8) 
where Ka,KTZ represents the ionization constant for the conjugate acid forms of KTZ.  Micellar 
solubilization of the non-ionized and ionized drug species in solution is as follows: 
aq m
BsK
B M B+ 

             (3.9) 
[ ]






=              (3.10) 
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BHsK
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+=             (3.14) 
where M is the surfactant micelle and Ks is the solubilization constant.  By substituting the 
appropriate equilibrium constants into equation 3.4, the drug solubility (Sdrug,T) as a function of 





2, 1, 2, 2, 1, 2,
[ ]
[ ] [ ] [ ] [ ]
[ ] 1 [ ]
drug T T
BHBH
s aq s aq aq aqB
aq s
a KTZ a KTZ a KTZ a KTZ a KTZ a KTZ
S KTZ
K H K H H H
B M K
K K K K K K
++ + + + +
=
  
  = + + + + +
    
       (3.15) 
Coformer Solubilization by Surfactant Micelles 
The total coformer concentration ([CF]T) in solution is the sum of the non-ionized (H2A) 
and ionized (HA- and A2-) coformer species in the aqueous and micellar pseudophases. 
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- 2- - 2-
2 2[ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ]T T aq aq aq m m mCF A H A HA A H A HA A= = + + + + +       (3.16) 
The ionization and micellar solubilization of the diprotic acid coformer can be described by the 
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=              (3.26) 
By substituting the appropriate equilibrium constants into equation 3.16, the total coformer 




2 1, 1, 2, 1, 1, 2,
2 2 2
[ ]
[ ] 1 [ ]
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T
HA A
S a CF s a CF a CF a CF a CF a CFH A
aq s
aq aq aq aq
CF
K K K K K K K K
H A M K
H H H H+ + + +
  
 = + + + + + 
    
     (3.27) 
where [H2A]aq is the non-ionized coformer concentration in the aqueous pseudophase. 
KTZ Cocrystal Solubility in Surfactant Media 
In order to simplify equations 3.15 and 3.27, the total micellar solubilization constants for 
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= + +           (3.28) 
and for coformer, 
- 2
2 1, 1, 2,
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s a CF s a CF a CFH ACF
s T s
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+ += + +          (3.29) 
where Ks,T is the total micellar solubilization constant incorporating all the non-ionized and 
ionized species of drug or coformer in solution.  The value of Ks,T is dependent on the type of 
solubilizing agent and solution condition such as pH. 
Substituting equations 3.2, 3.15, 3.27, 3.28, and 3.29 into equation 3.3 and rearranging 
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 Using equation 3.31, cocrystal solubility in the presence of surfactant micelles or other 
solubilizing agents can be quantitatively predicted with the knowledge of cocrystal Ksp, 
component pKa, solution pH, micellar/solubilizing agent concentration, and component Ks,T 
values at the corresponding pH. 
 
Materials and Methods 
Materials 
Ketoconazole (lot # BS1203355108, 98% purity) was purchased from Bosche Scientific 
(New Brunswick, NJ) and used as received.  Adipic acid (lot # 06807BE, 99% purity), succinic 
acid (lot # 037K0021, 99% purity), fumaric acid (lot # 09426EE, 99+% purity), acetic acid (lot # 
074K3658, 99%), sodium acetate anhydrous (lot # 100K0272), dipotassium hydrogen phosphate 
(lot # 103H0287, ACS reagent), and sodium chloride (NaCl) (lot # 094K0183, ACS reagent) 
were purchased from Sigma-Aldrich (St. Louis, MO) and used as received.  
FaSSIF/FeSSIF/FaSSGF instant powder (lot# 01-1504-03NP) was purchased from 
Biorelevant.com (London, United Kingdom) and used as received. 
HPLC grade methanol, HPLC grade 2-propanol, sodium phosphate monobasic 
(NaH2PO4•H2O) (lot # 017316), and hydrochloric acid (lot # 2AJK15038, ACS grade) were 
purchased from Fisher Scientific (Fair Lawn, NJ).  Acetone (ACS reagent 99.5%) and 
phosphoric acid (lot # B0506524, 85+%) were purchased from Acros Organics (NJ) and used as 
received.  Trifluoroacetic acid (spectrophometric grade, 99%) was purchased from Aldrich 
Company (Milwaukee, WI).  Sodium hydroxide pellets (NaOH) was purchased from J.T. Baker 
(Philipsburg, NJ).  Water used in this study was filtered through a double deionized (DI) 




KTZ cocrystals (1:1 stoichiometric ratio) were prepared by reaction crystallization 
method at room temperature.34-35  KTZ-FUM and KTZ-SUC cocrystals were synthesized in 
acetone.  KTZ-ADP cocrystal was synthesized in 2-propanol.  Full conversions to cocrystals 
were observed between 24 to 48 hours.  The solid phases were characterized by X-ray powder 
diffraction (XRPD) and differential scanning calorimetry (DSC), and the stoichiometries were 
verified by HPLC. 
Media Preparation 
FaSSIF and FeSSIF media were prepared according to the method and composition 
described by Galia et al (table 3.1).19 
Table 3.1.  FaSSIF, FeSSIF, and blank media composition and pH.19, 21 
 Blank FaSSIF FaSSIF Blank FeSSIF FeSSIF 
Sodium 
taurocholate 
-- 3 mM -- 15 mM 
Lecithin -- 0.75 mM -- 3.75 mM 
NaOH 8.7 mM 8.7 mM 101 mM 101 mM 
NaH2PO4•H2O 29 mM 29 mM -- -- 
CH3CO2H -- -- 144 mM 144 mM 
 NaCl 106 mM 106 mM 203 mM 203 mM 
pH 6.5 6.5 5.0 5.0 
 
Blank FaSSIF (pH 6.50 phosphate buffer) was prepared at room temperature by dissolving 0.683 
g of NaOH (pellets), 7.902 g of NaH2PO4•H2O, and 12.372 g NaCl in 2 L of purified DI water.  
The pH was adjusted to 6.50 (± 0.04) with 1 M NaOH and 1 M HCl solutions.  Blank FeSSIF 
(pH 5.00 acetate buffer) was prepared at room temperature by dissolving 8.089 g NaOH 
(pellets), 16.4 mL acetic acid, and 23.748g NaCl in 2 L of purified DI water.  The pH was 
adjusted to 5.00 (± 0.03) with 1 M NaOH and 1 M HCl solutions.  FaSSIF and FeSSIF media 
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were prepared by dissolving appropriate amount of FaSSIF/FeSSIF/FaSSGF powder in the blank 
media, then stored at room temperature and were used within 48 hours. 
FeSSIF and FaSSIF media used here have the same surfactant compositions (sodium 
taurocholate + lecithin, 4:1 molar ratio).20  FeSSIF media has 5 times higher surfactant 
concentration than FaSSIF and possesses a lower pH (pH 5 vs. pH 6.5, respectively).20  The 
micellar concentration ([M]) is equal to the total surfactant concentration minus the critical 
micellar concentration (CMC).  The CMC value for sodium taurocholate in the presence of 
lecithin in a 4:1 ratio, 0.1 M NaCl, at 25°C is reported to be 0.25 mM.36-37  The micellar 
concentrations of FaSSIF and FeSSIF under the same solution conditions are 3.0 mM and 15 m 
M, respectively.36-37 
Solubility Measurements 
 Cocrystal component solubility was measured by adding excess solid to 3 mL of solution 
media.  The solutions were magnetically stirred and were kept in water bath at 25 ± 0.4°C for up 
to 96 hours.  0.5 mL aliquots of the suspension were sampled every 24 hours.  Collected samples 
were filtered via centrifuge through a 0.45 µm pore cellulose acetate membrane, and the pH 
values of the solutions were measured.  The concentrations of drug or coformer in the solutions 
were analyzed by HPLC. 
 The equilibrium solubility of each cocrystal was determined at the eutectic point, where 
the drug and cocrystal solid phases are in equilibrium with the solution.3, 38  The eutectic points 
were approached by cocrystal dissolution, where 150 – 200 mg of cocrystal and 50 – 80 mg of 
KTZ were suspended in 3 mL of solution.  The solutions were kept in water bath at 25 ± 0.1°C 
and magnetically stirred for up to 96 hours.  Solution samples (0.5 mL) were collected every 24 
hours and filtered via centrifuge through a 0.45 µm pore cellulose acetate membrane, and the pH 
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values were measured.  The solid phases were analyzed by XRPD and DSC to confirm both drug 
and cocrystal solid phases were present, indicating that the solutions were at the eutectic point.  
The filtered solutions were then analyzed by HPLC after proper dilutions with the mobile phase. 
Cocrystal and Drug Powder Dissolution  
 Powder dissolution studies of drug and cocrystals were conducted using an overhead 
stirrer with a glass propeller at 150 rpm over 3 hours.  30 mL of dissolution media was used to 
dissolve 30 mg of KTZ drug and 30 mg drug-equivalent mass of each cocrystal were used for 
each dissolution experiment.  Both drug and cocrystal powders were sieved through mesh 
screens and the particle size between 106 and 125 µm was used.  The dissolution media were 
kept in water bath with temperature of 24.5 (± 0.5) °C throughout the dissolution process.  
Solution pH was measured before and after the dissolution of KTZ and its cocrystals.  Solution 
samples of 0.5 mL were taken at time points of 1, 2, 5, 10, 20, 30, 60, 90, 120, and 180 minutes 
(min) with a syringe.  The solution samples were filtered using PVDF membrane syringe filters 
with pore size of 0.45 µm.  The solution concentrations of drug and coformers were analyzed by 
HPLC after proper dilution with mobile phase. 
X-Ray Powder Diffraction (XRPD) 
A Rigaku Miniflex X-ray diffractometer (Danverse, MA0) using Cu-Kα radiation, a tube 
voltage of 30 kV, and a tube current of 15 mA was utilized for analysis and characterization of 
solid phases.  Measurements were taken from 5° to 40° at a continuous scan rate of 2.5°/min. 
Thermal Analysis 
TA instrument differential scanning calorimetry (DSC) (Newark, DE) was used to 
analyze the collected solid phases from the solubility studies after they were dried at room 
109 
 
temperature.  The heating rate of the experiments was 10°C/min under dry nitrogen atmosphere.  
Standard aluminum sample pans and lids were used for these measurements. 
High Performance Liquid Chromatography (HPLC) 
Solution concentrations of the drug and coformer were analyzed by a Waters HPLC 
equipped with a UV spectrometer detector.  A Waters Atlantis C18 column with the dimension 
of 250 x 4.6 mm and 5 µm particle size was used for separation at ambient temperature.  The 
flow rate was set at 1mL/min and the injection volume was 20 µL.  For KTZ-ADP and KTZ-
FUM cocrystals, the mobile phase used was composed of 60% methanol and 40% water with 
0.1% trifluoroacetic acid (TFA).  For KTZ-SUC cocrystal, different methods were used to 
analyze each component due to poor separation of SUC peak from the solvent peak.  The KTZ 
component of KTZ-SUC cocrystal was analyzed using mobile phase composed of 60% methanol 
and 40% water with 0.1% TFA.  The SUC component was analyzed using a gradient method 
with flow rate of 1mL/min starting with mobile phase composed of 25% methanol and 75% 
water with 0.1% TFA.  The composition changed to 80% methanol and 20% water with 0.1% 
TFA after 2.5 min, then reverted back to 25% methanol and 75% water with 0.1% TFA after 6 
min.  The wavelengths used for the analytes were as follows: 230 nm for KTZ, 220 nm for FUM, 
and 210 nm for SUC and ADP. 
 
Results and Discussion 
Cocrystal Experimental Solubility 
 KTZ drug and cocrystal solubilities were measured in FaSSIF, FeSSIF, blank FaSSIF, 
and blank FeSSIF media, and all three cocrystals were found to be more soluble than the drug.  
This means that the cocrystals have the potential to generate supersaturation in solution with 
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respect to drug solubility and can undergo solution-mediated conversion.  Therefore, cocrystal 
solubility was evaluated at the cocrystal and drug eutectic point, where both solid phases coexist 
in equilibrium with solution saturated with drug and cocrystal.  KTZ and CF total (ionized + 
non-ionized) concentrations at eutectic are listed in table 3.2, and cocrystal stochiometric 
solubility values (Scc,T) were determined with equation, 
, , ,[ ] [ ]cc T eu T eu TS KTZ CF=            (3.32) 



















Table 3.2.  Cocrystal stoichiometric solubility determined from KTZ and CF concentrations at 
the cocrystal and drug eutectic point.  Error values are standard errors. 




























































































































a. FaSSIF and blank FaSSIF initial pH = 6.50 ± 0.04.  FeSSIF and blank FeSSIF initial pH 
= 5.00 ± 0.03. 
b. pH at equilibrium. 
c. Calculated with equation 3.32. 
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Since drug and cocrystal eutectic point was used for equilibrium solubility measurement, 
KTZ eutectic concentration is also the drug solubility at the corresponding pH and solution 
condition.  As observed in table 3.2, KTZ eutectic concentrations/solubility values increased in 
surfactant containing media (FeSSIF and FaSSIF) from the corresponding blank media (≤ 440% 
increase).  This indicates that KTZ is solubilized by sodium taurocholate and lecithin present in 
the biorelevant media.  The effect of surfactants on coformer eutectic concentrations are less 
compared to that of the drug (≤ 65% increase). 
Cocrystal stoichiometric solubility values were determined with KTZ and CF eutectic 
concentrations, and cocrystal solubility is higher than that of the drug for all three cocrystals 
under all media conditions used.  In general, the enhancement of cocrystal solubility by 
surfactant containing media is less than that of the drug.  This is because of the preferential 
solubilization of drug over coformer leading to non-linear increase in cocrystal solubility with 
surfactant concentration.12-15  In most cases, for both drug and cocrystals, solubility increase was 
more pronounced from blank FeSSIF to FeSSIF compared to from blank FaSSIF to FaSSIF.  
FeSSIF contains more surfactants than FaSSIF, and this can contribute to larger solubility 
enhancements from blank FeSSIF to FeSSIF. 
It is important to note that during the cocrystal solubility studies, acidic coformers caused 
the solution pH to decrease as equilibrium was reached.  The pH alterations were very large in 
FaSSIF and blank FaSSIF media, with final pH decreased 2 - 2.5 pH units from the initial pH 
6.5.  KTZ-FUM cocrystal exhibited the lowest final pH of the three cocrystals, likely due to 
fumaric acid being the most acidic coformer (lowest pKa values) and having the highest cocrystal 
solubility under the media conditions.  In FeSSIF and blank FeSSIF, the changes in pH from 
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initial pH conditions (pH 5) were less pronounced, with < 0.8 pH unit decrease from initial pH 
for all cocrystal studies. 
pH has a huge impact on cocrystal solubility, as was discussed in detail in Chapter 2.  
Equilibrium pH values in FaSSIF and blank FaSSIF (pHeq range 4.00 – 4.50) for these cocrystals 
were slightly lower than their equilibrium pH values in FeSSIF and blank FeSSIF (pHeq range 
4.26 – 4.67).  This resulted in more similar cocrystal solubility values than would be expected 
had the pH remained unchanged from the initial pH values of the media.  On the other hand, 
solution pH changed very little during single component KTZ drug solubility studies (non-
eutectic studies) as equilibrium was reached.  Drug and cocrystal solubility and corresponding 




































Figure 3.1.  (a) KTZ cocrystals and drug experimental solubility in FaSSIF, FeSSIF, blank 
FaSSIF, and blank FeSSIF media.  Numbers above the columns indicate equilibrium pH.  (b) 
Solubilization ratio (SR) of KTZ drug and cocrystals in surfactant vs aqueous media. SR is 
calculated according to equations: 𝑆𝑆𝑆𝑆𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹 =
𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹
𝐹𝐹𝐵𝐵𝐵𝐵𝐹𝐹𝐵𝐵𝐵𝐵𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹




Cocrystals demonstrated higher solubility values and smaller SR compared to the drug in 
different media. This indicates that the cocrystals are less sensitive to pH and surfactants than the 
drug.  Error bars indicate standard errors. 
 
Solubilization ratio (SR) is defined here as the ratio of the solubility of drug or cocrystal 
in surfactant media and their solubility in the corresponding blank aqueous buffer (SR = 
Ssurf/Saq).   Both drug and cocrystal solubility values were observed to increase in surfactant 
containing media from the corresponding blank media.  KTZ drug SRFaSSIF (solubility ratio of 
FaSSIF vs blank FaSSIF) was 4.7 and SRFeSSIF was 6 (figure 3.1b).  Cocrystal SRFaSSIF values are 
between 1.1 and 1.4 and SRFeSSIF values are between 1.4 and 2.7. 
 In previous publications from Rodriguez lab, we have established a simple relationship 
between cocrystal and drug solubilization ratios, where a 1:1 cocrystal solubilization ratio will 
equal the square root of the drug solubilization ratio.14, 16  This relationship applies to cases 
where coformer is not solubilized by solubilizing agents.  Based on the experimental drug 






















KTZ           KTZ-ADP      KTZ-FUM KTZ-SUC
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cocrystal solubilization ratio (SRcc) to be about 2.2 for FaSSIF and 2.4 for FeSSIF.  However, the 
experimental cocrystal SR ratios were different from the expected values due to (equilibrium) pH 
differences during cocrystal and drug solubility measurements.  Table 3.3 compares the predicted 
vs. experimental SRcc values under the same pH conditions. 
 
Table 3.3.  KTZ cocrystal and drug predicted vs. experimental solubilization ratio (SR). 






Blank FaSSIF 4.43 ± 0.02 
1.31 1.14 1.47 
FaSSIF 4.50 ± 0.02 
Blank FeSSIF 4.59 ± 0.02 
4.98 2.23 2.69 
FeSSIF 4.67 ± 0.03 
KTZ-FUM 
Blank FaSSIF 4.00 ± 0.01 
1.27 1.13 1.11 
FaSSIF 4.07 ± 0.02 
Blank FeSSIF 4.26 ± 0.07 
1.73 1.32 1.40 
FeSSIF 4.37 ± 0.04 
KTZ-SUC 
Blank FaSSIF 4.40 ± 0.01 
1.35 1.16 1.07 
FaSSIF 4.43 ± 0.03 
Blank FeSSIF 4.62 ± 0.01 
5.40 2.32 2.24 
FeSSIF 4.63 ± 0.01 





, using drug eutectic concentration 
from table 3.2, which is equal to the solubility of drug at that pH and surfactant 
concentration.   
b. SRcc predicted using the relationship: 𝑆𝑆𝑆𝑆𝑐𝑐𝑐𝑐 = �𝑆𝑆𝑆𝑆𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑, under the assumption that 
coformer solubilization is negligible. 







Decreases of media pH from initial pH values (pH 6.5 and 5) due to coformer ionization 
have increased drug solubility and made the effect of surfactants on drug and cocrystal solubility 
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less prominent.  The SRcc values predicted from the square root of SRdrug are in excellent 
agreement with the experimentally observed SRcc values under the same pH conditions.  This 
shows that the simple relationship between drug and cocrystal SR holds true for the KTZ 
cocrystals, and it can be used to quickly assess cocrystal solubility behavior in surfactant 
containing media based on drug solubility behavior.  Smaller SRcc compared to SRdrug can lead to 
reduced food-effects, and can also reduce the risk of cocrystal conversion to drug in solution by 
decreasing cocrystal solubility advantage. 
Predicting Cocrystal Solubility as a Function of pH and Solubilizing Agents 
Although the ionization properties of cocrystal components make measuring their 
solubility under certain conditions (pH > 5) difficult, the equations derived in the theoretical 
section can be used to predict drug and cocrystal solubility in solutions of different surfactant 
and pH conditions.  Cocrystal Ksp, component pKa, and Ks values are needed for the calculations.  
Ksp values for the three KTZ cocrystals have been determined and reported in Chapter 2.  The 
component pKa values are readily available in the general literature.  The drug and coformer 
solubilization constants (Ks,T) are specific to each component, solubilizing agent, and solution 
conditions (temperature, pH, etc.), and it can be determined experimentally. 
Differences in pH will lead to different extents of ionization for the drug and coformer, 
therefore Ks,T value of each cocrystal component determined in the presence of the surfactants is 
specific for that pH.  In order to determine Ks,T values for KTZ and coformers, single component 














































































580 ± 10 
1.1 






660 ± 10 
 
One can observe in table 3.4 that the drug solubility was enhanced to a larger extent than 
the coformers from blank FeSSIF to FeSSIF media.  KTZ solubility is 6 times higher in FeSSIF 
than blank FeSSIF, whereas the coformer solubility values changed by ≤ 1.2 fold.  High 
solubility and ionization of the acidic coformers caused the pH of the solution to drop 1 to 2 pH 
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units in FeSSIF and blank FeSSIF from the initial pH 5.  KTZ solubility values were higher in 
pH 5 (FeSSIF and blank FeSSIF) than pH 6.5 (FaSSIF and blank FaSSIF), due to increase in 
drug solubility with decreasing pH.  The SR of KTZ was also higher in FeSSIF than FaSSIF, 
which could be due to higher level of surfactants in FeSSIF. 
Equations 3.15 and 3.28 can be combined and rearranged to solve for Ks,TKTZ 
,












=         (3.33) 
where [KTZ]T is the total (non-ionized and ionized species in both aqueous and micellar 
pseudophases) KTZ concentration, and [B]aq is the non-ionized drug concentration in solution. 
Equations 3.27 and 3.29 can be combined and rearranged to solve for Ks,TCF  
2
,












=        (3.34) 
where [CF]T is the total coformer concentration and [H2A]aq is the non-ionized coformer 
concentration in solution.  Ks,T values for KTZ cocrystal components were calculated using 
equations 3.33 and 3.34, with the pKa and experimental solubility values of the components at 















5.00 ± 0.03 5.00 ± 0.01 14400 ± 400 
6.48 ± 0.02 6.45 ± 0.01 1600 ± 70 
ADP 5.00 ± 0.03 3.91 ± 0.06 0 
FUM 5.00 ± 0.03 3.04 ± 0.02 29.1 ± 0.2 
SUC 5.00 ± 0.03 3.00 ± 0.01 9.5 ± 0.2 
 
Ks,T values of KTZ are much larger compared to the coformers, and this supports our 
expectation that the surfactants will preferentially solubilize the more lipophilic drug over the 
more hydrophilic coformers.  ADP does not appear to be solubilized by the surfactant micelles, 
resulting in its Ks,T being 0.   FUM and SUC are both slightly solubilized by the surfactants. 
Ks,T is calculated at a specific pH.  Using Ks,T determine at one pH to predict solubility at 
a different pH can lead to incorrect solubility evaluations.  KTZ and CF can each ionize into 3 
species, which can be solubilized by surfactants to different extent.  The value of Ks,T will 
depend on the distribution and concentration of the ionized species.  Figure 3.2 illustrates the 






























































































 KTZ goes from being nearly entirely in BH+ form at pH 5 to about half non-ionized (B) 
and half BH+ forms at pH 6.5.  Based on the Ks,T values of KTZ in table 3.5, it appears that the 
ionized form of KTZ is solubilized to a higher extent than the non-ionized drug.  The reason for 
this is not clear.  One of the possibilities could be the ionic interaction between positively 
charged drug and taurocholate anions,39 but further studies are needed to confirm this hypothesis.  
In this study, however, pH 5 and 6.5 are the most relevant for our purposes.  The effect of KTZ 
ionization states on its Ks,T value across different pH ranges is not within the scope of this study 
and not investigated here. 
 Figure 3.2 shows that the coformer fraction ionized can range from < 10% ionized to 
100% ionized from pH 3 to 6.5.  The coformer Ks,T values were determined between pH 3.00 and 
3.91, and the Ks,T values were used for predictions in the pH range studied (pH 5 to 6.5).  The 
assumption here is that the coformer Ks,T dependence on pH is negligible and will have little to 
no impact on cocrystal solubility predictions.  One would expect the coformer Ks,T to decrease 
with increasing pH (due to higher extent of coformer ionization).  Because the coformer Ks,T 
values were already quite small to begin with (at pH 3 to 4), we expect the assumption is 
reasonable in this case.  One of the potential consequences is overestimating cocrystal solubility 
in our predictions if the assumption is not justified. 
Predicted cocrystal and drug solubility values were calculated with equations 3.15 and 
3.31 based on media conditions (pH and [M]) and the corresponding parameter values of Ksp, 
pKa, and Ks,T.  Figure 3.3 shows that the predicted cocrystal and drug solubility values are in 
excellent agreement with the experimentally determined values.  This means that the solubility 
equations and associated parameters can quantitatively predict cocrystal solubility, which can in 
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turn provide valuable information on cocrystal solubility and stability behavior without the need 
for extensive experimentation. 
 
  
Figure 3.3.  Predicted vs. observed solubility of KTZ drug and cocrystals in surfactant 
containing media (closed symbols) of FeSSIF and FaSSIF, and in blank media (open symbols).  
KTZ drug is represented by (◊), KTZ-ADP is represented by (○), KTZ-FUM is represented by 
(□), and KTZ-SUC is represented by (Δ).  Predicted solubility values for drug and cocrystals 
were calculated with equations 3.15 and 3.31 using appropriate Ks,T values from table 3.5.  
Observed solubility values were determined experimentally at the eutectic point using equation 
3.32. The dotted line represents where the predicted and experimental solubilities are equal.  
Observed solubility standard error values are less than 4% and are within the data points. 
 
Cocrystal Keu 
 For metastable cocrystals with higher solubility than their parent drugs, cocrystal 
equilibrium solubility can be determined at the eutectic point.3, 40  In this study, the eutectic 
points between the drug and cocrystal were used to determine the stoichiometric solubility of 
KTZ cocrystals under various media conditions.  Eutectic concentrations of KTZ and CF are 




























Figure 3.4.  Cocrystal component eutectic concentrations in FaSSIF, FeSSIF, blank FaSSIF, and 
blank FeSSIF media.  Numbers on top of the columns indicate equilibrium pH.  (a) KTZ-ADP 
(b) KTZ-FUM (c) KTZ-SUC.  Error bars indicate standard error. 
 
 CF eutectic concentrations are higher than that of KTZ for all cocrystals under conditions 
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means that the cocrystals are more soluble than the drug.  The ratio of coformer to drug eutectic 
concentrations is used to approximate the eutectic constant, Keu, which is defined as the activity 
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= ≈             (3.35) 
The notation “𝑎𝑎” represents the activity of coformer or drug. 
Keu > 1 for a 1:1 cocrystal indicates Scc > Sdrug, and the cocrystal is thermodynamically 
unstable with respect to drug, and vice versa.3, 11, 38, 41   In general, Keu values are larger in blank 
media than in surfactant containing media.  Keu can be related to cocrystal SA, and this 
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             (3.36) 
This relationship for KTZ cocrystals is illustrated in figure 3.5, and the experimentally observed 
values are in excellent agreement with this prediction.  All Keu values are > 1, and this means 





Figure 3.5.  Relationship between Keu and cocrystal solubility advantage (SA) for KTZ 
cocrystals.  Line was generated from the logarithmic form of equation 3.36, ( )log 2logeuK SA= .  
Open symbols correspond to blank media, and closed symbols correspond to surfactant 
containing media (FeSSIF and FaSSIF).  Keu standard errors are less than 6% and are within the 
data points. 
 
Effect of Surfactants on Cocrystal Dissolution Behavior 
Preferential solubilization of drug over coformer reduces cocrystal SA, and it can help 
stabilize cocrystal in solution and slow its conversion to less soluble forms (usually the drug) 
during kinetic studies.11-12, 14-17  Bile salts present in the GI tract and simulated intestinal fluids 
(FeSSIF and FaSSIF) can act as drug solubilizing agents and have been shown in the previous 
sections to reduce KTZ cocrystal SA by up to 60%.  To evaluate the influence of cocrystal SA on 
dissolution and conversion to KTZ, dissolution studies were conducted in FeSSIF, FaSSIF, and 
corresponding blank media.  The mass of drug and cocrystals used for dissolution is 1 mg KTZ 
equivalent per mL to reflect the KTZ dose (200 mg) dissolving in 200 mL of water, which 
corresponds to 1.9 mM.  At this dose, the cocrystals are fully dissolved under the conditions of 























For clarity, only KTZ concentrations (not CF concentrations) were plotted in the figures 
of this section to compare cocrystal dissolution advantage over the pure drug.  Both CF and KTZ 
concentrations were measured during cocrystal dissolution, and CF concentrations during 
dissolution confirmed that the cocrystals were fully dissolved.  CF concentrations during 
dissolution in blank media are presented in appendix 2C, where pH 6.5 media = blank FaSSIF 
and pH 5.0 media = blank FeSSIF.  CF concentrations in surfactant media (FeSSIF and FaSSIF) 
are presented in appendix 3A. 
Figure 3.6 compares the dissolution of drug and cocrystals between FaSSIF and blank 
FaSSIF media (initial pH = 6.5).  Cocrystals showed clear dissolution advantages compared to 
the drug in every case except for KTZ-FUM in blank FaSSIF.  Dissolution of pure drug showed 
that the drug dissolved and reached a plateau corresponding to its solubility (~0.01 mM in blank 
FaSSIF and ~0.04 mM in FaSSIF).  Cocrystals generated supersaturation levels of KTZ (σ = 
(C/S)drug) up to 30 times above drug solubility during dissolution.  Although the cocrystals were 
fully dissolved, supersaturation of drug in solution led to KTZ precipitation.  This explains why 
the measured KTZ concentration never reached 1.9 mM, which corresponds to σ ≈ 170 in blank 
FaSSIF and σ ≈ 56 in FaSSIF. 
 











































(c)  (d)  
(e)  (f)  
(g)  (h)  
 
Figure 3.6.  KTZ drug and cocrystal dissolution in blank FaSSIF and FaSSIF (initial pH 6.5). 
KTZ concentration vs. time in (a) blank FaSSIF and (b) FaSSIF.  % drug dissolved vs. time in 
(c) blank FaSSIF and (d) FaSSIF.  Supersaturation with respect to drug (σ) vs. time in (e) blank 
FaSSIF and (f) FaSSIF.  Bulk solution pH vs. time in (g) blank FaSSIF and (h) FaSSIF.  Purple 
dashed line in (a) and (b) represents the KTZ concentration if cocrystal/drug were fully dissolved 
(1.9 mM).  Black dotted line in (a) and (b) represents drug solubility (Sdrug), in (c) and (d) 
represents 100 × (Sdrug / 1.9 mM), and in (e) and (f) represents σ = 1 (no supersaturation).  Error 





















































































Cocrystal dissolution in FaSSIF achieved higher drug concentrations, % drug dissolved, 
and σ values compared to dissolution in blank FaSSIF, indicating that the presence of surfactants 
enhanced cocrystal dissolution and slowed cocrystal conversion to drug.  This is especially 
pronounced for KTZ-FUM cocrystal, which demonstrated little to no dissolution advantage 
compared to drug in blank FaSSIF (~0.01 mM or 0.6 % drug dissolved), but in FaSSIF KTZ-
FUM generated near supersaturation level near 30.  KTZ-ADP and KTZ-SUC also showed 
improvements from blank FaSSIF to FaSSIF, with maximum supersaturation level (σmax) 
increasing from about 15 (blank FaSSIF) to 23 and 30 (FaSSIF), respectively. 
Figure 3.7 illustrates KTZ cocrystal dissolution in FeSSIF and blank FeSSIF.  Lower pH 
(pH 5) of FeSSIF and blank FeSSIF media increases KTZ solubility and decreases cocrystal SA 
(by 30 to 100 fold) compared to the pH 6.5 media (FaSSIF and blank FaSSIF).  Higher surfactant 
concentration in FeSSIF compared to FaSSIF can further enhance solubility and dissolution of 
KTZ drug and cocrystals.  The cocrystals were observed to outperform the drug during 
dissolution in FeSSIF and blank FeSSIF. 
 











































(c)   (d)  
(e)   (f)  
(g)  (h)  
 
Figure 3.7.  KTZ drug and cocrystal dissolution in blank FeSSIF and FeSSIF (initial pH 5.0).  
KTZ concentration vs. time in (a) blank FeSSIF and (b) FeSSIF.  % drug dissolved vs. time in 
(c) blank FeSSIF and (d) FeSSIF.  Supersaturation with respect to drug (σ) vs. time in (e) blank 
FeSSIF and (f) FeSSIF.  Bulk solution pH vs. time in (g) blank FeSSIF and (h) FeSSIF.  Purple 
dashed line in (a) and (b) represents the KTZ concentration if cocrystal/drug were fully dissolved 
(1.9 mM).  Black dotted line in (a) and (b) represents drug solubility (Sdrug), in (c) and (d) 
represents 100 × (Sdrug / 1.9 mM), and in (e) and (f) represents σ = 1 (no supersaturation).  Error 




















































































In figure 3.7a, cocrystals show clear dissolution advantage over drug in blank FeSSIF, 
reaching 74 – 88% drug dissolved (compare to 11% dissolved from pure drug) and generating σ 
up to 7.8 at Cmax.  Conversion from cocrystal to drug occurred in blank FeSSIF, indicated by 
decreasing KTZ concentrations over time.  In FeSSIF, cocrystals remained fully dissolved and 
sustained σ ≈ 1.5 for the entire duration of the study.  This relatively low supersaturation may 
help explain why no drug precipitation was observed during dissolution in FeSSIF. 
Tables 3.6 and 3.7 summarize results from cocrystal and drug dissolution and 
corresponding SA values.  Cmax and σmax show the ability of the cocrystals to generate 
supersaturation during dissolution.  AUC provides information on the ability of the cocrystals to 
sustain supersaturation.  SA is the main driving force for cocrystal to drug conversion and affects 
Cmax, σmax, and AUC values achieved during dissolution.  The largest SA values were observed 
in blank FaSSIF (pH 6.5, no surfactants), ranging from 440 to 3118.  The smallest SA values 
were observed in FeSSIF (pH 5.0, with surfactants), ranging from 5 to 13.  SA has an inverse 
relationship with Cmax and AUC, with the lowest SA corresponding to the highest Cmax and AUC 











Table 3.6.  Cocrystal supersaturation index (SA=Scc/Sdrug), drug Cmax, AUC, and maximum 










































































































a. SA values predicted at corresponding final pH of dissolution for each drug and cocrystal, 
calculated with equations 3.15 and 3.31. 
 
From blank FaSSIF to FaSSIF, SA values decrease roughly by a half for each cocrystal, 
while Cmax, σmax, and AUC values all increased.  The most dramatic improvement is the KTZ-
FUM cocrystal, with about 30 times higher Cmax, 14 times higher σmax, and 57 times higher AUC 
from blank FaSSIF to FaSSIF.  KTZ-ADP and KTZ-SUC also showed improvements in Cmax (4 




Table 3.7.  Cocrystal supersaturation index (SA=Scc/Sdrug), drug Cmax, AUC, and maximum 









































































































a. SA values predicted at corresponding final pH of dissolution for each drug and cocrystal, 
calculated with equations 3.15 and 3.31. 
 
Cocrystal SA values in FeSSIF and blank FeSSIF are much smaller (SA ≤ 36) comparing 
to in pH 6.5 media (FaSSIF and blank FaSSIF).  Cmax and AUC in pH 5 media were also higher.  
Cocrystals were fully dissolved and no drug precipitation occurred during dissolution in FeSSIF, 
and the highest AUC and Cmax values were observed in this media. 
Figure 3.8 illustrates Cmax and AUC from drug and cocrystal dissolution under different 
media conditions.  The cocrystals (except for KTZ-FUM in blank FaSSIF) generated higher KTZ 
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concentrations compared to pure drug dissolution.  Although drug precipitation occurred in all 
media except FeSSIF, the cocrystals still outperformed the drug in most cases. 





Figure 3.8.  (a) KTZ Cmax and (b) AUC during dissolution of drug and cocrystals in different 
media.  Numbers on top of the columns indicates (a) σmax, which is defined as Cmax/Sdrug and (b) 
AUC ratio of cocrystal to drug (AUCcc/drug).  Error bars indicate standard errors. 
 
KTZ cocrystals improve dissolution by generating supersaturation in solution.  However, 
any system that can generate supersaturation has the potential to precipitate.11, 17, 43-45  SA can 




































































Figure 3.9 shows the maximum supersaturation level achieved and AUC enhancement by 
cocrystal dissolution in relation with SA.   
 
Figure 3.9.  Cocrystal σmax and AUCcc/drug as a function of cocrystal supersaturation index (SA). 
Letters “A”, “S”, and “F” by the symbols represent cocrystals KTZ-ADP, KTZ-SUC, and KTZ-
FUM, respectively.  pH 5.0 represents FeSSIF and blank FeSSIF media, and pH 6.5 represents 
FaSSIF and blank FaSSIF media.  Error bars indicate standard error.  Error bars that are not seen 
is due to error within data points. 
 Figure 3.9 shows the advantage of KTZ cocrystals compared to drug.  In FaSSIF, σmax 
values (22 – 30) are 1.5 to 15 times higher than in blank FaSSIF.  AUCcc/drug values (10-15) are 5 
to 57 times higher than in blank.  In FeSSIF, the cocrystals fully dissolved and no drug 
precipitation occurred.  σmax and AUCcc/drug values in FeSSIF are lower than in blank FeSSIF due 
to higher Sdrug in FeSSIF.  Scc also increases in FeSSIF, but to a lesser extent than Sdrug.   
The highest σmax and AUCcc/drug values in FaSSIF indicate that higher supersaturation 














































critical supersaturation value (about 800 to 1400 in both blank and FaSSIF).  Rapid nucleation 
occurs at SA ~ 3000 in blank FaSSIF at σmax > 14. 
The relationship between kinetic dissolution behavior of KTZ cocrystals and SA values 
showed how the cocrystal with the highest solubility and largest SA did not necessarily show 
superior dissolution behavior.  SA represents the driving force for drug precipitation.  Phase 
conversion between cocrystal and its constituent drug can be described by the following 
equation46 
  ( )lncocrystal drugG RT SA→∆ = −             (3.37) 
ΔG is the Gibbs free energy change for the process, and it is negative for a spontaneous process.  
Cocrystal to drug conversion is favored when Scocrystal > Sdrug.  The rate of drug nucleation is 
proportional to ΔG, which is in turn proportional to the logarithmic of SA.  An extremely large 
SA can lead to fast conversion of cocrystal to a less soluble form, and it is undesirable for 
generating and maintaining supersaturation.  One must find the right balance between solubility 
enhancement and risk of precipitation in order to optimize drug supersaturation behavior. 
 
Conclusion 
Cocrystals and drugs can encounter both endogenous and synthetic solubilizing agents 
during the pharmaceutical development process and in the GI environment.  Solubilizing agents 
that preferentially solubilize the drug over coformer can reduce cocrystal SA and improve 
dissolution by enhancing and sustaining supersaturation of the drug in solution.  Understanding 
cocrystal solubility and stability in the presence of solubilizing agents is crucial for correct 
interpretation of experimental results and rational selection of additives to achieve better in vitro 
and in vivo performance.  The equations derived in this chapter provide a material-sparing and 
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time-efficient approach for quantitative evaluation of metastable cocrystal solubility and SA.  
KTZ cocrystals were shown to be more soluble than drug under all media conditions used in this 
study, although the cocrystal solubility enhancement in biorelevant media were not as high as 
that of the drug.  We have shown that surfactants in biorelevant media reduced cocrystal SA and 
improve drug solution levels by slowing cocrystal conversion to drug during dissolution. 
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Cocrystal Dissolution in FaSSIF 
 Both KTZ and CF concentrations were monitored during dissolution to assess the extent 














































Figure 3A.1.  KTZ cocrystal component concentrations during dissolution in FaSSIF media.  
Purple dashed line indicates the concentration at which the cocrystal is fully dissolved.  Blue 
dashed line indicates KTZ drug solubility.  Error bars on the symbols indicate standard errors. 
 
As cocrystal dissolved, both CF and KTZ were released into solution.  FUM concentrations 
increased with time and reached full dissolution around 90 min.  This shows that KTZ-FUM 
cocrystal was fully dissolved in FaSSIF and KTZ drug was precipitating out of the solution 
during dissolution.  Poor UV absorption of SUC and ADP led to their solution concentrations not 
able to be determined during dissolution.  However, KTZ-SUC and KTZ-ADP cocrystal 
solubilities are between 5 and 10 times above the concentration at full dissolution (1.9 mM), 
therefore the cocrystals are expected to be able to fully dissolve. 
Cocrystal Dissolution in FeSSIF 
 During dissolution in FeSSIF, no precipitation of any solid forms was observed for any of 
the cocrystals.  All three cocrystals remained fully dissolved and maintained σ level of about 1.8 

























Figure 3A.2.  KTZ cocrystal component concentrations during dissolution in FeSSIF media.  
Purple dashed line indicates the concentration at which the cocrystal is fully dissolved.  Blue 

































































FUM is the only coformer which concentration could be measured during dissolution in FeSSIF.  
The FUM concentrations can be seen to overlap that of KTZ during KTZ-FUM dissolution, and 






Cocrystal powder dissolution in FaSSIF and FeSSIF media were also conducted with 
magnetic stirring (200 rpm) to see how different conditions might affect the dissolution and 
conversion rate of these cocrystals.  The total dissolution volume used was 21 mL, the mass of 
cocrystal and drug used was 0.8 mg KTZ equivalent/mL, which corresponds to the dose of KTZ 
(200 mg in 250 mL of water/stomach volume), at 24.5 (± 0.5) °C.  The drug and cocrystal 
powders used were sieved and collected between 106 – 125μm particle size.  Sampling 
procedure and HPLC methods used were the same as the other dissolution studies with overhead 
propellers, as described in the Materials and Methods section. 
Cocrystal Dissolution in FaSSIF (Magnetic Stirring) 
Figure 3B.1 illustrates the drug and cocrystal dissolution behavior in FaSSIF media.  If 
the full mass of drug/cocrystal added to solution were dissolved, the solution concentration of 
KTZ would be equal to 1.5 x 10-3 M.  In figure 3B.1a, one can observe that KTZ drug dissolved 
to its solubility in FaSSIF (3.5 x 10-5 M at pH 6.5) in 10 to 20 min and plateaued for the 




























Figure 3B.1.  KTZ drug and cocrystal dissolution in FaSSIF with magnetic stirring. (a) KTZ 
concentration vs. time. The purple dashed line indicates the KTZ concentration if the cocrystal or 
drug added were fully dissolved. The black dotted line indicates the solubility of KTZ in FaSSIF. 
(b) σ with respect to KTZ solubility. The black dotted line indicates where σ = 1, or no 
supersaturation. (c) Bulk pH during dissolution. 
 
 In comparison to dissolution conducted with overhead propeller studies, which also used 
a larger volume (30 mL) and slightly more drug/cocrystal (1.9 x 10-3 M), dissolution using 
magnetic stirring appeared to achieve lower drug Cmax values and have a faster conversion rate.  
The Cmax from the cocrystals decreased 12 - 30% in dissolution with magnetic stirring, and σmax 
decreased 0.7 - 24%.  The Tmax of KTZ-FUM and KTZ-SUC were also affected, and they were 
20 and 10 min earlier in comparison to previous dissolution studies, respectively.  KTZ-ADP 





























dissolution studies occurred at the same time point, the Cmax value decreased about 15% 
compared to dissolution with overhead stirring, and it exhibited only 0.7% decrease in σmax.   
Cocrystal Dissolution in FeSSIF (Magnetic Stirring) 
Cocrystal dissolution in FeSSIF with magnetic stirring was able to achieve full 
dissolution in less than 20 min and remained fully dissolved for the duration of the experiment 
(figure 3B.2).  The σ values from cocrystal dissolution were small (about 1.3), and the cocrystals 
were able to maintain this supersaturation and no drug precipitation was observed.  In this case, 
there appeared to be no large variation in cocrystal dissolution/conversion behavior between the 
two sets of dissolution conditions. 
 















































Figure 3B.2.  KTZ drug and cocrystal dissolution in FeSSIF with magnetic stirring. (a) KTZ 
concentration vs. time. The purple dashed line indicates the KTZ concentration if the cocrystal or 
drug added were fully dissolved. The black dotted line indicates the solubility of KTZ in FeSSIF. 
(b) σ with respect to KTZ solubility. The black dotted line indicates where σ = 1, or no 













ASSESSING SUPERSATURATION AND CONVERSION BEHAVIOR OF COCRYSALS 
OF A BASIC DRUG USING pH-SHIFT DISSOLUTION TEST 
 
Introduction 
 Weakly basic drugs with low solubility under high pH conditions can have impaired oral 
absorption in patients whose gastric pH is elevated.1-8  A young and healthy individual usually 
has a fasting gastric pH of around 2, but in patients with hypochlorhydria conditions caused by 
diseases (AIDS, gastric cancer) or medications (gastric acid suppressing agents) the fasting 
gastric pH can increase to above 7.9-13  Ketoconazole (KTZ) is a broad-spectrum antifungal drug 
that has been effective in treating fungal infections and was commonly used in AIDS patients.14-
18  The FDA has issued a warning in 2013 regarding hepatotoxicity caused by oral KTZ and has 
since restricted its use to severe cases or when alternatives are unavailable.18-20  Although the 
clinical use of KTZ has become less frequent, the solution properties of this drug and its 
cocrystals were found to be quite interesting.   KTZ drug and cocrystals can serve as model 
compounds to improve understanding of systems with similar physicochemical properties. 
KTZ is a lipophilic, weakly basic drug, whose primary dissolution site is the stomach.  
Fasting gastric pH is expected to play a major role in assisting or inhibiting its dissolution 
behavior.  Kostewicz et al. demonstrated that when gastric pH is elevated, incomplete dissolution 
of the dose occurred and oral absorption was reduced for the weakly basic compounds studied.5  
In another study of pH-dependent dissolution and absorption of two weakly basic drugs, 
150 
 
dipyridamole and ketoconazole, Zhou et al. found that in vitro dissolution and drug plasma 
concentration profiles in dogs decreased as media and gastric pH increased.  Decrease in 
treatment efficacy due to poor oral drug absorption can have detrimental effects on patient health 
and prognosis. 
Cocrystals with ionizable components are known to impart or alter solubility-pH 
dependence compared to the parent drug.21-24  Previous chapters demonstrated how cocrystals of 
KTZ with acidic coformers can improve solubility and dissolution under elevated pH (pH > 4) 
conditions.  Coformer ionization properties altered the solubility-pH profiles of KTZ cocrystals 
from that of the parent drug, resulting in reductions in pH-sensitivity in cocrystal solubility and 
the existence of solubility transition points, pHmax.  pHmax is an important parameter that defines 
pH regions where cocrystals are thermodynamically stable and where cocrystals have solubility 
advantage over drug.22-27  Similar solubility behavior has been observed for other cocrystals 
consist of basic and acidic components, or components with amphoteric properties in previous 
studies from Rodriguez lab.22-24 
KTZ cocrystals demonstrated the ability to generate and maintain supersaturation for up 
to 30 times above drug solubility during in vitro dissolution at pH above pHmax (3.6 – 3.8).  To 
better understand how these dissolution advantages can translate to in vivo absorption and 
bioavailability, pH-shift dissolution studies were used to simulate the solution environments the 
cocrystals are expected to encounter during oral dosing.  A simple in vitro microdissolution test 
was developed to assess the pH-dependent absorption risk for weakly basic drugs by Mathias et 
al. in a 2013 publication.28  KTZ was one of the drugs used in the study.  KTZ dissolved rapidly 
in SGF pH 2 and was able to remain fully dissolved after the addition of FaSSIF at a 
supersaturation level around 10 until 75 minutes, after which KTZ slowly precipitated.28  In the 
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SGF pH 6 to FaSSIF study, KTZ dissolution was poor and was not able to reach drug solubility 
during the test.28  The in vitro pH-effect of KTZ was calculated by taking the ratio of the AUC of 
SGFpH6→FaSSIF and SGFpH2→FaSSIF dissolution.28  The results are in good agreement with 
reported clinical (human) pH-effect AUC ratio of KTZ, demonstrating that this dissolution test 
can provide a quick and effective assessment to predict drug in vivo behavior.28  KTZ cocrystals 
demonstrated less sensitivity to pH than the drug, and pH-shift dissolution test can help us to 
better understand and predict how KTZ cocrystals might behave in the gastrointestinal tract. 
This study aims to (1) conduct pH-shift dissolution test on KTZ drug and cocrystals to 
determine the effect of gastric pH on dissolution and supersaturation behavior, (2) assess the 
potential solution advantages the cocrystals can provide during dissolution and transfer from the 
gastric to intestinal compartment, and (3) determine KTZ precipitation behavior during 
dissolution. 
 
Materials and Methods 
Materials 
Ketoconazole (lot # BS1203355108, 98% purity) was purchased from Bosche Scientific 
(New Brunswick, NJ) and used as received.  Adipic acid (lot # 06807BE, 99% purity), succinic 
acid (lot # 037K0021, 99% purity), fumaric acid (lot # 09426EE, 99+% purity), acetic acid (lot # 
074K3658, 99%), sodium acetate anhydrous (lot # 100K0272), potassium phosphate monobasic 
(ACS reagent), and sodium chloride (NaCl) (lot # 094K0183, ACS reagent) were purchased 
from Sigma-Aldrich (St. Louis, MO) and used as received.  FaSSIF/FeSSIF/FaSSGF powder 
was purchased from biorelevant.com (London, United Kingdom) and used as received.  HPLC 
grade methanol, HPLC grade 2-propanol, sodium phosphate monobasic (NaH2PO4•H2O) (lot # 
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017316), and hydrochloric acid (lot # 2AJK15038, ACS grade) were purchased from Fisher 
Scientific (Fair Lawn, NJ).  Acetone (ACS reagent 99.5%) and phosphoric acid (lot # B0506524, 
85+%) were purchased from Acros Organics (NJ) and used as received.  Trifluoroacetic acid 
(spectrophometric grade, 99%) was purchased from Aldrich Company (Milwaukee, WI).  NaOH 
(pellets) was purchased from J.T. Baker (Philipsburg, NJ).  Water used in this study was filtered 
through a Milli-Q Reference Water System from Millipore Co. (Bedford, MA). 
Cocrystal Synthesis 
1:1 cocrystals of KTZ and the dicarboxylic acid coformers were prepared by reaction 
crystallization method at room temperature.29  KTZ-FUM and KTZ-SUC were synthesized in 
acetone.  KTZ-ADP was synthesized in 2-propanol.  Full conversion of drug to cocrystal was 
observed between 24 to 48 hours.  The solid phases were verified by X-ray powder diffraction 
(XRPD) and differential scanning calorimetry (DSC); cocrystal component stoichiometry was 
verified by HPLC. 
Dissolution Media 
All aqueous media were prepared at room temperature with DI water filtered by Milli-Q 
Reference Water System.  Simulated gastric fluid (SGF) of two different pH values was 
prepared.  0.01 M of HCl solution was prepared for SGF at pH 2.08 ± 0.04.  Phosphate buffer 
was prepared with potassium phosphate monobasic and NaOH for SGF at pH 6.03 ± 0.03 to 
represent elevated gastric pH condition.  Concentrated FaSSIF was prepared by using 1.5 times 
the concentrations of each media component based on the method and composition described by 
Dressman and coworkers.30-31  The surfactants used in FaSSIF (lecithin and sodium taurocholate) 
were from premade FaSSIF/FeSSIF/FaSSGF powders purchased from Biorelevant.com.  
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Concentrated blank FaSSIF (1.5x) was prepared with the same ingredients and procedure as 
FaSSIF, except blank FaSSIF did not contain lecithin and sodium taurocholate. 
pH-Shift Dissolution 
 Dissolution setup is based on the Microdissolution pH-Shift Test described in the 2013 
publication by Mathias et al.28  The pH-shift dissolution was conducted in two stages, in order to 
mimic the transfer from gastric to intestinal compartment.  KTZ drug and cocrystals were first 
dissolved in 7 mL of simulated gastric fluid (SGF) at pH 2 (normal) or pH 6 (elevated) for 20 
minutes (min).28, 30-31  At 20 min, 14 mL of the concentrated (1.5 x) FaSSIF or blank FaSSIF was 
added to cause a pH-shift to pH 6.5, and dissolution continued till 180 min.  The mass of solid 
used for drug and cocrystal dissolution translates to concentrations between 1.5 x 10-3 and 1.6 x 
10-3 M (corresponding to the 200 mg KTZ dose/250 mL) in the initial SGF media, and becomes 
approximately 5 x 10-4 M following dilution by the addition of the second media.   
Dissolution was conducted in 25 mL beaker with magnetic stirring (200 rpm) set in a 
water bath at 24.8 ± 0.02 °C.  Powder of drug or cocrystal used was sieved between 106 – 125 
μm.  Solution samples (approximately 0.4 mL) were taken with syringe at selected time points 
both prior and following pH-shift.  Sample volume was not replaced.  Loss in volume of the 
initial dissolution media was accounted for in the calculation of theoretical maximum 
concentrations (fully dissolved).  The solution samples were filtered using syringe filter with 
PVDF membrane of 0.45 µm pore size.  The solution concentrations of drug and coformers were 






High Performance Liquid Chromatography (HPLC) 
Solution concentrations of the drug and coformer were analyzed by a Waters HPLC 
equipped with an UV spectrometer detector.  A Waters Atlantis C18 column with the dimensions 
of 250 x 4.6 mm and 5 µm particle size was used for separation at ambient temperature. The 
flow rate was set at 1mL/min.  Injection volume of 20µL was used for KTZ and FUM, and 
injection volume of 100µL was used for SUC and ADP.  For KTZ-ADP and KTZ-FUM 
cocrystals and their components, the mobile phase used composed of 60% methanol and 40% 
water with 0.1% trifluoroacetic acid (TFA).  The KTZ component of KTZ-SUC cocrystal was 
analyzed using mobile phase composed of 60% methanol and 40% water with 0.1% TFA.  The 
SUC component was analyzed using a gradient method with flow rate of 1mL/min starting with 
mobile phase composed of 25% methanol and 75% water with 0.1% TFA.  The composition 
changes to 80% methanol and 20% water with 0.1% TFA after 2.5 min then reverts back to 25% 
methanol and 75% water with 0.1% trifluoroacetic acid after 6 min. The wavelengths used for 
the analytes were as follows: 230 nm for KTZ, 220 nm for FUM, and 210 nm for SUC and ADP. 
X-Ray Powder Diffraction (XRPD) 
A Rigaku Miniflex X-ray diffractometer (Danverse, MA0) using Cu-Kα radiation, a tube 
voltage of 30 kV, and a tube current of 15 mA was utilized for analysis and characterization of 
cocrystals synthesized prior to the dissolution experiments.  Measurements were taken from 5° to 
40° at a continuous scan rate of 2.5°/min. 
Thermal Analysis 
TA instrument differential scanning calorimetry (DSC) (Newark, DE) was used to 
analyze and characterize the solids collected from the cocrystal synthesis via RCM.  The heating 
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rate of the experiments was at 10°C/min under dry nitrogen atmosphere.  Standard aluminum 
sample pans and lids were used for these measurements. 
Light Microscopy Studies 
KTZ phase separation/precipitation behavior in supersaturated solutions was studied 
under bright field microscopy using a Leica DMi8 microscope.  Sample solution was prepared 
by dissolving 8 mg of KTZ in 10 mL of 0.01 M HCl solution (pH 2) in a scintillation vial with 
magnetic stirring.  After all solid drug was dissolved, 1.1 mL of 0.1 M NaOH solution was added 
to solution to raise the pH to 6.5 ± 0.1 and induce supersaturation of drug.  200 μL of the solution 
was sampled and transferred into a 96-well plate to be observed under the microscope.  20x 
magnification objective lens was used for the observations. 
 
Results and Discussion 
SGF pH 2 to Blank FaSSIF 
 First, the effect of pH-shift from pH 2 to 6.5 without surfactants was examined.  Low 
gastric pH is favorable for KTZ dissolution and absorption, and at pH 2, the drug is more soluble 
than the cocrystals.  Figure 4.1 shows the KTZ concentration and supersaturation level during 
cocrystal and drug pH-shift dissolution from SGF pH 2 to blank FaSSIF (pH 6.5) if full 
dissolution was achieved.  The mass of drug and cocrystals used in dissolution is 0.8 mg KTZ 
equivalent per mL in the initial media, which corresponds to the oral dose of KTZ (200 mg) 
dissolving in gastric volume of 250 mL.11, 32-33  This corresponds to KTZ concentrations (fully 





Figure 4.1.  KTZ concentration that can be achieved during cocrystal and drug pH-shift 
dissolution from SGF pH 2 to blank FaSSIF (pH 6.5).  KTZ drug and cocrystal solubility-pH 
profiles (solid lines) from pH 1 to 7 were generated using equations 2.2 and 2.3 and parameter 
values reported in Chapter 2.  Experimental solubility values for drug and cocrystals are 
presented as symbols: KTZ (○), KTZ-ADP (□), KTZ-FUM (◊), and KTZ-SUC (Δ).  The 
standard errors of experimental solubility values are less than 4% and are within the data symbol.  
Concentrations of drug and cocrystal before and after pH-shift are indicated by “ж”, and pH-shift 
is indicated by “→”.  σ in this plot represents the theoretical supersaturation level (σtheoretical) of 
KTZ if drug or cocrystal is fully dissolved, and it is equal to (C/S)drug.  The range of σ values is 
due to the slight pH variations from the dissolution studies. 
 
 
 Figure 4.1 shows that at initial pH (pH ~ 2.2), both drug and cocrystals can fully dissolve.  
After the pH-shift (final pH 6.0 - 6.3), KTZ solubility drops dramatically (≤ 0.025 mM), and the 
drug and cocrystals, if fully dissolved, will generate supersaturations between 20 and 33 with 
respect to drug.  This theoretical supersaturation with respect to drug is represented by σtheoretical.  

































The kinetics of precipitation can vary greatly due to many factors including 
supersaturation, solute concentration, pH, solution composition, stirring, and temperature.34-38  
Supersaturation is a major driving force of KTZ precipitation.  As supersaturation levels 
increase, so does drug precipitation, resulting in lower levels of drug concentration.25, 27, 38  If 
drug precipitation is relatively slow, supersaturation can be achieved and maintained for longer 
periods of time.  The ability of drug and cocrystals to maintain supersaturation following pH-














































Figure 4.2.  pH-shift dissolution of SGF pH 2 to blank FaSSIF (pH 6.5) for KTZ drug and 













































profile after pH-shift (20 – 180min).  (c) Percent drug dissolved (100 × [KTZ] / 0.5 mM after 
pH-shift) vs. time.  (d) KTZ supersaturation vs. time.  (e) Solution pH during dissolution.  Black 
dotted vertical line in (a) represents where pH-shift occurred.  Purple dashed lines in (a) and (b) 
indicate the concentration if drug and cocrystals fully dissolve.  The drop in theoretical 
concentration at 20 min indicates the dilution.  Blue dashed line in (a) and (b) represents Sdrug in 
blank FaSSIF, and in (c) represents 100 × (Sdrug / 0.5 mM).  The black dashed line in (d) 
indicates where σ = 1. 
 
Figure 4.2 shows that the cocrystals and drug exhibited similar experimental 
supersaturation levels (σexp) and KTZ precipitation behavior during dissolution.  Cocrystal or 
drug added to the initial media dissolved within minutes and remained fully dissolved prior to 
pH-shift.  Concentrations of drug and coformers were measured at 19 min, right before the pH-
shift, and the concentrations confirmed full dissolution of drug and cocrystals.  Coformer 
concentrations during dissolution can be found in appendix 4A. 
Immediately after pH-shift into blank FaSSIF, a slight cloudiness was observed in the 
bulk solution.  KTZ concentrations dropped below the full dissolution concentration at 0.5 mM 
(σtheoretical = 20 – 33) to between 0.25 – 0.4 mM but still generated σexp between 16 and 18 up to 
the 50 min time point (about 30 min after the pH-shift).  At and after 60 min, KTZ 
concentrations were observed to decrease, indicating crystallization of drug was occurring. 
 The presence of a supersaturated plateau region immediately following pH-shift that is 
below full dissolution but above drug solubility suggests an initial precipitation state.  This phase 
that forms in this state was further evaluated to be a metastable phase, that over time converts to 
crystalline KTZ, which will be discussed in a subsequent section.  
SGF pH 2 to FaSSIF 
 The differences between gastric and intestinal compartment is not only pH but also the 
presence of solubilizing agents as physiologically relevant surfactants.  In Chapter 3, we have 
demonstrated that sodium taurocholate and lecithin present in FaSSIF and FeSSIF can enhance 
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solubility and slow cocrystal to drug conversion.  In this section, FaSSIF was used for the pH-
shift study to determine the effect of endogenous surfactants on cocrystal conversion kinetics.  
Figure 4.3 shows the observed and predicted influence of pH with and without surfactants on 
KTZ drug and cocrystal solubility. 
  
Figure 4.3.  KTZ concentration that can be achieved during cocrystal and drug pH-shift 
dissolution from SGF pH 2 to FaSSIF.  Solid curves represent KTZ drug and cocrystal solubility-
pH profiles from pH 1 to 7.  The influence of surfactants in FaSSIF on drug and cocrystal 
solubility is represented as dashed lines.  Experimental solubility values for drug and cocrystals 
are presented as symbols: KTZ (○), KTZ-ADP (□), KTZ-FUM (◊), and KTZ-SUC (Δ).  Open 
symbols indicate solubility in aqueous buffer, and closed symbols represent solubility in FaSSIF.  
The standard errors of experimental solubility values are less than 4% and are within the data 
symbol.  Concentrations of drug and cocrystal before and after pH-shift are indicated by “ж”, 
and pH-shift is indicated by “→”.  σ in this plot represents the theoretical supersaturation level 
(σtheoretical) of KTZ if drug or cocrystal is fully dissolved, and it is equal to (C/S)drug.  The range of 
σ values is due to the slight pH variations from the dissolution studies. 
 
 Figure 4.3 shows the pH conditions before and after pH-shift, as well as the concentration 
of drug and cocrystals used in dissolution study relative to their solubility.  Drug and cocrystal 
































drug are fully soluble before the pH-shift.  After the pH-shift, cocrystals remain fully soluble but 
the drug solubility drops below 0.5 mM, with σtheoretical between 13 and 14 at full dissolution.  
σtheoretical in FaSSIF is lower than blank FaSSIF due to higher Sdrug, and this can lead to a slower 
rate of drug precipitation. 
Figures 4.4a and 4.4b show that KTZ concentrations immediately after pH-shift falls to 
theoretical concentration of 0.5 mM, which indicates full cocrystal and drug dissolution.  Bulk 
pH values were similar for drug and cocrystal dissolution studies, and they increased from 
around 2.2 to about 6.3 before and after the pH-shift.  Unlike blank FaSSIF, the bulk solution 
remained clear and no cloudiness or precipitation was observed immediately following the pH-
shift.   
 

















































































Figure 4.4.  pH-shift dissolution of SGF pH 2 to FaSSIF for KTZ drug and cocrystals.  (a) KTZ 
concentration-time profile during dissolution. (b) KTZ concentration-time profile after pH-shift 
(20 – 180min).  (c) Percent drug dissolved (100 × [KTZ] / 0.5 mM after pH-shift) vs. time.  (d) 
KTZ supersaturation vs. time.  (e) Solution pH during dissolution.  Black dotted vertical line in 
(a) represents where pH-shift occurred.  Purple dashed lines in (a) and (b) indicate the 
concentration if drug and cocrystals fully dissolve.  The drop in theoretical concentration at 20 
min indicates the dilution.  Blue dashed line in (a) and (b) represents Sdrug in FaSSIF, and in (c) 
represents 100 × (Sdrug / 0.5 mM).  The black dashed line in (d) indicates where σ = 1. 
 
 Surfactants in FaSSIF appeared to have a positive effect on cocrystal and drug pH-shift 
dissolution.  KTZ concentrations were higher, supersaturations were lower (13 – 15 in FaSSIF 
vs. 16 – 18 in blank FaSSIF) and were sustained longer.  The initial supersaturation levels (σexp 
between 13 and 15) were sustained until the 75 min time point (55 min after pH-shift) for KTZ-
SUC and KTZ-ADP, 60 min time point (40 min after pH-shift) for KTZ-FUM, and 50 min time 
point (30 min after pH-shift) for KTZ drug.  By the end of the dissolution (180 min), KTZ 
concentrations did not drop to drug solubility, but remained supersaturated with σexp values 
between 3 and 4. 
KTZ drug pH-shift dissolution from SGF pH 2 to FaSSIF from this study was compared 
with the results from the Mathias et al. study (gastric pH 2 to FaSSIF) at 37°C temperature in 














Figure 4.5.  KTZ pH-shift dissolution (SGF pH 2 to FaSSIF) comparison between this study and 
study published by Mathias et al.28 
 
The results from this study are in very good agreement with those from Mathias et al.  In both 
cases, KTZ drug dissolved rapidly and completely in the initial media, then remained fully 
dissolved initially after pH-shift ([KTZ] ≈ 0.5 mM in this study and ≈ 0.4 mM in Mathias et al. 
study).  KTZ was observed to begin precipitating between 60 min and 75 min, reaching final 
concentration values (at 180 min) of 0.1 mM in both studies.28  The main differences between the 
two studies were temperature (25°C in this study vs. 37°C in Mathias et al. study) and analytical 
methods (HPLC vs. UV probe) for drug concentration measurements.28 
SGF pH 6 to FaSSIF 
 Unlike in the previous section pH-shift studies, the dose of KTZ drug is not fully soluble 
in the initial media of SGF pH 6 (figure 4.6).  This resulted in undissolved solid in solution 
before pH-shift for both cocrystal and drug dissolution studies.  The solid could either be from 
undissolved drug/cocrystal or from cocrystal conversion to drug.  In this case, the pH difference 























higher in final media (FaSSIF) compared to in initial media (SGF pH 6) due to the solubilizing 
effect of FaSSIF surfactants.  Although KTZ has demonstrated poor solubility, dissolution, and 
oral absorption at this gastric pH,2, 4-5, 39 all three cocrystals have higher solubilities and can have 
dissolution advantages over the drug. 
 
 
Figure 4.6.  KTZ concentration that can be achieved during cocrystal and drug pH-shift 
dissolution from SGF pH 6 to FaSSIF.  Solid curves represent KTZ drug and cocrystal solubility-
pH profiles from pH 4 to 7.  The influence of surfactants in FaSSIF on drug and cocrystal 
solubility is represented as dashed lines.  Experimental solubility values for drug and cocrystals 
are presented as symbols: KTZ (○), KTZ-ADP (□), KTZ-FUM (◊), and KTZ-SUC (Δ).  Open 
symbols indicate solubility in aqueous buffer, and closed symbols represent solubility in FaSSIF.  
The standard errors of experimental solubility values are less than 4% and are within the data 
symbol.  Concentrations of cocrystal before and after pH-shift are indicated by “ж”, 
concentrations of drug before and after pH-shift are indicated by “×”, and pH-shift is indicated 
by “→”.  σ in this plot represents the theoretical supersaturation level (σtheoretical) of KTZ if 
cocrystal is fully dissolved, and it is equal to (C/S)drug.  The range of σ values is due to the slight 
pH variations from the dissolution studies. Since KTZ drug cannot dissolve above its 




















σ = 52 - 66
Final pH









 Figure 4.6 shows that before pH-shift (pH 5.9 - 6.1), the mass of cocrystal and drug used 
would be 52 and 66 times above the drug solubility if fully dissolved.  This means that cocrystal 
dissolution can generate supersaturation and undergo solution-mediated conversion to drug prior 
to pH-shift.  After pH-shift, σtheoretical values decreased to between 12 and 14. 
Drug supersaturation generated by cocrystal dissolution in the initial media can be 
maintained after pH-shift, and any undissolved solid cocrystals could continue to dissolve in 























































































Figure 4.7.  pH-shift dissolution of SGF pH 6 to FaSSIF for KTZ drug and cocrystals.  (a) KTZ 
concentration-time profile during dissolution. (b) KTZ concentration-time profile after pH-shift 
(20 – 180min).  (c) Percent drug dissolved (100 × [KTZ] / 1.5 mM before pH-shift and 100 × 
[KTZ] / 0.5 mM after pH-shift) vs. time.  (d) KTZ supersaturation vs. time.  (e) Solution pH 
during dissolution.  Black dotted vertical line in (a) represents where pH-shift occurred.  Purple 
dashed lines in (a) and (b) indicate the concentration if drug and cocrystals fully dissolve.  The 
drop in theoretical concentration at 20 min indicates the dilution.  Blue dashed line in (a) and (b) 
represents Sdrug in FaSSIF, and in (c) represents 100 × (Sdrug / 0.5 mM) after pH-shift.  The black 
dashed line in (d) indicates where σ = 1. 
 
 Figure 4.7 shows that cocrystal dissolution generated much higher KTZ concentrations in 
solution compared to pure drug dissolution.  KTZ concentrations from cocrystal dissolution were 
observed to increase immediately following the pH-shift, indicating that there might have been 
some undissolved cocrystal prior to pH-shift.  Cocrystals generated σexp values between 14 and 
18 before the pH-shift and between 5 and 8 after the pH-shift at Cmax (figure 4.7d).  The 
cocrystals also maintained σexp between 2 and 3 by the end of dissolution (180 min). 
Pure drug dissolution in SGF pH 6 to FaSSIF showed much lower concentrations of KTZ 
compared to the dissolution starting with low initial pH (SGF pH 2), and similar observation can 
















Figure 4.8.  KTZ pH-shift dissolution (SGF pH 6 to FaSSIF) comparison between this study and 
study published by Mathias et al.28 
 
In this study, KTZ concentration in FaSSIF quickly reached 0.046 mM (within 10 min) after pH-
shift, and remained around drug solubility for the duration of the study.   In the Mathias et al. 
study, KTZ concentration initially appeared to drop to zero after pH-shift, then slowly increased 
over time toward drug solubility, reaching final concentration around 0.043 mM by the end of 
dissolution.28  Both studies reached similar final drug concentration values by 180 min, which 
corresponds to KTZ solubility in FaSSIF (between 0.026 and 0.05 mM).31, 40-42  Although the 
two studies appeared to exhibit some differences in KTZ concentrations during dissolution, it is 
important to note that the concentration values measured are very small (≤ 0.05 mM) making 
accurate quantifications more difficult.  This may have contributed to some of the differences 
observed. 
Elevated gastric pH condition is where the KTZ cocrystals truly demonstrated advantages 





















cocrystals were able to generate much higher drug levels both before and after pH-shift.  KTZ 
cocrystals reduced the negative impact of elevated pH on drug dissolution behavior. 
Drug and Cocrystal Dissolution Cmax and AUC 
Values of solution pH, KTZ Cmax, and σmax (Cmax/Sdrug) before pH-shift are summarized 
in table 4.1.   
 
Table 4.1.  Dissolution pH, KTZ Cmax, and σmax before pH-shift under different media 
conditions. 






pH 2  Blank FaSSIF 2.20 ± 0.01 1.66 ± 0.07 100 
pH 2  FaSSIF 2.23 ± 0.01 1.59 ± 0.02 100 
pH 6  FaSSIF 6.04 ± 0.02 0.025 ± 0.001 2 
KTZ-ADP 
pH 2  Blank FaSSIF 2.21 ± 0.06 1.616 ± 0.002 100 
pH 2  FaSSIF 2.23 ± 0.02 1.55 ± 0.03 100 
pH 6  FaSSIF 5.90 ± 0.03 0.51 ± 0.02 34 
KTZ-FUM 
pH 2  Blank FaSSIF 2.18 ± 0.05 1.58 ± 0.02 100 
pH 2  FaSSIF 2.21 ± 0.01 1.58 ± 0.02 100 
pH 6  FaSSIF 5.89 ± 0.03 0.449 ± 0.008 27 
KTZ-SUC 
pH 2  Blank FaSSIF 2.20 ± 0.02 1.58 ± 0.01 100 
pH 2  FaSSIF 2.23 ± 0.01 1.59 ± 0.01 100 
pH 6  FaSSIF 5.92 ± 0.06 0.44 ± 0.01 29 
a. % drug dissolved calculated with 100 × [KTZ]Cmax before pH-shift / 1.5 mM. 
 
Table 4.1 shows that before pH-shift, KTZ drug and cocrystals were 100% dissolved in 
SGF pH 2 media.  Full dissolution did not occur in SGF pH 6, the cocrystals were able to 
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achieve between 27% and 34% drug dissolved before pH-shift, which are much improved 
compared to pure drug, which only achieved about 2% dissolved in SGF pH 6.  
Values of final solution pH, KTZ Cmax, σmax (supersaturation at Cmax), AUC, and 
cocrystal to drug AUC ratio after the pH-shift are summarized in table 4.2.  Drug and cocrystal 
dissolution achieved similar Cmax, σmax, and AUC values after pH-shift from SGF pH 2.  In 
dissolution SGF pH 6 → FaSSIF, the cocrystals demonstrated dissolution advantages over drug, 
achieving 3 – 4 times higher AUC values and σmax values between 5 and 8 after pH-shift.  Higher 
extent of KTZ dissolution achieved by the cocrystals under elevated pH condition can lead to 

















Table 4.2.  Final dissolution pH, KTZ Cmax, σmax, AUC, and cocrystal to drug AUC ratio 
following pH-shift under different media conditions. 
Drug/ 
Cocrystal 





 (mM × min) 
AUCcc/drug 
KTZ 
















































































































































b. σmax = Cmax/Sdrug.  Sdrug values are predicted using equations and parameter values 
established in Chapter 2 and Chapter 3. 
 
A comparison of KTZ Cmax from drug and cocrystal pH-shift dissolution studies in figure 





Figure 4.9.  KTZ Cmax (a) before and (b) after pH-shift for drug and cocrystal dissolution.  
Numbers on top of columns in (a) indicate % drug dissolved at Cmax which is equal to 100 × 
[KTZ]Cmax / 1.5 mM, and in (b) indicate σmax values (Cmax/Sdrug).  pH values in legend indicate 
initial media pH.  Error bars indicate standard errors. 
 
The cocrystals and drug had similar performance during dissolution when the initial 
media pH was low (figures 4.2, 4.4, and 4.9).  Cocrystals, in most cases, exhibited similar Cmax 
values as the drug for dissolution starting with SGF pH 2.  The exception being KTZ-SUC in 







































































FaSSIF are lower than those in FaSSIF following pH-shift from SGF pH 2 for both drug and 
cocrystals.  This correlates with the initial drop in drug concentration to below full dissolution 
immediately after pH-shift into blank FaSSIF, and the formation of metastable drug forms during 
this time.  High levels of supersaturation in solution can cause phase separation and metastable 
forms to occur prior to drug crystallization.35, 43-44  This precipitation behavior is described in the 
next section. 
AUC values for cocrystals and drug were calculated between time points 21 and 180 min 
(after pH-shift) and shown in figure 4.10a.  AUC can be an indicator of KTZ oral absorption and 
bioavailability since it quantifies the overall exposure of drug under pH and endogenous 
surfactants conditions of the small intestine, where the KTZ is absorbed.  Cocrystals show 
superior performance in FaSSIF following pH-shift from SGF pH 6, and their AUC values are 3 
to 4 times higher than the drug.  This suggests that cocrystals may improve oral absorption of 

































Figure 4.10.  (a) KTZ AUC after pH-shift (21 – 180 min) for drug and cocrystal dissolution. 
Number on top of the column indicates AUC ratio of cocrystal to drug (AUCcc/drug). (b) Cocrystal 
and drug AUC ratio in different media. 
 
Dissolution in SGF pH 6 to FaSSIF exhibited the lowest σmax values, and cocrystal 
dissolution led to supersaturation that was sustained for the entire duration of this study.  As a 
result, cocrystal AUC in pH 6 → FaSSIF were 3 – 4 times higher than the drug (figure 4.10a).  
Cocrystal and drug AUC ratios in figure 4.10b show that cocrystal dissolution appears to be less 
sensitive to pH than the drug.  Drug dissolution showed more than 6 fold difference between 
AUCpH2→FaSSIF and AUCpH6→FaSSIF, while the cocrystal AUC values changed only about 2.5 fold.  
Cocrystal AUCpH2blank FaSSIF/AUCpH6FaSSIF and AUCpH2FaSSIF/AUCpH6FaSSIF ratios are less 
than half of those of the drug, and this implies that the cocrystals may exhibit less variability in 
dissolution and bioavailability based on gastric pH conditions than the drug. 
Cocrystal AUCpH2FaSSIF/AUCpH2blank FaSSIF ratios show more variability for KTZ-ADP 
and KTZ-SUC, while KTZ-FUM exhibited a similar AUC ratio as the drug.  Since KTZ 
cocrystals and drug were fully dissolved in SGF pH 2, the variability of AUC after pH-shift is 
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cocrystals have shown clear advantages with elevated gastric pH condition, which is known to 
pose serious problems for KTZ oral absorption.2, 4, 39 
The study of Mathias et al. reported KTZ pH-effect ratio of the AUC values of the full 
dissolution profiles (0 to 180 min) from gastric to intestinal transfer 
(AUCSGFpH6FaSSIF/AUCSGFpH2FaSSIF) to be 0.22, and this was compared to the clinical ratio of 
0.19.28  The AUC in our work was determined after pH shift (21 to 180 min), but they can still be 
used to understand the effect of gastric pH on KTZ exposure in the intestinal environment.  The 
after pH-shift AUC ratios (SGF pH6 → FaSSIF vs. SGF pH2 → FaSSIF) for KTZ drug, KTZ-
ADP, KTZ-FUM, and KTZ-SUC are: 0.15, 0.40, 0.39, and 0.40, respectively.  Larger AUC ratio 
values of the cocrystals indicate that the pH-effect on cocrystals are less pronounced than the 
drug. 
Metastable Phases of KTZ During Precipitation 
 The solution behavior of KTZ in blank FaSSIF immediately following pH-shift suggested 
that metastable form of KTZ have formed.  A highly supersaturated solution can undergo liquid-
liquid phase separation, which is a process also known as spinodal decomposition, prior to 
crystallization.35, 43-49  This liquid-liquid phase separation can be induced by rapid generation of 
high supersaturation with respect to drug.43-44, 46, 50  In the case of KTZ, this can be accomplished 
by rapidly increase pH of a drug solution from 2 to 6.5 with the addition of NaOH, generating 
high supersaturation level of drug (σ = 150).  The previously clear drug solution immediately 
turned cloudy upon NaOH addition, similar to what was observed during pH-shift dissolution 
from pH 2 to blank FaSSIF.  A sample of this solution was taken and observed under the 




Sample solution under the microscope was initially too cloudy to make out any clear 
image.  After about 10 to 15 min, the solution was settled enough that liquid-like droplets could 
be seen on the bottom of the well.  This confirmed that KTZ does indeed undergo liquid-liquid 
phase separation under high supersaturation conditions.  The phase separated droplets gradually 
increased in size and began merging with each other, as can be observed in figure 4.11 as the 
island-like formations.  Also present were smaller spherical phases, which gradually increased in 
size and number with time but did not appear to merge with each other.  During this time period, 
no crystalline drug was observed. 
 
 
Figure 4.11.  Islands and spherical domains of phase separated KTZ. The photo was taken at 40 





At 180 min (figure 4.12), the liquid-like phases formed islands as droplets merged, while 
the spherical phase grew in size and number.  Small KTZ crystals began to form (< 30 μm) by 
this time.  Figure 4.12 shows two of the crystals. 
 
 
Figure 4.12.  Metastable forms of KTZ observed 3 hours after pH-shift. The liquid phase has 
merged into islands.  The spheres are larger in size and more numerous.  Drug crystals began to 
form (indicated by arrows). 
 
 
The small crystals of KTZ grew in solution over time, and they became clearly visible 
and much larger in size (60 – 90 μm) by 6 hours (figure 4.13).  As the crystals grew, the liquid-
like phase receded from the growing crystals, and the spheres also disappeared from that area.  






Figure 4.13.  Metastable phases formed at high supersaturations convert to crystals.  After 6 
hours, the KTZ crystals have grown significantly in size.  As crystals grew, the surrounding 
metastable phases are depleted. 
 
Formation of metastable drug forms may be favorable for oral absorption in vivo.  These 
metastable KTZ phases exhibit higher solubility than the crystalline form, and their formation 
can delay the onset of crystallization thus allowing higher levels of drug exposure.  Future 
studies will investigate the conditions under which these metastable states form, and their 
compositions and structures.  This is beyond the scope of this chapter. 
 
Conclusion 
 pH-shift dissolution studies that simulated fasting gastric and intestinal pH conditions 
demonstrated the advantages of KTZ cocrystals over the dug.  The most important improvements 
in dissolution behavior were shown by cocrystals under SGF pH 6 condition, where the drug 
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dissolution was very poor and could lead to poor oral absorption in vivo.  Supersaturation of 
KTZ achieved by cocrystals (between 5 and 8 fold) can lead to oral absorption enhancement 
under elevated gastric pH conditions and improve bioavailability for this drug.  Under normal 
fasting gastric pH conditions (pH 2), the cocrystal and drug dissolution exhibited similar solution 
behavior with some differences in KTZ concentration vs time profiles following the pH-shift in 
FaSSIF.  These studies suggest that cocrystals may enhance the oral absorption of KTZ and 
mitigate the effect of elevated gastric pH. 
 KTZ goes through metastable phases during its precipitation prior to crystallization of the 
drug at high supersaturation levels induced by pH changes.  These metastable phases exhibit 
higher solubility than crystalline drug, and may also enhance oral absorption.  Additional studies 
are needed to determine the properties of these metastable phases and what conditions are 
required for their formation. 
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 To confirm that the cocrystals were fully dissolved, both drug and coformer 
concentrations were monitored during dissolution.  The figures in this appendix show the 
cocrystal component concentrations during dissolution. 
pH-Shift Dissolution: pH 2  Blank FaSSIF 
Drug and coformer concentrations from figure 4A.1 show that full dissolution of 
cocrystals was achieved in the initial media prior to pH-shift.  This can be observed as the ADP, 
FUM, and SUC concentrations were the same as that of the drug, and both were at full 
dissolution concentration (purple dashed lines).  Following the pH-shift, KTZ concentrations 
were observed to drop slightly below full dissolution, while the coformers ADP and FUM 
concentrations were seen to remain at full dissolution.  SUC has very poor UV absorption, and 
its concentration could not be detected by HPLC after pH-shift.  The coformer concentrations 
remained at full dissolution for the entire duration of the dissolution, indicating that the cocrystal 
was fully dissolved.  The differences between coformer and drug concentrations immediately 
after the pH-shift also suggested that the lower KTZ concentrations were likely due to drug 
precipitation behavior instead of experimental or instrumental errors. 
























Figure 4A.1.  Cocrystal component concentrations measured during pH-shift dissolution from 
SGF pH 2 to blank FaSSIF (pH 6.5, no surfactant). (a) KTZ-ADP. (b) KTZ-FUM. (c) KTZ-SUC. 
The purple dashed lines indicate the fully dissolved cocrystal/component concentration.  The 
blue dashed lines indicate KTZ drug solubility.  The dotted vertical black lines indicate where 
the pH-shift occurred. 
 
pH-Shift Dissolution: pH 2  FaSSIF 
Cocrystal component concentrations in the initial media (SGF pH 2) indicated full 
dissolution of the cocrystals.  As can be seen in figure 4A.2, drug concentrations were initially at 
full dissolution in FaSSIF.  FUM was the only coformer that could be analyzed by HPLC in 
FaSSIF.  FUM concentrations overlapped with KTZ concentrations until the drug began to 












































Figure 4A.2.  Cocrystal component concentrations measured during pH-shift dissolution from 
SGF pH 2 to FaSSIF (pH 6.5). (a) KTZ-ADP. (b) KTZ-FUM. (c) KTZ-SUC.  The purple dashed 
lines indicate the concentration at which the cocrystal is fully dissolved.  The blue dashed lines 






























































pH-Shift Dissolution: pH 6 FaSSIF 
In pH 6 media, the cocrystals are fully soluble but the drug is not.  In figures 4A.3(a) and 
4A.3(b), ADP and FUM concentrations in the initial media suggest that the cocrystals may not 
have been fully dissolved prior to transferring into FaSSIF.  SUC concentration was too low to 
be detected.  ADP and FUM concentrations were higher than KTZ concentration in the SGF pH 
6 media, indicating that drug precipitation may already be occurring.  Only FUM was able to be 
detected in FaSSIF, and its concentration-time profile in FaSSIF indicates that the cocrystal was 
still dissolving in FaSSIF.  Although coformers ADP and SUC concentrations could not be 
measured in FaSSIF, the drug concentration in FaSSIF exhibited initial increases before 
dropping down over time.  This also suggest that there are still solid cocrystals left to dissolve in 


























Figure 4A.3.  Cocrystal component concentrations measured during pH-shift dissolution from 
SGF pH 6 to FaSSIF (pH 6.5). (a) KTZ-ADP. (b) KTZ-FUM. (c) KTZ-SUC.  SUC concentration 
was too low to be detected in (c).  The purple dashed lines indicate the concentration at which 
the cocrystal is fully dissolved.  The blue dashed lines indicate KTZ drug solubility.  The dotted 











































CONCLUSIONS AND FUTURE WORK 
 
 This dissertation determined the mechanisms by which cocrystals of basic drugs with 
acidic coformers enhance solubility and dissolution under elevated pH conditions.  The 
objectives of this work were to (1) understand the effect of pH and physiologically relevant 
surfactants on cocrystal solubility, supersaturation index (SA), and dissolution behavior; (2) 
derive mathematical models that describe cocrystal solubility behavior based on cocrystal 
dissociation, component ionization and solubilization equilibria; and (3) provide better 
understanding of cocrystal kinetic behavior based on SA and thermodynamic stability.  Overall, 
this work aimed to expand current knowledge of the relationship between cocrystal 
thermodynamic and kinetic behaviors, and how this knowledge may be applied to optimize the 
advantages of cocrystals. 
 Cocrystals of a poorly water soluble, weakly basic drug ketoconazole (KTZ) with acidic 
coformers adipic acid (ADP), fumaric acid (FUM), and succinic acid (SUC) were used as model 
compounds to determine the effect of cocrystallization on solubility-pH behavior.  Equations 
were derived to quantitatively predict cocrystal solubility under different pH conditions from 
cocrystal Ksp and component Ka.  These predictions were validated with experimental solubility 
values of the cocrystals, and the equations were also capable of predicting solubility beyond the 
experimentally accessible pH range.  In addition, these equations can be expanded to incorporate 
the effect of solubilizing agents in solution, such as endogenous bile salts present in the 
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gastrointestinal (GI) tract.  The equations allow for accurate predictions of cocrystal solubility 
and SA without the need for extensive experimentation, saving both time and materials. 
 KTZ cocrystals exhibited distinctive solubility-pH behavior compared to the parent drug.  
While the basic drug solubility decreased with increasing pH to a constant value, the cocrystals 
have U-shaped solubility curves with pH.  Different solubility-pH dependence resulted in the 
cocrystals having lower solubility than the drug at low pH conditions (pH < 3) and becoming 
more soluble as pH increased (pH > 4).  Each of the cocrystals has a pHmax, ranging from pH 3.6 
to 3.8, where Scocrystal is equal to Sdrug.  This pHmax identifies pH region (pH > pHmax for these 
cocrystals) where the cocrystal can provide solubility and dissolution advantage compared to the 
parent drug.  Dissolution conducted at pH > pHmax led to supersaturation of the drug and can 
provide enhancement of oral drug absorption under elevated pH condition in the GI tract.  KTZ 
cocrystal supersaturation index (SA) values increased from 1 at pHmax to 900 – 6000 at pH 6.5.  
Larger SA can increase the rate of drug precipitation and lead to no dissolution advantage.  KTZ-
FUM cocrystal in pH 6.5 buffer had SA > 3000, which resulted in rapid solution-mediated 
transformation back to the less soluble drug.  This shows that cocrystal SA, which is a 
thermodynamic value, can be used to assess the kinetic behavior of cocrystals and risk of 
conversion. 
 Cocrystals and drugs can encounter many different types of solubilizing agents during the 
development process and oral dosing.  Both the synthetic additives in the formulation and the 
endogenous surfactants and lipids present in the GI tract can alter the solubility of drug and 
cocrystals.  Preferential solubilization of the more lipophilic drug component (KTZ) over the 
more hydrophilic coformers (ADP, FUM, and SUC) led to reduction of SA in the surfactant 
containing media (FeSSIF and FaSSIF).  In other words, the cocrystal solubility enhancement 
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was less pronounced (1 – 3 fold) than that of the pure drug (4 – 6 fold) by these surfactants.  The 
total solubilization constants (Ks,T) were determined for each component under relevant pH 
conditions and used in the prediction of drug and cocrystal solubility behavior.  The reduction in 
SA caused by solubilizing agents allowed KTZ cocrystals to achieve higher drug concentrations 
and sustained supersaturation during dissolution in FeSSIF and FaSSIF compared to blank media 
of the same pH.  Drug solubilizing agents that reduce SA can enhance cocrystal stability in 
solution and improve dissolution behavior. 
  Dissolution studies that mimic the pH change along the GI tract showed that the 
cocrystals performed much better than the drug under conditions where the gastric pH is 
elevated.  Basic drugs like KTZ often have poor dissolution and oral absorption when gastric 
acidity is compromised, leading to highly variable bioavailability with pH.  The cocrystals 
greatly improved the overall drug levels during dissolution following pH-shift from SGF pH 6 to 
FaSSIF media, achieving about 3 fold higher AUC than drug under the same media conditions.  
The cocrystals showed similar solution behavior as the drug under low gastric pH condition (pH 
2), even though their solubilities are lower than that of the drug at that pH 2.  The pH-shift 
studies provided a quick and effective way to assess the potential advantages these cocrystals can 
have in vitro and in vivo, and they also allowed us to observe the precipitation behavior of the 
drug. 
 During the pH-shift studies, we also observed that the KTZ drug can undergo spinodal 
decomposition (liquid-liquid phase separation) under high supersaturation levels, resulting in the 
formation of metastable drug phases during precipitation.  These metastable phases of KTZ 
appeared to have higher solubility compared to the crystalline form and can delay the onset of 
crystallization.  The presence of metastable KTZ forms in solution can lead to higher sustained 
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drug supersaturation (with respect to crystalline drug solubility), which can in turn improve oral 
absorption.  Microscopic studies showed two distinct metastable forms of KTZ.  One form 
resembled a droplet-like phase, and the other form has spherical shapes that would grow in 
number and size over time but do not appear to merge with each other.  These two distinct 
phases of KTZ were observed to coexist in solution prior to the formation of drug crystals, and 
they can be induced by rapid generation of high supersaturation level of drug through increasing 
solution pH. 
 The findings in this work supported that cocrystals of basic drugs with acidic coformers 
can improve solubility and dissolution under elevated pH conditions in the GI tract and reduce 
pH-sensitivity.  The unique solid and solution chemistry of cocrystals allows their solubility and 
dissolution advantages to be fine-tuned to optimize drug absorption.  The mathematical 
relationships developed in this work can be used as quick and effective tools to quantitatively 
assess cocrystal solubility and potential for supersaturation under a wide range of media 
conditions.  SA can be used to aid the interpretation of kinetic dissolution results, and it is a 
useful tool for a quick assessment of the risk of cocrystal conversion and drug precipitation. 
A preliminary model for KTZ precipitation behavior is under development.  This work is 
still in an early stage and further studies are required to validate and optimize this model.  
Further studies that involve a wider selection of drugs, cocrystals, additives, and solution 
conditions are needed to establish the relationship between cocrystal SA values and the kinetic 
behaviors.  The influence of cocrystals on drug supersaturation, permeability, and absorption in 
vivo remains to be established.  This knowledge will aid in developing better predictions for in 
vivo behavior based on in vitro studies.   
